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Résumé 
Les rétinopathies ischémiques (RI) sont la cause majeure de cécité chez les 
personnes âgées de moins de 65 ans. Il existe deux types de RIs soit la rétinopathie 
du prématuré (ROP) ainsi que la rétinopathie diabétique (RD). Les RIs sont décrites 
en deux phases soit la phase de vasooblitération, marquée par une perte importante 
de vaisseaux sanguins, et une phase de néovascularisation secondaire à l’ischémie 
menant à une croissance pathologique de vaisseaux. Cette seconde phase peut 
générer des complications cliniques telles qu’un œdème dans l’humeur vitré ainsi que 
le détachement de la rétine chez les patients déjà atteints d’une RI. Les traitements 
approuvés pour les RIs visent à réduire la formation des vaisseaux pathologiques ou 
l’œdème; mais ceux-ci malheureusement ne règlent pas les problèmes sous-jacents 
tels que la perte vasculaire et l’ischémie.  
La rétine est un tissu hautement vascularisé qui contribue à l’irrigation et à 
l’homéostasie des neurones. L’interaction neurovasculaire, comprenant de neurones, 
vaisseaux et cellules gliales, contribue au maintien de cette homéostasie. Durant le 
développement, les neurones et les cellules gliales jouent un rôle important dans la 
vascularisation de la rétine en sécrétant des facteurs qui stimulent l'angiogenèse. 
Cependant, nos connaissances sur l’interaction neurovasculaire dans les RIs sont 
limitées. En identifiant les interactions importantes entre les cellules composant cette 
unité neurovasculaire dans la rétine, nous pourrons viser des cibles qui engendreront 
une revascularisation seine afin de diminuer les signes pathologiques chez les 
patients atteints d’une RI. 
Les travaux présentés dans cette thèse visent à mieux expliquer cette 
interaction neurovasculaire en soulignant des concepts importants propres aux RIs. 
En utilisant un modèle de rétinopathie induite par l’oxygène chez la souris, qui 
reproduit les caractéristiques importantes de la ROP (et en certaines instances, la 
RD), nous identifions quelques molécules clés jouant un rôle significatif dans les RIs 
soit la sémaphorine 3A (sema3A), l’IL-1β, ainsi que le récepteur PAR2.  
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Nos résultats démontrent que Sema3A, sécrétée par les cellules 
ganglionnaires rétiniennes (CGRs) durant une ischémie, empêche la 
revascularisation normale et que cette expression est induite par l’IL-1β provenant 
des microglies activées. En bloquant Sema3A directement ou via l’inhibition de l’IL-
1β, nous remarquons une revascularisation seine ainsi qu’une diminution importante 
des vaisseaux pathologiques. Cela nous indique que Sema3A est impliquée dans la 
guidance vasculaire et qu’elle contribue à la pathogenèse des RIs. L’activation de 
façon exogène de PAR2, identifié aussi comme régulateur du récepteur de l’IL-1β (IL-
1RI) sur les CGRs, se traduit par une diminution séquentielle de l’IL-1RI et de 
Sema3A ce qui mène également à une revascularisation seine.  
En conclusion, ces travaux soulignent l’importance de l’interaction 
neurovasculaire ainsi que la guidance vasculaire dans les RIs. Ils renforcent 
l’importance de la communication entre neurone, vaisseau et microglie dans la 
pathogenèse des RIs. Finalement, nous identifions quelques molécules clés qui 
pourront servir comme cibles afin de lutter contre l’ischémie qui cause des problèmes 
vasculaires chez les patients atteints d’une RI.   	  	  
Mots clés 
sémaphorine 3A, interleukine-1β, récepteur activé par protéase 2, vaisseaux, cellules 
ganglionnaires rétiniennes, microglies, vasooblitération, néovascularisation, 
revascularisation, rétinopathies ischémiques 	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Abstract  
 
 Ischemic retinopathies (IRs), namely, retinopathy of prematurity (ROP) and 
diabetic retinopathy (DR), are the major cause of blindness in persons under the age 
of 65. IRs are biphasic disorders described by an initial vasoobliterative phase 
marked by a persistent microvascular degeneration, which leads to ischemia. Retinal 
ischemia, secondary to vessel loss, incites a second neovascularization phase 
represented by an aberrant, misdirected neovessel formation into the vitreous, which 
can cause adverse clinical complications including vitreous hemorrhaging and 
tractional retinal detachment. While current treatments aim at reducing vitreous/retinal 
hemorrhaging and/or pathological pre-retinal neovascularization, these regimens fail 
to address the underlying problem; that is, microvascular decay and retinal ischemia.  
 The retina is a highly metabolic tissue that requires a significant amount of 
nutrients and oxygen. This is supplied by an intricate and highly regulated vascular 
network required to maintain homeostasis and proper function. The intricate cellular 
interactions in the neurovascular unit – the consortium of vessel, neurons and support 
glia – are required for regulating and maintaining homeostasis under normal 
conditions. However, the understanding of how this unit functions under ischemic 
stress, that which is seen in patients suffering from IRs, is not well defined. The 
present work underlines several important concepts of neurovascular coupling in IRs 
in efforts to identify potential therapeutic agents that may help curb retinal ischemia by 
stimulating normal revascularization. 
 Using a mouse model of oxygen-induced retinopathy (OIR), which reproduces 
the salient features of ROP (and in some instances DR), we identified key players 
involved in generating the pathophysiological signatures associated with IRs; namely, 
semaphorin3A (Sema3A), interleukin-1β (IL-1β) and protease-activated receptor 2 
(PAR2). Our results show that neuronal-derived Sema3A, secreted by ischemic 
retinal ganglion cells (RGCs), acts as a potent vaso-repulsive molecules that impedes 
normal revascularization. Activated microglia contribute to this process by secreting 
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IL-1β, which induces paracrine release of Sema3A expression contributing to 
microvascular decay as well as pathological pre-retinal neovascularization. Inhibition 
of Sema3A or IL-1β translates to rapid revascularization and, as a result, a significant 
reduction in pathological neovessel formation. These results demonstrate that 
Sema3A is directly involved in vascular guidance and precipitates the patho-
physiological features associated with IRs. PAR2, found on RGCs, was also identified 
as a key regulatory mechanism involved in dampening IL-1β induced Sema3A-
mediated vascular decay by reducing IL-1 receptor (IL-1RI). Exogenous activation of 
neuronal PAR2 translates to a sequential reduction of both IL-1RI and Sema3A 
resulting in accelerated revascularization and consequentially pre-retinal 
neovascularization. 
  In conclusion, these studies highlight the importance of neurovascular coupling 
associated with IRs. Herein, we demonstrate the consorted interaction between 
neuron, vessel and glia and its impact on shaping the retinal vasculature during 
disease. Moreover, we underscore the significant impact of neuronal guidance cues in 
manifesting the salient vascular features of IRs. Finally, we identify key players that 
may serve as potential therapeutic avenues in curbing retinal ischemia in efforts to 
reduce vascular complications associated with IRs.  
 
 
Key Words: 
Semaphorin 3A, Interleukin-1β, Protease-activated receptor 2, vessels, retinal 
ganglion cells, microglia, vaso-obliteration, neovascularization, revascularization, 
ischemic retinopathies 	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Lay Summary 
Ischemic retinopathies (IRs), which include Retinopathy of prematurity (ROP) 
and diabetic retinopathy (DR), are major causes of blindness worldwide. The onset of 
these diseases is complex and involves several factors, many of which have only 
begun to be unraveled. Extensive work has been conducted on retinal 
neovascularization, which is the pathological formation of new blood vessels. 
Notwithstanding, studies indicate that ischemia (or lack of nutrients and oxygen) 
precedes the pathological vessel formation has a significant impact on vision health. 
There is growing evidence from our laboratory demonstrating the importance of 
neurons in the retina and their ability to influence their environment. This proposal 
aims at discerning the role of inflammation in vessel repair, growth and death, and the 
role of neurons in this process. Relevantly, we have shown that a population of retinal 
neurons called the ganglion cells can greatly influence the formation of new blood 
vessels both in physiological and pathological settings, as in IRs. A class of 
molecules that repel growing blood vessels called semaphorins, specifically Sema3A, 
have a significant impact on the severity of pathological neovascularization and thus 
IRs. Moreover, we identify that inflammation plays a significant role in generating 
Sema3A. 
Our laboratory has unveiled preliminary data indicating the role of non-specific 
inflammatory responses (observed in most IR cases) as the underlying trigger of 
these repulsive cues. The PhD project presented here is designed to investigate the 
role of inflammation, which inadvertently constrains these vaso-sensitive neurons 
beyond a specific threshold thereby changing their initial pro-angiogenic phenotype 
for that of an anti-angiogenic profile. These findings will contribute to our greater 
understanding of factors that aggravate ROP and thus pre-disposes premature-born 
babies as well as diabetic patients to blinding retinal detachment.  
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General Introduction 	  
1. Brief Overview 
Ischemic retinopathies (IRs), namely, diabetic retinopathy (DR) and retinopathy 
of prematurity (ROP), are the leading cause of visual impairment and blindness 
affecting primarily working-age and pediatric populations, respectively. With the 
overwhelming incidence of diabetes increasing globally1 as well as increased survival 
rate of prematurely born infants2, IRs are becoming a significant encumbrance on the 
health care system both directly and indirectly. The underlying causes of these 
diseases are predominantly vascular-based whereby a sudden microvascular dropout 
(phase I) translates to an overcompensated, uncontrolled vascular growth that 
protrudes into the vitreous (phase II). The latter accounts for multiple clinical 
complications including macular edema, vitreous hemorrhaging, fibrosis and tractional 
retinal detachment2,3. While current treatments involve tackling the problematic during 
the latter stages of the disease (excess vessel growth and extravasation into the 
retina and vitreous), there are few options that address the underlying problem 
leading to excess vessel growth; namely vessel loss and ischemia. 
Recently, there is evidence demonstrating the importance of the neurovascular 
unit––the consortium of neurons, vessels and glia that make up the retina––in retinal 
diseases4. These cells bidirectionally communicate to maintain homeostasis and 
ensure proper functioning of the neuro-retina. When perturbations occur, as seen in 
ROP and DR, it affects the entire unit. We now know that IRs are not only vascular-
based but also neuronal-based diseases. Notwithstanding, there is still a significant 
amount of knowledge regarding neurovascular coupling that remains to be unveiled. 
Formal understanding of the neurovascular coupling will help propagate the discovery 
of novel therapeutic avenues that will aid in curbing retinal ischemia and vessel loss 
that precedes excess vessel growth.  
	   15	  
This investigation herein covers a series of topics related to neurovascular 
coupling between vessels, glia and neurons in efforts to discern the important 
interactions involved in propagating the disease. Using a mouse model of oxygen-
induced retinopathy (OIR), which mimics the cardinal features of ROP (and to a 
certain extent DR), we highlight key players and concepts that contribute to the 
observed vessel loss and subsequent pathological vessel growth associated with IRs. 
Herein, we specifically target these molecules to essentially curb vessel loss, 
accelerate normal revascularization and prevent excess vessel growth; in other words, 
reestablishing a normal vascular network in the retina to reinstate homeostasis in the 
neurovascular unit. 
 
2. Epidemiology of Ischemic Retinopathies 
The incidence of Ischemic Retinopathies (IRs), namely, retinopathy of 
prematurity (ROP) and diabetic retinopathy (DR), has increased drastically since the 
1950’s5. In 2000, the World Health Organization (WHO) published a report on the 
incidence of blindness globally, whereby 50,000 children and 1.7 million working-age 
persons were blinded as a direct cause of ROP and DR, respectively5. With 
increasing survival rates in preterm born children2 and an alarming increase in 
diabetes globally1, these numbers are expected to surge drastically in the next 10 to 
15 years; the WHO has now classified these eye ailments as “priority eye diseases”. 
Essentially, IRs will be the major contributing cause of irreversible blindness globally 
in persons below the age of 60, which will impart a significant burden to the health 
care systems. 
2.1. Retinopathy of prematurity (ROP) 
Worldwide approximately 10% of all newborns are born before term (<37 
gestational weeks)6. Although prematurity is still one of the leading causes of death in 
neonates7, there has been a drastic improvement in survival rates since the use of 
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supplemental oxygen incubators in the 1940’s. This, however, has also lead to a 
significant increase in ROP among neonates and is now one of the leading cause of 
blindness in children2,5.  
ROP afflicts primarily extremely low birth-weight (typically ≤1500 g) and low 
gestational-age (≤ 30 weeks) neonates accounting for the large majority of reported 
blindness8,9. However, the incidence of ROP also occurs in moderate birth weight 
(>1500g) and gestational age (> 31 weeks) due to use of supplement oxygen, which 
remains one of the major risk factors for development of ROP (see below Etiology of 
retinopathy of prematurity)10,11. Statistically, while low incidence of ROP has been 
reported in some countries (in Australia and New Zealand <10% neonates have 
severe ROP), other epidemiological studies report very high incidence of ROP among 
prematurely born babies (Sweden reports ~33% of neonates have severe ROP)2. 
Although racial, genetic or environmental factors may influence epidemiological 
variations, infant mortality rates and ROP are highly correlated and vary widely 
between countries9. Notably, study design, survival rates and treatment use may also 
skew reported population statistics2,11. Complementary screening algorithms (e.g. 
WINROP) and centralized registries (e.g. SWEDROP) are now being employed in 
various countries in efforts to yield accurate numbers and reduce sampling errors 
between study groups2,12,13. 
While the incidence of ROP may be high in some population groups9, less that 
15% of neonates diagnosed with the disease develop sight-threatening vision loss 
requiring clinical intervention2,14. In most patients, characteristics of ROP 
spontaneously regress. Notwithstanding, neonates afflicted with moderate forms of 
ROP – not having suffered complete vision loss – often suffer from other ocular 
impairments including: significant reduction in visual acuity, refractory errors (e.g. 
myopia), amblyopia or strabismus, defects in ocular growth and retinal dysfunction15. 
Recent studies have associated abnormal or delayed child growth and perturbations 
in neurovascular homeostasis as underlying bases for these deficiencies15,16. 
Consequently, understanding the underlying mechanisms of ROP disease 
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progression will be beneficial in not only preventing blindness but also improving 
visual acuity and eye function in children. 
2.2. Diabetic retinopathy (DR) 
In 2000, the World Health Organization reported an approximate 171 million 
people worldwide have been diagnosed with Diabetes Mellitus and was estimated 
that by 2030, approximately 366 million people will have diabetes globally5. The 
International Diabetes Federation, however, published a report in 2011 approximating 
that an 366 million have already been afflicted with this disease1. Thus, in nearly a 
third of the estimated time (11 years instead of 30 years) the incidence of Diabetes 
Mellitus has more than doubled globally. Pertinently, it is estimated that approximately 
75% of all diabetes patients (type 1 and 2) will develop some form of DR after 20 
years17. With a reported 93 million diabetic patients suffering from DR in 2010 (28 
million having vision threatening DR)18, there has been a recent push to improve 
screening methods, increase metabolic control and patient follow-up, and research 
and develop novel treatment regimes in efforts to combat this sight-threatening 
ailment3,4. 
Epidemiological studies show that uncontrolled glycemia, elevated blood 
pressure and lipid levels – commonly found in diabetes patients – are associated with 
increased incidence and progression of proliferative DR (PDR)4. While strict metabolic 
control reduces the incidence and development of DR19, up to 20% of patients 
diagnosed with diabetes still developed PDR after 30 years, which accounted for an 
estimated 17 million people globally in 201018. Serum levels of adiponectin20, 
prolactin21 and homocysteine22 as well as non-alcoholic liver diseases23, genetic 
factors, insulin resistance and low levels of physical activity4 have been proposed as 
potential risk factors in PDR; however, relative influences of these factors in the 
development of proliferative DR have thus far not been well established. Clinical 
macular edema also contributes to significant vision loss accounting for an estimated 
6.8% of diabetic patients or 21 million people worldwide18. While similar risk factors 
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are associated with incidence and progression of diabetic macular edema and PDR4, 
distinct classification, management and treatment regimes for clinical macular edema 
are now being observed3. The underlying causes for onset and development of 
macular edema or PDR, however, still remain elusive. 
While diabetic care has improved in the last few decades in most developed 
countries, insufficient eye care in emerging countries remains a significant 
problematic, particularly in areas where the incidence of diabetes is staggeringly high 
(~80% of diabetic persons live in low- or middle income countries)1,18. Moreover, there 
are a significant number of persons living with diabetes that have not yet been 
diagnosed1, thus creating a significant encumbrance to health care systems 
predominantly in countries where substantial eye care for diabetic patients are sub-
optimal or unavailable. Thus, improved classification guidelines and effective 
screening methods will be necessary to help clinicians better diagnose DR in the 
coming years. 
 
3. Etiology of Ischemic Retinopathies 
IRs are biphasic disorders caused by an imbalance in vascular homeostasis in 
the neural retina. The first phase is marked by a persistent degeneration of the retinal 
microvasculature leading to a state of ischemia. In ROP, the major underlying 
contributor leading to the abrupt vessel loss is excess oxygenation2, while in DR 
sustained hyperglycemia and inflammation are proposed as contributing factors to 
substantial vessel loss3. Improper oxygen supply due to sustained vessel loss 
(ischemia) results in significant biochemical changes in retinal cells (neurons and glia) 
that mount an overcompensated, uncontrolled vessel growth in attempt to reinstate 
vascular homeostasis – the second phase. This excessive and misguided neo-
vascularization protrudes towards the vitreous and, if left untreated, can cause 
significant perturbations in visual acuity and irreversible vision loss. While similarities 
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exist between ROP and DR, the underlying pathophysiological mechanisms of 
disease onset, nonetheless, remain distinct. 
3.1. Pathogenesis of Retinopathy of Prematurity 
Preterm birth causes an abrupt cessation in retinal vascular growth, which 
under normal circumstances matures only at term (e.g. week 40 gestational age)24 
[see section 4.2]. Since retinas of premature infants are only partly vascularized, the 
incidence and progression of ROP is directly proportional to the gestational age upon 
birth. As a result, the immature and highly susceptible retinal vasculature is vulnerable 
to a number of stressors including high levels of oxygen delivery, suppression of key 
vascular survival factors, including vascular endothelial growth factor (VEGF) and 
erythropoietin (Epo), and inadequate supply of maternally-derived cytoprotective 
factors, such as insulin-like growth factor (IGF-1). Clinically, this translates to a vaso-
obliteration of retinal vessels known as the first phase of ROP (Stage 1 and 2 of ROP; 
see Table 1 for details). 
As the eye continues to grow and become functional, the metabolically active 
retinal cells prompt a rapid response in efforts to counter the relative hypoxia in the 
retina. In some ROP cases spontaneous revascularization does occur; however, 
hypoxia triggers massive increase in vaso-proliferative cues, such as VEGF25 and 
Epo26, while simultaneous increase in non oxygen-regulated molecules, such as IGF-
127 leads to an overcompensated vessel growth that protrudes into the vitreous cavity 
(Stage 3). Left unchecked, the immature and highly leaky vessels can lead to scarring 
fibrotic lesions, which result in, upon regression, tangential retinal shearing leading to 
partial (Stage 4) or complete detachment of the retina (Stage 5) and thus blindness.  
Notwithstanding, clinical investigations8 and use of animal models28,29 has 
greatly enhanced our understanding of the pathophysiological changes that occur in 
the retina of preterm infants. We now understand that ROP is not only a vascular-
based disorder but is also causes functional visual defects. Recent studies have 
underscored the important neurological changes that occur during ROP are mainly 
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due to hyperoxia and ischemia15,16. Although hyperoxia affects particularly the 
photoreceptors, likely via perturbations in choroidal development30, there is also 
mounting evidence showing the effect of oxidant stress on the inner retina 
structure15,31 indicating that neurons in these layers also suffer from ensuing ischemia. 
The information regarding this occurrence, however, remains elusive. 
While oxygenation remains a significant player in ROP, several other factors 
have also been attributed to the pathogenesis of the disease. 
3.1.1. Risk factors for ROP 
Hyperoxia 
Excess oxygenation has been described as the most dominant factor in the 
development and severity of ROP in both human2,8 and animal studies28,29. Hyperoxia, 
as a result of supplemental oxygen ventilation (typically between 85 – 100% O2), 
translates to an arrest in retinal vascular growth and regression of the pre-existing 
vasculature (vaso-obliteration). In humans, even room air–considered hyperoxic 
compared to in utero levels–can cause obliteration of retinal vessels. Relevantly, 
attempts to lower oxygen saturation levels (pO2) have been implemented in neonatal 
care units in efforts to lower ROP severity; however, this remains controversial, 
particularly since use of lower pO2 correlates to increased neonatal mortalities2. Use 
of supplemental oxygen in the second vaso-proliferative phase, however, does not 
appear to affect the severity of ROP32,33. 
At the molecular level, the hostile hyperoxic environment in the neonate retina 
promotes formation of various reactive oxygen species (ROS) and their peroxidation 
products, which contribute to microvascular injury during this first phase of ROP10,34. 
Increased enzymatic activities of cyclooxygenase (COX), phospholipases (PLA2) and 
nitric oxide synthase (NOS) in retinal endothelium contribute to observed 
vasoobliteration through release of thromboxane (TXA2), platelet activating factor 
(PAF), lysophosphatidic acid (LPA) and trans-arachidonic acid (TAA)10. 
Correspondingly, use of antioxidants or genetic ablation and pharmacological 
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inhibition of these enzymes translates to decreased microvascular decay in animal 
models of ROP10,35.  
High oxygen levels also tips the balance between pro-angiogenic and anti-
angiogenic cues whereby increased oxygen tension in the retina favors the latter. 
Hyperoxia downregulates important oxygen-regulated angiogenic factors, VEGF36,37 
and Epo26,38, which are indispensible vessel growth and survival factors required 
during this crucial phase of retinal vessel development. Conversely, release of anti-
angiogenic factors, thrombospondin-1 (TSP-1)39 and tumor necrosis factor α (TNF-
α)40, as a result of high oxygen tension contribute to observed vascular decay as 
seen in ROP patients by inducing endothelial cell apoptosis. 
 
Gestational age, birth weight and postnatal weight gain 
Aside from oxygen, gestational age (≤ 30 weeks) and birth weight (≤1500 g) 
are major risk factors in the outcome of ROP. Both factors impart a direct link to 
retinal development; low birth weight and low gestational age are proportionally 
related to underdeveloped neural and vascular networks, which are highly susceptible 
to injury. This is mainly associated with loss of key factors provided by the intrauterine 
environment and slow production of these factors in preterm neonates2, which can 
impact ROP progression. Moreover, birth weight is an important contributing factor in 
the outcome of ROP; low birth weight directly affects incidence and severity of ROP in 
preterm infants born before 31 weeks41-45. It has been proposed that intrauterine 
growth restrictions are attributed to this phenomenon2. 
Weight gain post-conceptionally also contributes to the progression and 
severity of ROP in humans46 and animals47. Essentially, animals and humans with 
inferior weight gain postnatally demonstrate increased exacerbation in ROP 
characteristics while excessive weight gain shows the inverse46,47. IGF-1 serum levels 
strongly correlate with preterm infant weight gain46 and thus contributes both directly 
and indirectly in the outcome of ROP (see below). Notably, factors such as metabolic 
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rate, hyperglycemia, nutrition, infections and illnesses also affect premature infant 
weight gain and should be carefully monitored during postnatal weeks following birth2. 
  
Maternally derived factors 
 One of the crucial disparities between babies born preterm and those born at 
term is loss of vital maternally-derived factors, the most important being IGF-148,49 and 
omega-3 polyunsaturated fatty acids (ω-3 PUFAs)50. Preterm birth severs the 
maternal-fetal interaction thus preventing influx of these essential factors, which are 
particularly necessary during the third trimester of gestation48. Importantly, these 
essential nutrients and factors have a profound effect on infant development as well 
as incidence and progression of ROP and other disorders caused by prematurity 
(cerebral palsy, chronic lung disease)46,51,52. 
IGF-1, a polypeptide protein hormone, is an essential factor for fetal 
development during all stages of pregnancy53. Premature birth severs the essential 
supply of IGF-1 from the placenta and utero thus slowing growth and development of 
the preterm infant49. Moreover, premature infants born before 33 weeks produce very 
low levels of IGF-1 compared to full term born infants48. Relevantly, serum levels of 
IGF-1 are inversely correlated the severity of ROP in preterm infants46; lack of IGF-1 
and its binding protein (IGFBP3) results in significant loss of retinal vessels during the 
vaso-obliterative phase27,54. Experimental animal models of ROP have demonstrated 
that exogenous administration of recombinant human (rh) IGF-1 resulted in significant 
weight gain, rapid maturation and considerably less severity of OIR55. In this regard, 
use of fresh frozen placenta (a significant source of IGF-1) or rhIGF-1 and rhIGFBP3 
is now commonly used in pediatric clinics to help augment serum IGF-1 in preterm 
infants to normal in utero levels in efforts to reduce ROP incidence and severity56,57. 
ω-3 PUFA are essential nutrients obtained from our diet that exert powerful 
biological activities. An important influx of ω-3 PUFA is normally transferred from 
mother to fetus during the third stage of pregnancy, which is lost as a result of 
premature birth. Since the eye contains the highest concentration of docosahexaenoic 
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acid (DHA, the major metabolite of ω-3 PUFA) in the body, it is no surprise that 
exogenous supplementation of DHA in preterm infants correlated with increased 
visual acuity50. More recently, animal studies of ROP demonstrate that lactating 
mothers fed with ω-3 PUFA enriched diets resulted in a significant decrease in vaso-
obliteration and pathological neovascularization in mice pups58,59. Exploration into the 
molecular mechanisms shows that ω-3 PUFA diet translated to significant increase in 
cytoprotective and anti-inflammatory resolvins and neuroprotectins, which impart their 
beneficial effects via suppression of TNF-α59, likely via peroxisome proliferator-
activated receptor (PPARγ)58. The same group also demonstrated that 4-hydroxy-
DHA (formed from ω-3 PUFA via 5-lipoxygenase) potentiates anti-angiogenic 
properties by selectively activating PPARγ on endothelial cells (ECs). Although 
supplementation of ω-3 PUFA in premature infants is not exercised clinically, anti-
angiogenic effects of supplemented ω-3 PUFA have been reported in patients 
suffering from related neovascular eye diseases, such as age-related macular 
degeneration (AMD)60,61. 
 
3.2. Pathogenesis of Diabetic Retinopathy 
Although there is no established animal model for DR, the development of the 
OIR models in rodents28,29 has shed much light on the mechanisms involved in vaso-
proliferative phase of DR; however, the pathophysiological mechanisms underlying 
the onset of DR remain largely unknown. Nonetheless, a large body of data suggests 
that the dysfunctional changes that occur in the retina in DR patients are of 
neurovascular origin rather than a pure microvascular phenomenon. The interaction 
between inner retinal neurons (RGC, amacrine, bipolar cells), glia (microglia, 
astrocytes, Müller cells) and retinal microvasculature – cells that make up the 
neurovascular unit – is so finely tuned that perturbations can lead to neuronal 
dysfunction as seen in the brain62. In DR, these perturbations are quite often 
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asymptomatic but can lead to diabetic macular edema3, vitreous hemorrhaging and 
later tractional retinal detachment diminishing visual acuity and causing loss of vision.  
The initial phase of vessel loss in diabetic patients begins with breakdown of 
the blood-retina-barrier (BRB), which often leads to noticeable microaneurysms in the 
retina3. The BRB is normally composed of endothelial cell (EC) tight-junction and 
adherence proteins as well as pericytes that wrap around blood vessels to limit 
extracellular fluid exchange between blood and retina62 (see below section 4). 
Increased cytokine expression in the retina of DR patients, such as interleukin-1β (IL-
1β) and TNF-α63, which can induce intercellular adhesion molecule 1 (ICAM-1) 
expression64 contribute to BRB breakdown by increasing leukocyte adhesion and 
activation in retinal vessels65. VEGF, first described as a vascular permeability 
factor66, increases significantly in the vitreous of patients with DR67 and contributes 
directly to disruption of BRB integrity by disrupting EC tight-junction proteins and 
pericyte adhesion68. Other factors, such as increased activity of protein kinase C 
isoforms69 (particularly PKCβ), advanced-glycosylation end-products (AGE)70 as well 
as increased activity of kallikrein-bradykinin71 pathways also appear to contribute to 
compromised vessel integrity in the early stages of DR. This can lead to severe non-
proliferative DR marked by venous bleeding, multiple blot hemorrhages and 
intraretinal microvascular abnormalities3 which creates pockets of non-perfuse tissue.  
The resulting ischemia that occurs secondary to vessel loss induces an over-
compensated albeit pathological neovascularization response similar to that observed 
in ROP patients. HIF-1α, triggered by hypoxia, increases a plethora of vascular 
response cues, principally VEGF and Epo38,72, which play a central role in neovessel 
formation in proliferative DR73,74. However, this attempt to reinstate vascular 
homeostasis, instead of revascularizing non-perfuse areas of the retina, grows 
aberrantly towards the posterior segments of the vitreous cavity3. The highly 
immature neovessels are often leaky resulting in bleeding into the vitreous and inner 
retina, which cause perturbations in visual acuity and obstruction of vision. Left 
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untreated, these immature and leaky neovessels can form fibrotic scars that, upon 
retraction, can cause blinding retinal detachment.  
Poor blood sugar regulation in diabetic patients has been shown to increase 
the incidence and progression of DR4; however, despite proper metabolic control 
there is still a percentage of diabetic patients that develop DR19 indicating that the 
appearance of retino-complications associated with DR may be multi-factorial. These 
include various facets of hyperglycemia, chronic inflammation and pathological 
angiogenesis discussed below.  
 
3.2.1. Risk factors for DR 
Hyperglycemia  
In the CNS, glucose is the major metabolite used by cells in the neurovascular 
unit for supplying energy. In diabetic patients, hyperglycemia translates to a 
significant influx of glucose in the retina and brain and has is associated with 
observed microvascular complications in retinas of diabetic patients4. One 
complication linked directly to high glucose levels in the retina is formation of 
advanced-glycosylation end-products (AGE). AGEs form non-enzymatically from 
glucose or other glycating compounds, reacting with proteins lipids, or DNA70. 
Formation of AGEs can result in altered function of intracellular proteins, interrupt 
extracellular matrix proteins interactions as well as entitle their own functionality by 
binding to receptors for AGE (RAGE)75. Activation of RAGE results in increased ROS 
generation (discussed below) as well as activation of transcriptional factor NFκB, 
which lead to pathological gene expression changes76. Pertinently, accumulation of 
AGE in retinal pericytes can be detrimental precipitating cell death77; in retinal ECs, 
however, AGE-RAGE signaling can potentiate angiogenesis via upregulation of 
Ang278 and VEGF79 indicating that AGEs can have a distinct roles in both phases of 
DR. 
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Hyperglycemia can also activate various protein kinase C (PKC) isoforms, 
which plays a pivotal role in disease progression of DR69. PKC activity is normally 
upregulated by intracellular Ca2+ and diacylglycerol (DAG); these molecules are 
significantly increased in retinal vessels by hyperglycemia, which lead to activation of 
various PKC isoforms in diabetic patients75. For instance, PKCβ increases as a result 
of hyperglycemia and is well known for disrupting tight-junction proteins on ECs 
causing subsequent breakdown of BRB69. Another study demonstrated that 
hyperglycemia-activated PKCδ phosphorylates and activates of mitogen activated 
protein kinase (MAPK) signaling via p38α; activation of p38α translates to 
phosphorylation of SHP-1 (Src homology-2-domain-containing-phosphotase-1) and 
subsequent inactivation of PDGF receptor β (PDGFRβ), which results in pericyte 
death and thus increased retinal extravasation in mice80. Moreover, PKC activity can 
lead to the formation of ROS, which imparts its own degenerative role in DR. PKCβ 
and δ are also expressed in other retinal cell types albeit their relative contributions to 
the pathogenesis of DR has not been well established. 
Hyperglycemia increases oxidative stress in the neurovascular unit through 
ROS formation via increased mitochondrial respiration, AGE-RAGE signaling and 
PKC activity. ROS formation can lead to increased lipid peroxidation in endothelial 
cells (and other retinal cells)75, which further exacerbate vessel loss similar to what is 
seen in ROP patients34. Excess ROS in the retina also augments endothelial cell 
death via indirect signaling pathways; for instance, oxidative stress can lead to the 
formation of peroxynitrite (ONOO-), which cause micro-vascular complications via 
inhibition of matrix metalloprotease-7 (MMP-7) activity81. MMP-7 is required for 
proteolytic processing of the precursor form of nerve growth factor (ProNGF) to its 
mature form and inhibition of MMP-7 leads to increased pro-apoptotic activity of 
ProNGF through neurotrophin receptor P75 (P75NTR)81 on endothelial cells, which 
has shown to increase fluid extravasation in murine retinae82 (as seen in DR patients).  
Studies highlighting the mechanistic effect of hyperglycemia on retinal neurons 
and glia cells, however, remain limited. 
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Chronic inflammation 
Current research attributes inflammation as having a causal role in DR. There 
are studies pointing to a significant contribution of inflammatory molecules and cells 
having a direct contribution to the pathogenesis of DR. Inflammatory cytokines and 
chemokines have been detected in the vitreous of patients with DR (non-proliferative 
or proliferative), the most prominent being TNF-α, IL-1β, IL-6, IL-8 and monocyte 
chemotactic protein-1 (MCP-1 or CCL2)4,83. These inflammatory molecules can have 
direct toxic effects on retinal endothelium (such as TNF-α40) but typically exacerbate 
vessel degradation via increased adhesion of circulating leukocytes (via elevated 
ICAM-1 expression)64,65 and activation of resident microglia84. Moreover, during the 
vasoproliferative phase, inflammatory cytokines/chemokines can contribute to 
pathological angiogenesis via stromal-cell derived factor-1 (SDF-1/CXCL12), which 
stimulate migration and proliferation of endothelial cell progenitors (ECPs) into the 
retina85, or via upregulation of important vascular growth factors such as VEGF86. 
In diabetes, there is an increase in circulating lipids resulting in a modification 
of the lipid profile in the retina87, which can cause elevated eicosanoid production in 
diabetic retinae. Arachidonic acid (AA), produced from lipid membranes by PLA2, is 
quickly metabolized into prostaglandins and leukotrienes via cyclooxygenases (COX) 
and lipoxygenases (LOX), respectively, which contribute to the pathogenesis of DR. 
For instance, increased COX-2 levels have been found in epiretinal membranes 
(fibrotic lesions between vitreous and retina)88 of DR patients and has shown to be 
implicated in pericyte death and capillary dropout in diabetic animals89. 
Correspondingly, inhibition of COX-2 (but not COX-1) impedes diabetes-induced 
microvascular degeneration in these animals90. Other studies report increased 
leukotrienes (and leukotriene derivatives) in the vitreous of DR patients91 and 
selective deletion of 5-LOX resulted in reduced microvascular degeneration in diabetic 
mice retina89 highlighting the relative importance of leukotrienes in the DR. 
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Eicosanoids can also exacerbate vascular permeability via increase in inflammatory 
molecules, such as VEGF and NF-κB89.  
 
Pathological angiogenesis 
The formation of pathological neovessels in the retina is major contributing 
cause of vision loss in DR. Pathological angiogenesis typically occurs around the 
optic disk and at the edge of non-perfuse retinal tissue3. The exponential increase in 
VEGF, resulting from tissue hypoxia, has been revealed as the principal cause for the 
increase in pathological vessel formation in the retina and subsequent hemorrhaging 
into the vitreous92. Notwithstanding, other growth factors have shown to be involved in 
stimulating angiogenesis (e.g. Epo74), which may account for the reported non-
responsiveness of some patients to diagnosed anti-VEGF treatment3. Potential 
targets are now being revealed as having a significant impact on abhorrent vessel 
formation and inhibition thereof results in decreased pathological angiogenesis in 
various models of vaso-proliferative retinopathies93. 
The apparent vascular response to tissue hypoxia originates principally from 
proximal neurons16 and glia94. Studies are now beginning to underline the importance 
of these cells in releasing growth factors, or other factors, that potentiate pathological 
angiogenesis in the retina4. However, the observed pathological angiogenesis that 
protrudes into the vitreous in DR (and ROP) patients remains a puzzling 
phenomenon; that is, production of growth factors from the neuro-retina should 
maintain neovessels on the surface of the superficial plexus. Thus, it appears other 
forces are involved in misguiding these neovessels toward the vitreous. To 
understand this phenomenon, we must understand the functional aspects of vascular 
biology. 
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4. Vascular biology in Ischemic Retinopathies 
Understanding the underlying mechanisms of vessel formation is important in 
developing novel treatments to combat sight-threatening IRs. This section covers the 
important processes involved in vessel formation highlighting key players that govern 
this phenomenon. Moreover, this section sheds light on the steps involved in 
vascularization of the retina, which becomes vital for in understanding ROP in preterm 
born infants. Finally, the last sections cover the importance in neuron and vessel 
cross talk––more aptly known as neurovascular coupling––involved in angiogenesis 
as well the vaso-modulatory effects of inflammatory molecules and cells in the retina 
(and the CNS). 
4.1. Angiogenesis, Vasculogenesis and Arteriogenesis 
The necessity for oxygen and nutrients from metabolically active tissue 
stimulates production of new blood vessels. Formation of neovessels occurs via two 
major pathways; namely, vasculogenesis and angiogenesis. Arteriogenesis is an also 
important process in higher animals that own complex circulatory systems. 
Understanding of the processes of vessel formation is crucial in determining potential 
targets involved in vessel degradation and pathological neovascularization in 
ischemic retinal diseases such as ROP and DR.  
4.1.1. Vasculogenesis 
Vasculogenesis is the formation of vessels de novo via mesoderm-derived 
progenitor cells that migrate to non-perfuse tissues. Mesoderm-derived progenitor 
cells are pluripotent stem cells that can produce both hematopoietic stem cells, which 
give rise to all blood cell lineages, and angioblasts, that can differentiate into 
endothelial cells (EC)95. ECs are specialized and dynamic cells that line the inner wall 
of blood vessel; they maintain the integrity of vessels and respond to environmental 
changes. Aggregation of differentiated angioblasts, or ECs, leads to the formation of 
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tube-like structures (vessel cords)95 that eventually disperse into an array of arteries, 
veins and capillaries. 
Once formed, primary vessel cords have the capacity to form both arteries and 
veins. The exact fate of arterio-venous formation depends on the genetic signature of 
the ECs lining the vessel cord95,96. Notch signaling, which depends almost exclusively 
on cell-to-cell contact97, is one of the major contributors to arterial fate and its cell 
surface receptors, Notch1, and Notch4, and ligands, Jagged (Jag)1, Jag2 and delta-
like ligand 4 (Dll4), are highly expressed in arteries via arterial-specific transcription 
factors, FOXC1 and FOXC2. In veins, however, Notch proteins are systematically 
suppressed via the vein nuclear receptor, COUP-TFII95. Mutations or deletion of notch 
genes give rise to arterial defects in mice that often die during embryonic stages. 
Notch signaling also regulates ephrin-Eph family of cell surface proteins that are 
important for arterio-venous formation95. Expression of ligand ephrinB2 is found 
exclusively in arteries while the EphB4 receptor is found singularly in veins and 
alteration of gene function of ephrinB2-EphB4 causes irregularities in arterial-vein 
remodeling.   
The environment surrounding newly formed vessels cords can also promote 
arterio-venous formation. Typically, molecules are secreted from surrounding cells 
that help influence the differentiation process95. One class of secreted morphogens, 
namely, Hedgehog (Hh) proteins–sonic hedgehog (shh) and Indian hedgehog (ihh)–, 
have been shown to be involved in arterio-venous formation through patched (ptc) 1 
receptor via downstream regulation of Notch ligands and receptors95. This 
phenomenon appears to be piloted indirectly via induction of VEGF-A, which stimulate 
Notch proteins via VEGFR and Neuropilin (Nrp) signaling98. Deletion of shh, ihh or 
downstream transcriptional factor, Smoothened, cause arterio-venous abnormalities 
and death in both zebrafish and mice embryos95. Embryonic deletions of VEGF-A or 
its cognate receptors, however, cause a more profound effect resulting in gross 
abnormalities in vasculogenesis, hematopoiesis and overall vascularization and 
causes embryonic lethality. On the other hand, increased expression of shh or VEGF-
	   31	  
A results in exacerbated arterial development95 indicating that an appropriate balance 
of these genetic factors is required for proper arterio-venous formation and later 
development of a function circulatory system. 
Blood flow and pressure also contributes to arterio-venous differentiation99 
although the underlying molecular processes involved in the fate of arterial or venous 
from primary vessel cords remains largely unknown. Once an established 
arrangement of arteries and veins form, expansion of subsequent vascular network 
proceeds mostly by angiogenesis. 
4.1.2. Angiogenesis 
Angiogenesis is described as the formation of new vessels from pre-existing 
ones. There are two types of angiogenesis that exist: sprouting angiogenesis, 
spearheaded by specialized endothelial tip cells, and intussusception angiogenesis, 
which is defined as the splitting of vessels via insertion of tissue columns100. The 
exact mechanisms guiding intussusception, however, remain ill defined; as such this 
section will focus exclusively on sprouting angiogenesis. 
Before sprouting can occur, vessels must liberate the mural cell encasing and 
degrade the basement membrane (BM) that lies between the mural cells and ECs. 
Growth factors (e.g. VEGF), mechanical stress and other cytokines can initiate this 
process by inducing expression of matrix metalloproteinases (MMPs) proximally101, 
which degrade the BM102. MMPs also breakdown the extracellular matrix (ECM) 
surrounding the vessels, which release additional growth factors that stimulate 
angiogenesis101. Endothelial-derived Angiopoietin2 (Ang2) release allows for rapid 
detachment of mural cells from ECs. This allows ECs to respond directly to growth 
factors and allow selection of specialized ECs, called tip cells, which lead the 
angiogenic growth front.  
Notch signaling in ECs precipitates selection of tip cells versus stalk cells. 
Notch1 receptor is highly expressed in stalk cells compared to tip cells; tips cells 
express high levels of notch ligand Dll4, which upon binding to Notch1 inhibit tip cell 
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phenotype on adjacent stalk cells103. In contrast, stalk cells upregulate Jag1 that 
antagonizes Notch signaling (through Fringe glycosyltransferases) potentiating tip cell 
phenotype on the adjacent tip cells104. Loss-of-function studies demonstrate that 
inhibition of Dll4 leads to excessive tip cell formation while suppression of Jag1 
results in blunted vascular front with few tip cells selection103. VEGF-A commences 
the process of tip cell formation by binding to Nrp1, VEGFR2 and VEGFR3 and 
rapidly upregulating Dll4 in ECs. Dll4-to-Notch1 signaling on adjacent cells increases 
VEGFR1 (stalk-specific) and downregulates Nrp1, VEGFR2 and VEGFR3 (tip cell 
specific) potentiating stalk cell phenotype in those adjacent cells68. A fine-tuned 
transcriptional control mechanism involving TEL/CtBP repressor complex at the Dll4 
promoter allows ECs to regulate tip cell/stalk cell ratios at the growing front. 
Essentially, tip cells help probe the environment migrating in response to external 
guidance cues. 
Proximal cells (neurons, glia, etc.) secrete guidance molecules in efforts to 
chaperon the growing vascular front in a concerted manner towards non-perfuse 
areas. VEGF is a major chemoattractant cytokine that binds to VEGFR2 on tip cells 
activating Cdc42105, which coordinates filopodia formation. These cellular extensions, 
or arms, sense the environment ahead of the growing front. CXCR4 is also found on 
tip cells allowing it to respond chemotactically to secreted SDF-1/CXCL12. 
Conversely, repulsive cues also steer tip cells to avoid vascularization of unwanted 
areas. Netrins (1,2 & 4) family of secreted proteins can induce tip cell repulsion via its 
receptor, Unc5B106. Netrins can also bind to other receptors (DCC, neogenin) 
resulting in attraction107; however, this appears to depend on the differential 
expression of netrin receptors on tip cells. Roundabouts (Robos) receptors are known 
for their axon repulsive abilities via binding of Slit ligands and EC-specific Robo4 
apparently induces vaso-repulsion; however, there is controversy on whether Slit 
ligands mediate this effect106. Semaphorins are a large family of secreted or 
membrane-bound ligands that bind to receptor complexes Nrp/plexin or plexin 
alone106. Class 3 secreted semaphorins, Sema3E and Sema3F, which bind to 
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PlexinD1108 and Nrp2/PlexinA1109 complexes, respectively, have been shown to 
involved in vessel repulsion108,110. The relative contribution of membrane-bound 
semaphorins in vessel guidance, however, remains to be defined. Ephrin-Eph ligand-
receptor signaling differ in their repulsive abilities as they are exclusively membrane 
bound proteins111; however, ephrinB2-EphB4 signaling is also important for controlling 
tip cell behaviour as ECs lacking ephrinB2 have impaired sprouting112-115. Typically 
vaso-repulsive signals appear to mediate their effect via filopodia/lamellipodia 
retraction (Netrin1) and cytoskeleton collapse (Sema3F)109 but can also affect tip cell 
guidance by modulating VEGFR2 activity (Sema3E, ephrinB2, ROBO4)108,114-117. 
Guidance cues become particularly important in vascular-based diseases where an 
imbalance in vaso-attractive and -repulsive cues can lead to uncoordinated vessel 
growth (see section 4.3).  
Stalk cells that grow behind tip cells have an equally important role during 
angiogenesis by stabilizing vessels and forming lumen68. VEGF-A binding to VEGFR1 
on stalk cells induces elongation and proliferation thus allowing the vascular front to 
advance118. Notch signaling helps stabilize stalk cells by laying down a BM and 
increasing EC adhesion103. Endothelial stalk cells subsequently adjust their shape via 
Rho kinase (ROCK) and Ras-interacting protein 1 (RASIP1) and established a 
defined apical-basal polarity; this process allows adjacent ECs to form tube-like 
shapes using negatively charged glycoproteins on the apical cell surface to repel the 
surface juxtaposed to adjacent EC119. 
Once properly formed, vessels recruit mural cells to protect and support it. In 
capillaries, differentiated pericytes line the endothelium while smooth muscle cells 
(SMCs) cover larger arteries and veins. Mural cell recruitment is initiated by release of 
transforming growth factor β (TGF-β) and PDGF-B, which induces migration, 
differentiation and proliferation of mural cells120,121. Defective PDGF-B or TGF-β 
signaling can result in improper mural cell coverage of vessels and can lead to 
vascular deficiencies and hemorrhaging120. Recruited mural cells deploy an ECM to 
reinforce stability of neovessels while production of sphingosine-1-phosphate receptor 
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(S1PR), Notch3 and Ang1 help improve EC/mural cell interaction68. Finally, when 
vessels mature, ECs become quiescent and maintain their survival by autocrine 
release of fibroblast growth factor (FGF) and Ang1 that reinforce tight-junction 
proteins (claudins) and cell-adherence proteins (VE- and N-cadherin) as well as 
intracrine production of VEGF, which stimulates PI3K/Akt pro-survival molecules68. 
4.1.3. Arteriogenesis 
Smaller vessels have the capacity to form larger vessels via a process known 
as arteriogenesis. Arteriogenesis, however, is not limited to simply to ‘artery’ 
formation as the name suggests; rather, smaller vessel also have the aptitude to form 
veins and venules as well. Vessels adjust their size and diameter to accommodate 
increased blood flow122. For this reason the largest arteries and veins are found 
where blood flow is maximal. 
The major factor precipitating arteriogenesis is blood flow122,123. Increased flow 
in a vessel causes flow shear stress (FSS), which can activate ECs. The exact 
receptor or molecular response that occur on ECs as a result of FSS remains to be 
defined. What is known is that ECs increase cell-surface ICAM-1 and secrete GM-
CSF to attract monocytes and leukocytes to the designated areas122. Monocytes 
differentiate into macrophages and along with leukocytes stimulate EC growth via 
proximal release of VEGF and TNF-α122.  
Expansion and growth of vessels also requires multiplication of SMCs 
surrounding the engorging vessel. Macrophage-derived MMPs aid this process by 
breaking down the ECM, which liberate SMCs and allow them to proliferate and 
expand123. Release of basic FGF and PDGF-B from activated macrophages and ECs, 
respectively, provides the necessary proliferative potential for SMCs122,123. 
Proliferating SMCs cover the expanding vessel and reform the ECM.  
Increased vessel diameter proportionally decreases FSS stunting further 
vessel expansion. EC return to their quiescent form and SMC redifferentiate into a 
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contractile phenotype122. Under normal circumstances, arteriogenesis rarely occurs in 
adulthood. 	  
4.2. Formation of the retinal vascular network 
Vascularization of the human retina begins at 16th week of gestation and 
occurs by a combination of vasculogenesis and angiogenesis94. Vessels form de 
novo by aggregation of haemopoietic progenitor cells (angioblasts) near the optic disc 
that differentiate into endothelial cells (ECs) forming the primitive structures of the 
vessel network by vasculo-genesis124. Vessel sprouting occurs subsequently via 
sprouting angiogenesis, whereby new ECs are formed from pre-existing cells94,124-127.  
Vascularization of the primary retinal surface augments in response to low 
tissue oxygen levels driving hypoxia inducible factor-1α (HIF-1α)-mediated increases 
in VEGF and Epo25,26,38,72. These guidance molecules are secreted from proximal 
neuroglia118 as well as closely intertwined astrocytic bed128 and retinal ganglion cells 
(RGC)129 creating an effective gradient130, which help guide sprouting vessels towards 
non-perfuse areas until it reaches the peripheral retina. Astrocytes and RGC lay 
appropriate scaffolding support for the growing vessel front via upregulation of R-
cadherin131 and integrin αVβ8132, respectively. Non-hypoxia mediated angiogenic 
cues, IGF-1 and angiopoietins also increase during retinal vasculature 
development27,133. Sprouting angiogenesis is piloted by tip cells enriched with 
receptors for VEGF (VEGFR2 and VEGFR3)118, Netrins (Unc5B)107, EphrinB 
(EphB2)114 and semaphorins (Nrp1)134. This allows tip cells to sense their 
environment giving directionality to the advancing vessel front either by attraction or 
repulsion.  
Stalk cells proliferate and form lumen in the wake of tip cells; they receive 
specific cues from the surrounding environment (VEGF) and the growing vascular 
front (Dll4)104,118. β-catenin and VE-cadherins are tight junction proteins up-regulated 
in stalk cells increasing cell-cell adherence and stability of proliferating ECs135. As the 
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growing vascular front reaches the periphery the pre-existing vascular bed undergoes 
leukocyte-mediated pruning and remodeling, thus avoiding over-oxygenation of the 
tissue136.   
Once the primary plexus becomes vascularized, formation of the inner retinal 
vasculature ensues. Tip cells sprouting from the primary plexus dive towards the 
photo-receptors (outer vascular plexus) guided by resident myeloid cells via non-
canonical Wnt5a-Flt1 (VEGFR1) signaling137. Vessels migrate using scaffolds 
provided by cell surface R-cadherin131 and integrin αVβ8 expressed on Müller cells132 
while simultaneous secretion of Wnt proteins from these cells (Norrin, Wnt3a, 7a and 
10a) activate canonical Wnt signaling on retinal endothelium via low-density 
lipoprotein receptor protein 5 (Lrp5) and Frizzled4 allowing migration of ECs into the 
deeper layers of the retina138-140. Upon reaching the photoreceptor layer, vessels turn 
and begin proliferating towards the peripheral retina, presumably through the vessel 
repulsive cue, Sema3F expressed by underlying retinal-pigmented epithelium 
(RPE)141, and via suppressive Wnt5a-Flt1 signaling on retinal myeloid cells137. 
Despite these recent advances, however, the mechanisms guiding vascularization of 
the intermediate vascular plexus (between superficial and outer vascular plexus) 
remain largely unknown. 
Maturation of vessels is required for stability and maintenance of the final 
retinal vascular network. This is fulfilled by mural cell (pericytes or SMCs) recruitment 
via PDGF-B and TGF- β120,121. Once ECs mature, they remain quiescent maintaining 
their own stability and homeostasis via autocrine or intracrine release of EC-specific 
FGF, VEGF and Ang168. Complete vascularization of the retina concludes at term (i.e. 
40 weeks)24. 	  
4.3. Neurovascular coupling in angiogenesis 
The process of innervation and vascularization has been proposed as being 
anatomically coupled by Vesalius in the 16th century142. Later in the 19th century, use 
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of the light microscope permitted Ramon y Cajal to illustrate this phenomenon for the 
first time showing the coupling between neurons, glia and vessels143. Only recently, 
however, are we beginning to unravel the molecular mechanisms involved in the 
processes of innervation and vascularization, which is profoundly overlapping106. 
Vessels and neurons share high similarities in their growth projection 
patterning, particularly in the skin and the CNS where neurons and vessels are in 
close proximity106. Although neurons differ slightly from vessels in that a single 
neuronal axon can travel large distances before reaching its target, the axonal 
terminal growth cone and the vascular sprouting tip cell share analogous anatomical 
structures demonstrating the overlapping similarities between nerves and 
vessels106,144. Nerve cell axons grow in an atypical manner protruding axonal growth 
cones towards potential innervated targets; these growth cones extend filopodia 
allowing them to sense their environment guided by varying gradients of growth 
factors and repulsive cues. In a similar way, tip cells protruding from pre-existing 
vessels extend their filopodia outward guiding the vascular front towards non-perfuse 
areas105,144. In this fashion, nerves and vessels extend their networks often in parallel. 
Nerves and vessels cross communicate to satisfy their physiological needs; 
whereas neurons require oxygen and nutrients provided by the vascular network, 
vessels themselves require innervation to control vaso-dilation or constriction. Quite 
often, vessels and nerves grow in tandem utilizing similar growth paths. Evidence of 
this effect can be shown at the molecular level whereby neurons can release vascular 
proliferative factors (such as VEGF-A) in attempts to attract vessels106. Conversely, 
endothelial cells can secrete neuronal growth factors (such as NGF and Neurotrophin 
3 [NT-3]) that draw axonal growth cones alongside growing vessels145. Many other 
secreted neuronal molecules have recently been shown to affect vascular patterning 
and are typically secreted proximally to help guide axonal growth cones and vascular 
tip cells106,144; these molecules are discussed in detail below. Similarly, vascular 
survival factors have been shown to induce survival pathways in neurons146 further 
highlighting the importance of neurovascular coupling in maintaining homeostasis.  
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4.3.1. Nerve growth factor and neurotrophins 
Nerve growth factor (NGF) was one of the first neuronal secreted molecules 
identified as having post-natal angiogenic properties147. Initially, NGF (expressed also 
by ECs) was found to have pro-survival role in human umbilical cord ECs (HUVECs) 
and pig aortic ECs in vitro, but was later shown to have chemotactic properties on 
ECs expressing the trophic receptor for NGF, tropomyosin-receptor kinase (trk), 
which induce endothelial cell migration and proliferation in vivo and in vitro145. 
Moreover, over-expression of NGF during vascular injury enhances reparative 
angiogenesis148 further highlighting the importance of NGF in vascular diseases. Later, 
other neurotrophins, BDNF, NT-4/5 as well as NT-3, were identified as having pro-
angiogenic properties via their cognate trkB and trkC receptors, respectively145.  
Downstream signaling of NTs (NGF, BDNF, NT-3) on trk receptors signal 
typically via Akt/PI3K, which in turn activate upregulate VEGF-A expression in ECs 
mediating their angiogenic actions. VEGF-A can, in turn, activate eNOS propagating 
EC migration, proliferation and survival145. NTs can also stimulate production of MMP-
2145, which facilitates these processes in vivo. Conversely, NT can also signal 
apoptosis in ECs upon binding to its low-affinity neurotrophin receptors, P75NTR and 
sortilin149; this effect is typically observed whereupon pre-cursor neurotrophin 
isoforms (e.g. pro-NGF, pro-BDNF) accumulate during diseases (such as DR81,82), 
which have a markedly increased affinity for P75NTR145,149. However, there are 
conflicting studies regarding the atypical expression of endothelial P75NTR; that is, its 
expression depends largely on organ type and disease under investigation150-152.  
The importance cross-talk between NT and vessels can be demonstrated by 
gain-of-function or loss-of-function studies. In development, global knock out of BDNF 
reduces EC cell-cell contacts and increases intraventricular hemorrhaging153. 
Similarly, mice embryonically knocked out for trkB suffer from low blood vessel 
density and increased number of apoptotic ECs in the subepicardial regions of the 
heart154 indicating that BDNF-trkB signaling is responsible for cell survival and 
stimulating angiogenesis. Moreover, defects in BDNF or trkB result in significantly 
	   39	  
reduced CD133+ endothelial stem cell (ESC) migration, which comprises a portion of 
the vascular response mediated by BDNF155. Embryonic deletion of NT-3 in mice 
generates abnormalities in larger vessels formation and causes defects in myofibril 
formation of the truncus arteriosus156. Although embryonic deletion of NGF causes 
severe neuronal defects, genetic modification studies demonstrating the effect of NGF 
in vascular development remain lacking. In adult pathological angiogenic studies, 
neutralizing antibody to NGF in a hindlimb ischemia model reduces the overall 
angiogenic response and subsequent blood flow recovery148. Exogenous 
administration of NGF or BDNF causes the inverse. BDNF has similar effects as NGF 
whereby both NTs induce VEGF-A-mediated vessel formation and increase blood 
flow recovery in a hindlimb ischemia model145. In the retina, mice exposed to OIR 
model show increased NGF expression during peak neovascularization157. In DR, 
both NGF and BDNF were found to be significantly increased in the retina of diabetic 
patients and can stimulate CD133+ EPCs migration and proliferation both in vivo158 
and in vitro159. The latter study demonstrated that NGF had no direct effect on human 
retinal EC proliferation and migration159 indicating that NT-activated EPCs may play a 
more pivotal role in vasculopathies in the retina.  
4.3.2. Netrins and their receptors 
Netrins were first identified in the brain midline having chemoattractant abilities 
whence they bind to their receptor deleted in colorectal cancer (DCC)160. This would 
allow axons from commisural neurons to cross over the midline to reach their 
appropriate innervation target. Defects in DCC receptor or their ligands cause defects 
in midline crossing of commissural neurons161,162. Netrins can also bind to the Unc5 
receptor family (a-d)144, which induces repulsion in other neuronal axons163,164. 
In vessels, Netrin1 has shown to have an effect on vessel guidance inducing 
vessel repulsion by specifically binding to Unc5b receptor, which is enriched on 
endothelial tip cells. Treatment of netrin1 induces filopodia retraction on cultured 
endothelial cells and effectively guides intersegmental vessels (ISV) in zebrafish via 
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its receptor Unc5b165. Loss-of-function experiments in zebrafish show increased 
filopodia extension and misguidance of sprouting ISV upon inhibition of Unc5b. In 
mice, homozygous deletion of unc5b causes capillary defects increasing filopodia 
numbers and increasing vessel branching in embryos165. Similarly, in the retina 
injecting Netrin1 causes activation of Unc5b and retraction of endothelial cell 
filopodia165. Thus, Netrins play an important role in regulating normal vessel sprouting 
by controlling EC sprouting, migration and invasion. Also, Netrin1 and 4 expressions 
can be induced in EC following exhaustive VEGF stimulation, which can antagonize 
VEGF-induce cell migration and proliferation (as a negative feedback regulator)166. 
This effectively shows that EC have the capacity to regulate growth and invasion 
under normal circumstances via Netrin secretion. Interesting, endothelial Netrin 
expression can potentially affect proximal neuronal axon projections that grow in 
parallel in the development; however, this phenomenon has yet to be explored. 
In pathological settings, netrin appears to have dual roles. Several studies 
report inhibition of tumor invasion167 or reduced neovascularization in animal models 
of pathological angiogenesis, such as laser-induced choroidal neovascularization 
(CNV)166 and matrigel neovessel sprouting167, whereby Netrin1 and/or 4 effectively 
stalls proliferation and migration of ECs. Contrary to this, treatment of plasmids 
containing Netrin1 and 4 accelerated neovascularization in a hindlimb ischemia model 
in mice and can reverse neuropathy and vasculopathy in a diabetic mouse model107. 
The exact signaling mechanism, however, by which Netrins induce their differential 
roles in these pathological models, remains unclear. Reportedly, Netrin receptors 
have been found on cell types other than neurons and endothelial cells, such as 
macrophages/monocytes, which may have an indirect effect on angiogenesis144 and 
account for the differential effect of Netrins in vivo. 
4.3.3. Semaphorins, Neuropilin and Plexins 
Semaphorins are a large class of membrane-bound or secreted proteins that 
were initially described as having repulsive effects on neuronal axons in 
	   41	  
grasshoppers168. The secreted family or Class 3 semaphorins have been extensively 
studied in both neuronal and vascular patterning; semaphorin3A (Sema3A), initially 
called Collapsin due its neuronal growth cone collapsing properties, was the first 
mammalian identified semaphorin169. Later on other semaphorins were identified and 
finally consolidated into a single family based on their homologous structures170. 
There are eight (8) classes of semaphorin, two of which are exclusive to invertebrates 
(Class 1 and 2), one belonging to virus (Class V) and five (5) mammalian 
semaphorins (Class 3 to 7)170. This section will focus only on mammalian 
semaphorins (3 through 7). 
Semaphorin Classes 4 through 7 signal via direct binding to their Plexin 
receptors (A-D) while Class 3 semaphorins bind to their Neuropilin (Nrp1 and 2) co-
receptor, which then recruit Plexins to signal downstream171. Nrps have shortened 
intracellular regions that cannot signal intracellularly, which is why Plexins and Nrps 
are typically co-expressed on receptive cells to potentiate secreted Sema3 
signaling171. Commonly, plexins contain cytosolic GTPases, GTPase activating 
protein (GAP) activity, GTPase regulators or guanine-nucleotide exchange factors 
(GEFs) to transduce intracellular signals172. These signals frequently activate R-Ras 
or Rho (small G-proteins) that lead to downstream cytoskeleton rearrangements and 
repulsive axon guidance173,174. For instance, Sema4D binds to PlexB1 and stimulates 
RhoGEFs, which augments RhoA activity leading to actin-dependent reorganization of 
the cytoskeleton175. Similarly, Sema4D-PlexB1 complex signaling inhibits cell 
migration and axon outgrowth; this occurs via ErbB2, Rho kinase and 12-15 
lipoxygenase, which are involved in cellular morphogenesis and collapse173. 
Conversely, Sema4D in complex with PlexB2 promotes cell migration and axon 
growth via Met and Ron receptors, Pyk2, Src, Akt and PI3K pathway176. Anomalies in 
semaphorin signaling have been associated with many neurological diseases 
including Parkinson’s, retinal degradation and motor neuron degeneration177,178, which 
make semaphorins substantially important for neural development and have been 
recent targets for therapeutic venues. 
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Class 3 semaphorins are the most documented class having a substantial role 
in modulating angiogenesis. Sema3A competes directly with VEGF-A isoforms for 
binding to Nrp1 receptor to potentiate endothelial cell repulsion and inhibit 
angiogenesis179-181. When Sema3A binds to Nrp1, this complex can associate with 
PlexA1182 to inhibit cell adhesion via downregulation of Integrin-α5β1. At higher 
concentrations, Sema3A can induce caspase-3-mediated EC apoptosis134,183. Despite 
these findings, the exact mechanism by which Sema3A directs tip cell guidance has 
not been yet been elucidated. Insights into this mechanism can be found in studies on 
Sema3F, which inactivates RhoA to induce cytoskeleton collapse in human glioma 
cells upon binding to Nrp2 and PlexA1109. Similarly, Sema3B has shown to have anti-
angiogenic properties184. Sema3E-PlexD1 signaling also controls angiogenesis in a 
more intricate mechanism by negatively regulating VEGFR2 signaling in tip cells in 
the developing mouse retina108. 
Semaphorins have also been linked to cancer, particularly with cell metastasis, 
angiogenesis, viability and tumerogenesis (review in 185). Interestingly, studies show 
that some semaphorins exacerbate tumors while others diminish them. For example, 
Sema3F binds Nrp2, which inhibits E-cadherin-mediated cell adhesion and repulses 
breast and lung cancer cells, lowering their tumorigenicity186,187. Conversely, Sema3C 
maintains ovarian carcinoma survival by resisting cis-diammine-dichloroplatinum 
(CDDP)-mediated inhibition of metabolic enzymes (i.e. de-hydrogenases, 
synthases)188. 
 
4.3.4. Slits and Roundabouts 
Slits are large secreted proteins that bind to single passage transmembrane 
receptors, roundabouts (Robo)189,190, typically found on axons growth cones to 
mediate repulsive actions but can stimulate branching and elongation depending on 
the neurons that they are expressed106. In mammals, there are three (3) Slit secreted 
proteins and four (4) Robo receptors, one of which being EC specific (Robo4)191. 
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While better known for their axon repulsion on commissural neurons crossing the 
midline192, Slits have also been implicated in kidney induction193, leukocyte 
migration194 and angiogenesis195.   
 Robo4 plays an integral role in vessel formation by maintaining blood vessel 
integrity and number. In normal vessel development, Robo4 expression appears to be 
expressed in stalk cells, which inhibits VEGFR2 (directly or indirectly) to prevent 
sprouting angiogenesis behind the growing vascular front117. These results further 
contribute to the already complex mechanisms involved in regulating VEGF receptors 
in stalk cells involving Notch signaling pathways103,104. Intriguingly, Robo4 knockdown 
in zebrafish causes a lack of EC sprouting angiogenesis of ISV due to lack of proper 
tip cell guidance196, which differs significantly from the studies performed in mice 
whereby knockout of Slits2 and 3 or Robo4 causes significant increase in blood 
vessel density and complexity in breasts116. This indicates that although mice and fish 
share similar ectopic expression of Robo4 in ECs, the evolutionary function differs 
significantly.  
Mammalian Slit-Robo4 signaling also contributes to decreased angiogenesis in 
various models of pathological vessel formation in the eye. In the retina and choroid, 
Slit2 can activate Robo4, which inhibit VEGFR2-induced Src and downstream Rac1 
activation resulting in decreased pathological angiogenesis and hyper-permeability117. 
Interestingly, Robo1 has been reportedly found in the endothelium; however, there is 
much conflict in the literature regarding its localization and function in ECs116,144. More 
studies are required to identify the role of Robo1 in blood vessel formation. 
4.3.5. Ephrins and Eph receptors 
Eph receptors and their Ephrin ligands make up another class of short range 
signaling molecules with capacities for attraction and repulsion. Ephrins were first 
identified as repellent axon guidance molecules in the establishment of RGC axonal 
projections towards the brain197,198, but were later found to have roles in axon 
guidance at the midline, dendritic spine formation, guidance of neuronal cells, and 
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synaptic plasticity. In mammals, Eph receptors are categorized into two classes, A 
(EphA1-8) and B (EphB1-4 and EphB6), although they share structural similarity 
belonging to a larger family of Receptor Tyrosine Kinases (RTKs), which are single 
passage transmembrane receptors199. Ephrin ligand classed into A and B 
nomenclature as well but are distinct from each other based structural properties; 
EphrinA are anchored to the membrane via a glycosyl-phosphatidyl-inositol 
modification while EphrinB ligands contain transmembrane passages and cytoplasmic 
regions199. Eph A or B receptors typically bind Ephrins ligands of similar class (e.g. 
EphrinB to EphB), although there has been reports of cross-reactivity106. The most 
intriguing characteristic of Eph and Ephrin family of proteins is their ability to initiate 
both ‘forward signaling’ and ‘reverse signaling’; that is, upon binding Eph receptors 
initiate ‘forward signaling’ process on the receiving cell whereas the initiating cell 
signals simultaneously to propagate Ephrin-mediated ‘reverse signaling’199.  
Eph receptors and Ephrins have been extensively studied in the vascular 
system111. Much attention has been focused on Class B Ephs and Ephrins, which 
impart critical roles in various facets of vascular development; namely, 
vasculogenesis, sprouting angiogenesis and mural cell recruitment111. During early 
vascular development, for instance, EphB4 and ephrinB2––controlled by VEGF and 
Notch signaling––have important implications in arterial and venous specifications, 
respectively, and are critical for their maintenance95.  
The studies demonstrating the role of class B Eph-Ephrins in angiogenesis 
remain, thus far controversial. For instance, in mice, ephrinB2 help navigate 
protruding EphB3/EphB4-expressing ISVs through tissue boundaries preventing them 
from entering the somites supporting the repulsive role of Eph-Ephrins in 
angiogenesis114,115. Knockdown of ephrinB2 or its receptors EphB2 or B3 causes 
significant impairment in angiogenesis and remodeling of the vascular system114,115. 
Other studies, however, demonstrate that ephrinB2-EphB4 through forward and 
reverse signaling can stimulate sprouting angiogenesis and EphB4 activation leads to 
increase EC migration and proliferation through PI3K, Akt and integrin activity200,201.  
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Moreover, ephrinB2 limits angiogenesis via regulation of VEGR2 expressed on 
ECs112,113. While the role ephrinB-EphB signaling appears to demonstrate causal 
roles in angiogenesis, further studies are required to clarify their exact role of Eph-
Ephrins in this process. 
EphrinB2 also precipitates proper formation of mural cell-EC contact111; this 
occurs presumably through EphB binding on EC, although evidence alluding to this 
effect is lacking in the literature. Mural cell specific deletion of ephrinB2 results in poor 
mural cell adhesion and they fail to envelop endothelial monolayers202. Global 
deletion of ephrinB2 in mice results in perinatal lethality, edema and skin 
hemorrhaging202. EphrinA1-EphA4 also play a fundamental role in vSMC as well by 
controlling contractility, vascular tone and blood pressure via RhoA and Rac1203,204. 
Aside from its role in mural cell recruitment, EphrinA1 in cancer has been recently 
highlighted whereby ephrinA1 expressed on tumor cells help guide EphA2-expressing 
vessels towards the tumor and stimulate angiogenesis205.  
  
The evidence supporting neurovascular coupling is substantial. Of course, 
several neuronal guidance cues appear to have controversial roles (Robo4, ephrinB2-
EphB4); notwithstanding, their functional role in vessel formation remains 
substantiated. In this section we have covered the implicit role neuronal-derived 
proteins in modulating various facets of vascular biology, the coupling between 
neurons and vessels is unquestionably bidirectional106. In this regard, modulating 
factors through exogenous supplementation or inhibition of certain neurovascular 
cues can and most likely will affect both systems. This may be of particular 
importance in the advent of developing treatments for treating vascular- or neuronal-
based diseases, such as in IRs.  
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4.4 Inflammation and angiogenesis 
 The concept of inflammatory molecules and cells modulating angiogenesis is 
well established in the literature. Under normal conditions, acute inflammation can 
incite reparative angiogenesis; on the other hand, chronic inflammation results in 
significant perturbations in vascular homeostasis206. The contribution of inflammation 
in IRs, is highly pertinent; in DR, chronic inflammation is presumed to have a 
significant impact in the onset and progression of disease89, whereas in ROP, both 
hyperoxic and ischemic insults propagate inflammation as an innate response to the 
insult207. As such, targeting or suppressing key factors in inflammation in efforts to 
abate vasculopathies are now being employed in the treatment of IRs (see section 5 
below). Since immune response is associated with various pathological conditions, 
this section focuses specifically on the relative contributions of key inflammatory 
molecules and cells having potent vaso-modulatory effects in IRs. 
4.4.1. Cytokines and chemokines 
Cytokines and chemokines are large classes of small molecules that impart a 
variety of different cellular functions. Pertinently, cytokines/chemokiens have the 
ability to modulate angiogenesis via direct interaction with ECs or indirectly via 
inflammatory cell activation (see below). The most important of these being VEGF; 
first identified as a vascular permeability factor66, it was discovered to exert powerful 
vaso-proliferative effects upon binding to its receptor on retinal ECs25,73. Conversely, 
VEGF can also exacerbate inflammation by increases ICAM-1 and leukostasis in 
diabetic patients208. Another implicated cytokine is TNF-α that is commonly found in 
the vitreous of patients with IRs and corresponding animal models63,209. Animals 
lacking TNF-α are protected from OIR and inhibition of TNF-α using recombinant 
antibodies inhibits leukocyte adhesion, pericyte loss and capillary dropout in murine 
models of diabetic retinopathy89. However, mice devoid of the main TNF-α receptor, 
TNFR1, display defective neovascular regression and resolution following exposure to 
OIR210, indicating that TNF-α may have a dual role in IRs. 
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Interleukins (ILs) exert powerful immunological functions and have been shown 
to have vaso-modulatory effects. The most common of these is the IL-1 family (IL-1β 
and IL-18). IL-1β binds to its receptor IL-1RI to exert its biological action211 and 
inhibition of IL-1RI protects from diabetes-induced capillary dropout in rats212, while 
use of IL-1 receptor antagonist (IL-1Ra) reduces neovascularization in a mouse model 
laser-induced choroidal neovascularization (CNV)213. IL-18 activation, on the other 
hand, protects mice from OIR-induced retinal NV214 and laser-induced CNV215. IL-6 
has also shown to be implicated in angiogenesis216 and is reportedly elevated in 
patients with PDR and diabetic macular edema compared to non-diabetic control 
patients217; however, few studies have underlined their exact role in IRs. 
Chemokines also contribute to ocular neovascularization. MCP-1 is a powerful 
chemotactic protein for monocytes (macrophages and microglia) and has been 
detected at high levels in the vitreous of patients with PDR83. Studies suggest that 
MCP-1 may be involved in angiogenesis by directly by stimulating VEGF in ECs218 or 
indirectly by recruiting monocytes into the retina, although the latter has not been 
confirmed. CXCL8 (or IL-8) is also reportedly elevated in patients with PDR83 and has 
shown to be directly involved in angiogenesis219 Another important chemokine is 
Stromal-cell derived factor-1 (SDF-1/CXCL12), which stimulates migration and 
proliferation of endothelial cell progenitors (ECPs) into the retina85, or angiogenesis by 
directly upregulating VEGF in ECs86. 
4.4.2. Other relevant molecules 
NFκB is a major transcriptional factor commonly associated with inflammation. 
Its activity is upregulated in various cells in the retina (neurons, glia, ECs) of patients 
and animals suffering from IRs, and its activity further exacerbates the immune 
response by stimulating cytokines and other proteins (such as ICAM-1)83,206. As 
mentioned before, increased ICAM-1 expression in DR patients83 and animal models 
of IRs136,220 contribute to endothelial cell loss and BRB breakdown by increasing 
leukocyte adhesion and activation in diseased retinal vessels65,136. 
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Another class of signaling molecules that bridge the gap between inflammation 
and angiogenesis are protease-activated receptors, a unique class of G-protein 
coupled receptor (GPCR) that undergo proteolytic cleavage at their N-terminal to 
release their tethered ligand, thus activating it221. Classically associated with 
immunological response222, PARs (specifically PAR2) were found to generate 
reparative angiogenesis223. In the retina, activated PAR2 via proteolytic cleavage by 
Tissue Factor (TF) induces developmental and pathological angiogenesis in 
mice224,225 and is associated with pathological vessel formation in DR patients225. 
Similarly, injection of the agonist peptide corresponding to the tethered ligand of 
PAR2 also stimulated angiogenesis in mice retina via TNF-α and sequentially Tie2133. 
Lipid mediators of inflammation also contribute significantly to angiogenesis 
and pathogenesis of IRs. This has been thoroughly covered in Section 3 and 
reviewed in detail in 34. 
4.4.3. Inflammatory cells 
Activated resident microglia and inflammatory cells recruited to the retina 
(leukocytes and monocytes/macrophages) have the ability to modulate vessel 
integrity both in development and in IRs. Generally, infiltration of leukocytes and to a 
lesser extent monocytes (which differentiate into macrophages) and activation of 
microglia are associated with pathogenesis of ROP and DR. Their respective roles 
are covered herein.   
Resident microglia are typically the immuno-sensory cells of the retina 
engaging in the innate immune response to stressors, such as EC injury226. Initially, 
microglial precursors migrate into the retina during late embryonic development and 
early postnatal period227. Herein, they differentiate into their mature form performing 
largely phagocytotic actions and eliminating cellular debris from apoptotic neurons228. 
In retinal diseases, microglia––being the first line of defense in the retina––are 
majorly likely responsible for the increased inflammation in the retina observed in DR 
patients89 and in various models murine of DR and OIR226. More specifically, in 
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diabetic patients, there is an important induction of cytokines produced locally in the 
retina229, which is accompanied by activation of resident microglia89, which associate 
with vascular lesions, pathological vessel formation and areas of hemorrhaging84. 
Non-selective inhibition of microglia by minocycline reduced retinal inflammation in 
diabetic rodents209, indicating that microglia contribute to vasculopathy in IRs. In ROP 
the exact role of microglia are not well defined although their numbers are known to 
increase in the retina of mice undergoing OIR226.  
 Leukocyte and monocyte infiltration are also hallmarks of inflammation and 
has shown to be upregulated in IRs. Increased expression of ICAM-1 in ECs in IRs83, 
coupled with increased expression of MCP-183 (likely from microglia226), causes 
increased leukostasis and adhesion of monocytes in the retinal vasculature89. 
Inhibiting ICAM-1 or CD18, another inflammatory cell adhesion protein, results in 
decreased retinal inflammation and EC degeneration136,220. Leukostasis contribute to 
microvascular damage by increasing cytokines, superoxide or by physically occluding 
capillaries89. Monocytes/macrophages appear to contribute to the latter stages of the 
disease whereby they associate with neovascular tufts230. Inhibiting macrophages 
using clodronate liposomes decreased neovascularization formation in mice exposed 
to OIR231. 
Essentially, these studies highlight the important cross-talk between vessels 
and immune cells, which engage in bidirectional communication in both development 
and pathology in the retina, whereby Inflammatory molecules bridge the 
communication between vasculature and immune cells. In the retina, neurons also 
cross communicate with immune cells, which has been shown in the CNS232. 
However, to date there have been no studies highlighting a tripartite communication 
between neurons, vessels and immune cells in IRs. Since the neurovascular unit is 
quite dynamic and important in both development and pathology, it may be plausible 
that this cellular interaction contributes to vessel injury. 
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5. Current treatments for Ischemic Retinopathies 
Treatment of IRs typically involves ablating pathological neovessel formation in 
the retina and diminishing vitreous and retinal bleeding. Physical methods still remain 
a standard for treating IRs (laser photocoagulation); however, with the advent of anti-
VEGF treatment in 2006 biochemical products are now being employed in the clinic 
either alone or in combination with laser treatment. Unfortunately, accessing the 
neuro-retina has proven difficult due to the blood-retina-barrier; thus, these products 
are typically injected intravitreally, which often generates other complications 
(infection or raised intra-ocular pressure, IOP). 
5.1. Retinopathy of Prematurity (ROP) 
Laser photocoagulation is currently the only well-established therapy for 
treating ROP patients with threshold ROP (between stage 3 and 4)11. Typically an 
argon or diode laser is used for cauterizing pathological blood vessels and 
simultaneously burns peripheral tissue to reduce successive neovessel formation by 
damaging neuronal tissue that instigates the ensuing vascular response233. Although 
laser treatment improves visual outcomes and results in fewer side effects, there is 
significant loss of peripheral retinal function233. Furthermore, this treatment modality 
does not provide reconciliation for decreased central vision function that has been 
associated with ROP. 
Anti-VEGF treatment has been introduced in the clinic for neovascular eye 
diseases such as age-related macular degeneration and DR (see below) but its use in 
ROP remains controversial. One study used bevacizumab (antibody targeting VEGF) 
as monotherapy and reported a reduction in neo-vascularization following intravitreal 
administration of bevacizumab; however, patients with zone 2 ROP (see Table 1) did 
not appear to benefit from anti-VEGF treatment and visual outcomes were not 
reported234. Another study demonstrated beneficial effects of bevacizumab injections 
on posterior neovascularization but the sample size was exceedingly low to draw 
conclusive results235. Pertinently, a retrospective review noted severe retinal 
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complications, including complete retinal detachment (stage 5), in ROP patients 
receiving bevacizumab monotherapy236. It should be highlighted that VEGF is a 
potent vascular growth factor118 and crucial during development237 and anti-VEGF 
treatment raises concerns on potential systemic complications (presence of anti-
VEGF in circulation following intravitreal injection238). Moreover, VEGF has recently 
been shown to be a vital trophic and survival factor for retinal neurons146 and RPE239, 
thus anti-VEGF therapy may not be an ideal regiment option for treating ROP. 
A number of reviews are now highlighting the importance of preventative 
measures in efforts to improve ROP incidence and progression2,10,11. Lowering 
oxygen saturation levels has been exercised in the clinic with the goal to reduce the 
severity of ROP; however, conflicting studies report varying outcomes on ROP 
progression and is often scrutinized for augmenting mortalities2. Serum levels of IGF-
1, a crucial maternal factor for fetal development, have been shown to inversely 
correlate with ROP severity46 and animals studies demonstrate beneficial effects on 
ROP development by exogenously administrating IGF-155. A recent study showed 
that use of recombinant human (rh)IGF-1 and rhIGFBP3 augments serum levels of 
these proteins in preterm infants56 and clinical trials are now underway using 
exogenous administration of IGF-1 and IGFBP3 (NCT01096784) in efforts to reduce 
preterm complications including ROP.  
5.2. Diabetic retinopathy 
Panretinal and grid laser treatment remains the main prescribed option for 
treating patients with diagnosed proliferative DR or diabetic macular edema, 
respectively3. Since its implementation in 1978240, there has been significant 
improvement in laser therapy. Use of diode lasers has now effectively replaced 
conventional green argon lasers241, which diminishes perturbations at the 
photoreceptor-RPE layer previously observed with green lasers3. Laser 
photocoagulation, however, does have its limitations; that is, it is not recommended 
for persons with predominant macular ischemia, bleeding in or near the fovea and 
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was found to be ineffective when repeatedly performed on patients with history of 
laser therapy3. In this regard, laser treatment has been superseded by anti-VEGF 
treatment for diabetic macular edema in some countries; however, panretinal laser 
treatment remains the only standard treatment for proliferative DR3,4. 
The introduction of anti-VEGF therapy has facilitated the transition from 
physical methods to biochemical treatments for DR. While the main objective for anti-
VEGF treatment is to reduce vascular leakage–typically recommended for diabetic 
macular edema–3,4, there is also a potential benefit for reducing pathological 
neovascularization precipitated by VEGF92. Bevacizumab (Avastin®), a humanized 
mouse monoclonal antibody to VEGF-A, is an off-label treatment used for patients 
with diabetic macular edema having high efficiency and low cost242-244; however, it 
has yet to be approved for clinical use. Ranibizumab (Lucentis®), having a higher 
affinity for VEGF-A and is much smaller in size than bevacizumab, is typically 
prescribed in the clinic due to its high efficacy in reducing macular edema3. Aflibercept 
(Eyelea®), a fusion protein consisting of the VEGF binding domain of VEGFR 1 and 2 
and the immunoglobulin domain (IgG), has a higher affinity for all VEGF-A isoforms 
and placental growth factor (PlGF) and competes well against the other anti-VEGF 
molecules due to fewer required injections245; this being the major setback for anti-
VEGF molecules in that they have to be injected intravitreally, which imparts other 
complications including eye infection (endophthalmitis) that can significantly worsen 
vision3,4. There is also rising concern about anti-VEGF treatments entering the 
circulation and causing systemic complications; however, there are no studies that 
report any adverse systemic complications thus far. Despite its high cost, ranibizumab 
is the only anti-VEGF treatment approved by the Food and Drug Administration (FDA) 
and Emergency Medical Association (EMA). 
Inflammation plays a significant role in DR. Thus, the use of steroids has been 
recently employed in efforts to reduce inflammatory-mediated vascular permeability 
and hence diabetic macular edema. The fluocinolone implant (Iluvien®), which 
releases fluocinolone acetonide over a period of 36 months, is injected into the 
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vitreous cavity of patients suffering from diabetic macular edema. Despite the 
reportedly high occurrence of cataracts, the fluocinolone implants showed high 
effectiveness in reducing macular edema in DR patients246. Previously, Triamcinolone 
was prescribed for diabetic macular edema but prevalence of cataracts and glaucoma 
has restricted its use for diabetic macular edema247. Dexamethasone is one anti-
inflammatory steroid that has been highly effective in treating macular edema in 
patients suffering from retinal vein occlusion (RVO) whereby a biodegradable drug-
delivery implant is injected into the posterior segment of the vitreous cavity3,248. The 
EMA and National Institute for Health and Clinical Excellence (NICE) have approved 
this long-acting drug delivery system for RVO and clinical trials are underway for use 
in diabetic macular edema. Pertinently, steroids affect principally inflammatory 
cytokines, including VEGF, thus highlighting its potential for proliferative DR3; 
however, the use of steroids has consequently not been approved for patients with 
vaso-proliferative DR. Advantageously, long-acting steroid delivery system reduces 
the necessity of repeated injections often required with anti-VEGF treatment regimes. 
Nevertheless, there is the recurrent problem of cataracts and increased ocular 
pressure (IOP) in patients treated with intravitreal steroids, which often requires 
surgery. 
Management of diabetes is now common practice in the clinic in efforts to 
delay or prevent the progression and onset of DR. Typically the most proliferative 
treatment prescribed is insulin injections in attempts to avoid chronically elevated 
blood sugar levels––which appear to precipitate the early phases of DR––and reduce 
the onset of DR (clinical trials NCT00360815; DCCT; UKPDS)249-251. This is usually 
coupled with strict glycemic control as well (food intake, for instance)3. Other 
treatments involve targeting the renin-angiotensin system, such as Lisinopril® (clinical 
trials EUCLID)252, an angiotensin converting enzyme (ACE) inhibitor, as well as beta 
blockers (clinical trials UKPDS)251,253, which are used to control blood pressure in 
patients with type 2 diabetes and have been shown to reduce the risk of incidence of 
DR. Enalapril®, an ACE inhibitor, in combination with Losartan® (clinical trials RASS; 
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NCT00143949)254	   and Candesartan® (clinical trials NCT00252720; DIRECT-1)255, 
angiotensin II receptor inhibitors, are used for type 1 diabetic patients to control blood 
pressure displaying positive effects on risk of progression and incidence of DR, 
respectively. It should be noted that these treatment regimes are directed for patients 
with no clinical signs of retinopathy. On the other hand, Fenofibrate®, an activator of 
peroxisome proliferator activating receptor alpha (PPARα) is prescribed typically to 
type 2 diabetic patients with mild-to-moderate DR to reduce lipid levels with effective 
reduction in progression to PDR and macular edema (clinical trials 
ISRCTN647833481; NCT00542178; FIELD; ACCORD-eye)256. Advantageously, 
these metabolic-targeting treatment regimes help hinder DR progression and onset, 
which, in some cases, reduces the necessity of intravitreal injections of anti-VEGF 
and laser therapy253,257. While proper diabetes management may prevent the 
progression and onset of DR there are still some patients that progress into mild or 
severe forms of DR indicating that are other unknown factors involved in disease 
onset.   
While many treatments aim to curb vascular leakage or neo-vessel formation in 
IRs, there are no existing regimes that focus on curbing vascular decay or the 
ensuing hypoxia secondary to vessel loss. Preventative measures attempt to 
minimize, retard or even prevent vascular degeneration but there are a subset of 
patients that accede to the onset of retinopathy. Moreover, as summarized above, IRs 
are multifactorial indicating that monotherapy may not be sufficient to curb vascular 
anomalies associated with these diseases. Thus, other therapeutic avenues must be 
introduced––in combination with the current therapies––to combat these sight-
threatening illnesses. 
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6. Problem and general hypothesis 
Evidence highlighted above demonstrates that the neurovascular unit engages 
in bidirectional cross-talk between neurons, neuroglia and vessels. While we may 
have sufficient understanding of these processes in the developing tissue, few studies 
have demonstrated this phenomenon in pathological settings. Ischemic Retinopathies 
(IRs) are classified as such due to the systematic vessel loss that precipitates retinal 
cell ischemia, which can cause significant biochemical changes (inflammation, for 
instance) or even cell death. During this ischemic phase, lack of nutrients and oxygen 
prompts a massive vascular response in efforts to reinstate retinal homeostasis; 
however, instead of vascularizing the appropriate areas, vessels are misguided 
towards the vitreous. This appears rather counterintuitive in that surrounding hypoxic 
neurons and glia secrete angiogenic factors (particularly VEGF) that should retain 
vessel on the retinal surface. Thus, other forces are likely at play. It may be plausible 
that, in the retina, cells undergoing massive ischemia may secrete signals in efforts to 
divert metabolic stores away from perishing tissue. 
  
Based on these premises, we hypothesize that, 1) stimulating angiogenic 
factors while removing endothelial pro-apoptotic molecules from underlying neuronal 
or glia cells can help curb vessel loss and reduce retinal ischemia and, 2) specifically 
targeting neuronal-derived secreted molecules involved in vascular repulsion 
(semaphorins, for instance) can reduce misguidance of nascent vessels toward the 
vitreous. Essentially, the purpose of these studies is to identify therapeutic avenues 
that can promptly revascularize neuronal tissue to reduce ischemic stress and, 
consequentially, pathological vessel formation. 
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7. Description of the model: Oxygen-induced retinopathy 	  
The use of animal models has greatly augmented our understanding of 
pathology. In ischemic retinopathies (IR), the development of the oxygen-induced 
retinopathy (OIR) mouse model28 and rat models29 has lead to an exponential 
increase in the understanding of the pathology. Relevantly, over the last 20 years, the 
use of the OIR model has translated to over 10,000 peer-reviewed publications 
(National Centre for Biotechnology Information [NCBI] search using keywords “murine 
and oxygen induced retinopathy” October 31st, 2014) as well as the development of 
various treatment modalities for both ROP and DR2,3,93. 
The main premise for using murine OIR models in this context is to reproduce 
the salient features of ROP (as seen in preterm born babies) in efforts to better 
understand the neurovascular interactions involved in IRs. Notwithstanding, there are 
notable differences between human and murine retinopathologies; they are discussed 
herein. Importantly, the OIR model also reproduces several key features of DR–
particularly the second vaso-proliferation phase–, although the cause of vessel loss is 
vastly different in patients with DR.  
 
7.1 Mouse OIR model 
The mouse model was originally developed by LE Smith, et al.28 to reproduce 
human ROP in a laboratory setting in efforts to better understand the mechanisms 
involved in disease progression. Pre-term birth stunts retinal vasculature progression 
and the ensuing hyperoxic environment ex utero causes retinal vascular degeneration. 
Since the development of the vascular superficial plexus in mice begins post-natally 
(as of day 0)–corresponding to gestational week 16 in infants94– mice pups are 
exposed from post-natal day 7 (P7) to P12 to a high oxygen environment (75% O2) 
resulting in a halt in vascular growth followed by a substantial decay of retinal 
	   57	  
vessels125. This first phase of obliteration occurs centrally in mice retina while in 
humans loss of vessels occurs exclusively in the peripheral retina. Once the mice are 
returned to normal air, revascularization occurs and, as a result of the substantial 
vessel loss, retinal ischemia sets in (as seen in pre-term infants). Thus, the retina 
mounts an over-compensated uncontrolled vessel growth that, instead of perfusing 
the ischemic core, is misguided towards the vitreous. In humans, neovascularization 
typically occurs at the threshold between the central vascularized and peripheral 
avascular areas forming a ridge; in mice, neovascular ‘tufting’ occurs in an around the 
central area. This disparity likely accounts for why retinal detachment is almost never 
observed in mice. Notwithstanding, the pathomechanisms involved in the vessel loss 
and neovascularization are similar in mice and humans, despite geographical 
discrepancies.  
There are several advantages in using the mouse model of OIR; firstly, the 
ability to genetically manipulate mice DNA in order to insert or remove genes has 
provided enormous insight into the functional roles of certain genes in the patho-
genesis of IRs. For this reason, in chapter 3, we utilized the mice model to genetically 
remove PAR2 gene in efforts to determine its contribution in OIR. Second, the size of 
the litters (between 5 – 10 pups) provides sufficient animal numbers to attain 
appropriate statistical differences. Moreover, the gestational period in mice is only 
three weeks allowing for rapid sample collection. Finally, the reproducibility of the 
model allows for easily manipulation of experimental conditions (injections, 
modifications, etc) in efforts to determine their effects on vessel loss and neovessel 
formation. 	  
7.2 Rat OIR model 
The rat model of OIR consists of two types of distinct models described by JS 
Penn et al.29. As in mice, the development of the retinal vasculature occurs post-
natally. Thus, high oxygen model is used for replicating the first phase of ROP in rats 
by exposing them from post-natal day 5 (P5) to P10 to 80% oxygen, which causes a 
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central obliteration of retinal vessels. However, rats exposed to constant high oxygen 
develop much less pathological neovessel formation29; the exact reason why this 
occurs in rats and not mice is not fully understood. For this reason the cycling oxygen 
model is used (to measure neovascularization), whereby rat pups are exposed to 10 
and 50% oxygen from P1 to P14 in 24 h cycles. Importantly, obliteration of the retinal 
vessels and subsequent neovascularization occurs almost exclusively in the 
peripheral retina, which better represents the human pathology as it developed in pre-
term infants exposed to high oxygen levels. Thus, this second model of rat OIR offers 
more suitable insight into the patho-mechanisms involved in neovessel formation 
while the first constant oxygen rat OIR model is used for determining the effects of 
high oxygen on retinal vessel loss.  
The use of both high oxygen and cycling rat models allows one to easily 
monitor disease progression of IRs separately; that is, to see how experimental 
conditions distinctly affect vaso-obliteration and neovascularization. Another 
advantage of the rat cycling model of OIR is the geographical similarities in the areas 
of vaso-obliteration and neovascular formation, as seen in human ROP patients, 
which occur in the peripheral retina. Moreover, in comparison to mice, rat eyes are 
much larger allowing for easy user handling (enucleating and dissecting retinas, 
injections, etc). Also, the litter numbers are typically larger than mice (between 10 – 
12 pups) allowing for rapid attainment of statistical significance. Finally, as in mice, 
the reproducibility of the rat high oxygen and cycling models permits easy 
manipulation of experimental conditions in efforts to determine their effects on vessel 
loss and neovessel formation. 
Although, while some features of the models vary from the actual human 
pathology, our aim was to reproduce the major findings in both models to better 
understand the actual patho-mechanisms occurring in patients suffering from IRs; 
these include: 1) the importance of neurovascular coupling–between neurons, vessels 
and glia–in vascular-based retinal diseases; 2) the contribution of inflammatory 
cytokines (more specifically IL-1ß) in exacerbating these retinal pathologies; and 3) 
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the importance of vascular guidance cues (Sema3A) in perpetuating vascular patho-
phenotypes as seen in patients with IRs. It should be noted that several of the 
unprecedented findings unraveled herein using murine OIR models can be (or have 
been) directly measured in ROP and DR patients (e.g. increased vitreous levels of IL-
1ß63 or Sema3A258,259, elevated microglial counts226, etc.). 
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Chapter 1 
Ischemic neurons prevent vascular regeneration of neural tissue by 
secreting Semaphorin 3A 
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Abstract 
The failure of blood vessels to revascularize ischemic neural tissue represents a 
significant challenge for vascular biology. Examples include proliferative retinopathies 
(PRs) such as retinopathy of prematurity and proliferative diabetic retinopathy, which 
are the leading causes of blindness in children and working age adults. PRs are 
characterized by initial microvascular degeneration, followed by a compensatory 
albeit pathological hyper-vascularization mounted by the hypoxic retina attempting to 
reinstate metabolic equilibrium. Paradoxically, this secondary revascularization fails to 
grow into the most ischemic regions of the retina. Instead, the new vessels are 
misdirected towards the vitreous, suggesting that vaso-repulsive forces operate in the 
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avascular hypoxic retina. Here we demonstrate that the neuronal guidance cue 
Semaphorin3A (Sema3A) is secreted by hypoxic neurons in the avascular retina in 
response to the pro-inflammatory cytokine Interleukin-1β. Sema3A contributes to 
vascular decay and later forms a chemical barrier that repels neo-vessels towards the 
vitreous. Conversely, silencing Sema3A expression enhances normal vascular 
regeneration within the ischemic retina, thereby diminishing aberrant 
neovascularization and preserving neuro-retinal function. Overcoming the chemical 
barrier (Sema3A) released by ischemic neurons accelerates the vascular 
regeneration of neural tissues, which restores metabolic supply and improves retinal 
function; findings may be applicable to other neurovascular ischemic conditions such 
as stroke. 
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Introduction 
Proliferative retinopathies (PRs) are traditionally perceived as disorders limited 
to the microvasculature, given the characteristic profuse and deregulated growth of 
retinal vessels1. The mechanisms by which neo-vessels grow towards the vitreous 
and fail to revascularize ischemic zones are thought to result from high concentrations 
of pro-angiogenic factors, such as vascular endothelial growth factor (VEGF), in the 
vitreous of patients. However, if such an explanation was sufficient, retinal glial cells 
(astrocytes and Muller cells)2 and neurons3 that produce vast amounts of growth 
factors under hypoxic conditions should retain vessels on the retinal surface and 
ensure revascularisation of the retina proper. It is therefore compelling to hypothesize 
the presence of a vaso-repulsive force originating from the significantly hypoxic 
avascular retina, which repel neo-vessels away from the vasoobliterated retina and 
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grow towards the vitreous. 
Neurovascular crosstalk shapes vascular development but has received limited 
attention in a pathologic setting. In PRs, evidence points to an early decline in the 
function of ischemic regions of the neural retina as noted by multifocal 
electroretinogram (mfERG)4,5. Throughout the vaso-obliterative phase of retinopathy, 
the local retinal environment is hostile to both vasculature and neurons6. Following 
blood vessel degeneration, neurons are metabolically starved and undergo a number 
of adaptive cellular changes to counter the ischemic state of the tissue3,6. If adequate 
vascular supply is not reinstated in time to salvage deprived neurons, it is conceivable 
that these severely hypoxic cells mount a repulsive front in an attempt to shunt 
metabolic resources away from the perishing ischemic tissue toward less affected 
regions of the retina. In the process, excessive production of VEGF7 induces 
exaggerated neovascularization at the periphery of the ischemic and repulsive zones, 
into the pre-retinal region (normally devoid of vasculature), since re-establishing a 
vascular network to neurons that are unsalvageable would be wasteful. 
Attractive candidates that may mediate misguided growth of neovessels away 
from the ischemic retina include classic neuronal guidance cues given their 
established role in influencing endothelial cell (EC) behaviour8. During embryonic 
development, nerves and blood vessels establish architecturally optimized networks 
to ensure adequate transmission of sensory information and tissue perfusion. Of 
particular interest are the class III Semaphorins such as Sema3A. Sema3A binds to 
Neuropilin-1 (Nrp-1) to elicit (neuronal) cytoskeletal collapse9,10. In addition, VEGF165 
also binds to Nrp-1 to promote its angiogenic effects10-12. These opposing actions of 
Sema3A and VEGF, whereby Sema3A directly provokes EC apoptosis and inhibits 
VEGF-dependent chemotaxis, may be important contributors to the vascular 
phenotypes observed in PRs. 
Using an oxygen-induced model of PRs (OIR)13,14, we demonstrate that the 
inflammatory environment present in the ischemic neural retina, notably involving 
Interleukin-1β (IL-1β), induces robust production of Sema3A specifically in retinal 
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ganglion neurons. Sema3A was found to contribute to vascular decay and curtail 
revascularization of the ischemic zones, resulting in misguided intravitreal vascular 
growth in ischemic retinopathies. Our findings reach beyond previously reported anti-
angiogenic properties of Sema3A as we provide evidence for a counterintuitive 
uncoupling of neuronal metabolism and vascular supply. We show that in response to 
hypoxia, neurons secrete a chemical barrier (Sema3A) to repulse new vessels and in 
turn prevent revascularization of hypoxic retinal tissue; conversely, we demonstrate 
that rapid enhancement of retinal revascularization during early ischemic stages 
effectively prevents aberrant pre-retinal neovascularization. 
 
Methods 
Animals. All studies adhered to the Association for Research in Vision and 
Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision 
Research and were approved by the Animal Care Committee of the University of 
Montreal in accordance with the guidelines established by the Canadian Council on 
Animal Care. C57 Bl/6 wild-type, GFP-mice (C57BL/6-Tg(UBC GFP) 30Scha/J stock 
number 004353) and RGC-YFP-mice (B6.Cg-Tg (Thy1-YFPH) 2Jrs/J stock number 
003782) were purchased from Jackson Laboratories. 
 
O2-induced retinopathy. This model serves as a proxy to human ocular neovascular 
diseases such as ROP and diabetic retinopathy characterized by a late phase of 
destructive pathological angiogenesis1,15. Mice were exposed to 75% oxygen from P7 
to P12. Upon return to room air, hypoxia-driven neovascularization (NV) develops 
from P14 onwards16.13 Intravitreal injections were performed as described below. 
Twice daily intraperitoneal injections of IL-1R antagonist (Kineret; 20 mg/Kg) were 
administered from P10 for 4 days. The eyes were collected at documented time 
points. Retinal vasoobliteration was evaluated at P12, P14 and P17, while NV was 
evaluated at the disease peak (P17) as described previously52. Briefly, mice were 
given a lethal dose of Avertin (Sigma-Aldrich) and eyes were enucleated and fixed in 
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4% paraformaldehyde for 1h at room temperature. Retinas were dissected and 
stained overnight at room temperature with fluoresceinated Isolectin B4 (Alexa Fluor 
594 – I21413, Molecular Probes) in 1 mM CaCl2 in PBS. Lectin-stained retinas were 
whole-mounted onto Superfrost/Plus microscope slides (Fisher Scientific) with the 
photoreceptor side down and imbedded in SlowFade Antifade reagent (Invitrogen). 
For quantification of retinal neovascularization (NV) 20 images of each whole 
mounted retinas were obtained at Å~5 magnification on by fluorescence microscopy 
(Nikon Eclipse E800). Vaso-obliterated areas were assessed as the retinal area 
devoid of vasculature over total retinal retina. Neovascularization was analysed using 
the SWIFT_NV method17. All mice of less than 5.5g at p17 were excluded from the 
study eliminating all runty animals18. 
 
Reverse transcription and quantitative real-time PCR analysis. Eyes were rapidly 
enucleated and whole retinas (or laser-captured retinal layers or vessels) processed 
for RNA using TRizol (Invitrogen), followed by treatment with DNase I (QIAGEN) to 
remove any contaminating genomic DNA. The DNase-treated RNA was then 
converted into cDNA using M-MLV reverse transcriptase (Invitrogen). PCR primers 
targeting mouse and rat VEGFA, Sema3A, Sema3E, Sema3F, Neuropilin-1, IL-1β, IL-
6, TNFα and the control genes cyclophilin A and 18S were designed using Primer 
Bank and NCBI Primer Blast software. Quantitative analysis of gene expression was 
generated using an ABI Prism 7700 Sequence Detection System and the SYBR 
Green Master mix kit (BioRad) and gene expression was calculated relative to 
cyclophilin A or 18S universal primer pair (Ambion) expression using the ΔcT method. 
 
Western Blot. Retinal samples were obtained as described above. Samples were 
centrifugated and 50 μg of pooled retinal lysate from a minimum of three different 
animals was loaded on an SDS-PAGE gel and electroblotted onto a PVDF membrane. 
After blocking, the membranes were incubated overnight with 1:200 rabbit antibody to 
mouse VEGFA (sc-152 ; SantaCruz Biotechnology), 1:1000 rabbit antibody to mouse 
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Sema3A (ab23393; Abcam), 1:1500 rabbit antibody to mouse IL-1RI (sc-689; Santa 
Cruz Biotechnology), 1:200 goat antibody to rat IL-1β (MAB501; R&D) and 1:1000 
mouse antibody to mouse β-actin (sc-47778; Santa Cruz Biotechnology). After 
washing, membranes were incubated with 1:5,000 horseradish peroxidase-
conjugated anti-rabbit, anti-goat or anti-mouse secondary antibodies (Amersham) for 
one hour at room temperature. Bands were assessed using densitometry plugins in 
Image Pro 4.5 (Media Cybernetics). 
 
Laser capture microdissection. Eyes with oxygen-induced retinopathy (OIR) or 
normoxic controls were enucleated at P14 or P17 and embedded in OCT compound. 
The eyes were sectioned at 12 μm in a cryostat, mounted on RNase-free 
polyethylene naphthalate glass slides (11505189, Leica), and immediately stored at -
80°C. Slides containing frozen sections were fixed in 50% ethanol for 15 seconds, 
followed by 30 seconds in 75% ethanol, before being washed with DEPC-treated 
water for 15 seconds. Sections were stained with Haematoxylin/Eosin or 
fluoresceinated Isolectin B4 (Alexa Fluor 594 –I21413, Molecular Probes, 1:50 dilution 
in 1mM CaCl2 in PBS) and treated with RNase inhibitor (03 335 399 001, Roche) at 
25°C for three minutes. Layers or neovessels were laser-microdissected with the 
Leica LMD 6000 system (Leica Microsystems) and collected directly into lysis buffer 
from RNeasy Micro kit (Qiagen, Chatsworth, CA). 
 
Immunohistochemistry. For immunohistochemistry, eyes were enucleated from 
mice and fixed in 4%paraformaldehyde at room temperature for 4h incubated in 30% 
sucrose overnight and then frozen in OCT compound. Sagittal cross-sections were 
permeabilized overnight at 4 ºC and incubated with rabbit IL-1RI (sc-689; Santacruz 
Biotechnology) or rabbit Sema3A (ab23393; Abcam) and mouse Thy1.1 (Millipore), 
followed by fluoresceinated secondary antibodies (goat anti-mouse IgG Alexa Fluor 
594 and goat anti-rabbit IgG Alexa Fluor 488 and 594; Invitrogen) for localization 
studies according to manufacturers’ recommendations. Flatmount retinas were 
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stained with 0.1% Triton X-100 (T-8787, Sigma) in PBS, and stained with 
fluoresceinated Isolectin B4 (Alexa Fluor 594 – I21413, Molecular Probes) in 1 mM 
CaCl2 in PBS for retinal vasculature. Antibodies to rabbit Nrp-1 (sc-5541; Santa Cruz 
Biotechnology) were applied overnight and secondary Abs as above. Samples were 
visualized using 40x objectives by fluorescence microscopy (Nikon Eclipse E800). 
 
Lentivirus production. Lentiviral vectors (HIV-1-derived) were prepared by 
transfecting HEK293T cells with a vector plasmid containing the small hairpin RNA 
against Sema3A or Green Fluorescent Protein together with the third generation 
packaging plasmids; pV-SVG, pMDL and pREV (Open Biosystems). Approximately 
107 cells were seeded and transfected with the above plasmids in DMEM complete 
media (Invitrogen) and incubated for 30h. Subsequently, supernatant was replace 
with fresh complete DMEM media and incubated for an additional 30h. Secreted virus 
was collected and ultracentrifuged at 50,000g, resuspended in PBS, aliquoted and 
stored at -80°C. 
 
Intravitreal injections. Postnatal day 2 or day 14 C57BL/6 pups were anesthetized 
with 3.0% isofluorane and injected intravitreally with 0.5μl of lentivirus (see below) or 
recombinant Sema3A (rSema3A, 100ng/μl) respectively, using a 10 μl Hamilton 
syringe fitted with a 50 gauge glass capillary tip. Approximately 254 ± 11.0 ng/μl of 
lentivirus shGFP and 323.3 ± 15.3 ng/μl containing shSema3A was injected (virus 
titers were assessed by p24 ELISA kit; ZeptoMetrix). 
 
ERG Recordings and analysis. Adult (50 days old) mice subjected to OIR and 
receiving Lv.shSema3A in the left eye and Lv.shGFP in the contra-lateral right eye 
where used in this study and compared to room air raised controls. Mice were housed 
in the animal care facilities under a cyclic light environment (12h light at 80 lux / 12h 
dark). ERG recordings were obtained as previously described19. Briefly, prior to the 
recordings, the animals were dark adapted for a period of 12 hours and 
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anaesthesized. Drops of 1% cyclopentolate hydrochloride (Alcon, Texas, USA) were 
used to dilate the pupils. The animals were then placed in a chamber with a 
photostimulator (model PS22, Grass Instruments, Quincy, MA) and a rod 
desensitizing background of 30 cd.sec/m-2. The active DTL fibre electrode (27/7 X-
Static Silver coated conductive nylon yarn, Sauquoit Industries, Scranton, PA, USA) 
was placed on the cornea, a reference electrode was positioned in the mouth (Grass 
E5 disc electrode, Grass Instruments, Quincy, MA, USA) and a ground electrode 
(Grass E2 subdermal electrode) was inserted in the tail. Simultaneous recordings of 
full-field ERGs (bandwith: 1-1000 Hz; 10 000 X; 6 db attenuation; Grass P-511 
amplifiers) was performed with the Biopac data acquisition system (Biopac MP 100 
WS, Biopac System Inc., Goleta, CA, USA). Scotopic ERGs were obtained in 
response to progressively brighter flashes of white light ranging in intensity from -6.3 
log cd.s/m-2 to 0.9 log cd.s/m-2 in 0.3 log-unit increments (Grass photostimulator, 
interstimulus interval: 10 sec, flash duration 20us, average of 2-5 flashes). ERG 
amplitudes were measured according to a method commonly used20. In brief, the 
amplitude of the a-wave was measured from baseline to trough and the b-wave from 
the trough of the a-wave to the highest peak of the b-wave. 
 
Preparation of Conditioned Media (CM) from hypoxic RGC-5. The RGC-5 cell line 
was kindly provided by Neeraj Agarwal of the University of North Texas Health 
Science Center. All cells were terminally differentiated and prepared as previously 
described6. Approximately 106 cells were seeded prior to exposure to 2.0% O2 levels. 
Supernatant was collected at appropriate time points and centrifuged remove debris, 
filtered with 0.2μm filters (Millipore) and distributed for proliferation assays (see 
below). 
 
IL-1β stimulation of cultured RGC-5. Terminally differentiated RGC-5 cells (105/ 
well) were seeded in 6-well plates and incubated for 0-8 hours with recombinant 
murine IL-1β (500 pg/mL; PeproTech Inc. Cat# 211-11B). Cells were collected at 
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each time point using TRIzol reagent for mRNA extraction as described in “RT-PCR 
and Real-Time qPCR”. 
 
Cell proliferation assay. Rat brain microvascular endothelial cells (RBMVEC) were 
obtained from Cedarlane Laboratories (Applications) and used from passage 2–7. 
Cell number and division rates were determined using thymidine incorporation 
whereby [methyl-3H]-Thymidine (1μCu/well; Amersham) was introduced to RGC-5 
conditioned media upon seeding in 24-well plates. Cell proliferation was assessed 
after 24 hrs. 
 
Aortic explant microvascular growth assay. Aortae were explanted from adult 
C57BL/6 mice, sectioned into 1mm rings and placed into growth-factor reduced 
Matrigel (BD Biosciences) in 24-well plates. Rings were cultured in supplemented 
Endothelial Basal Medium (Lonza) prior to a 40h exposure to RGC-5 conditioned 
media. Treated rings were photographed using an inverted phase contrast 
microscope (Eclipse TE300, Nikon) and microvascular growth assessed using Image 
Pro 4.5 (Media Cybernetics, Silver Spring, USA) as described6. 
 
Real-time migration assay. RBMVEC migration rates were assessed following 
exposure to the CM described above using an Xcelligence Real Time Cell Analyzer 
with Dual Plate (RTCA DP) apparatus from Roche Applied Science. This migration 
assay provides a real-time measurement of endothelial cell migration by extrapolating 
changes in electrical impedance with the number of cells passing through a porous 
membrane. Briefly, 160 μl of complete RBMEC medium with or without 0.5 or 1.0 
μg/ml Sema3A was loaded on the lower chamber of the Cellular Invasion and 
Migration (CIM)-plate 16 (Roche). The upper chamber was then fitted on the lower 
chamber and loaded with 50μl RBEC basal medium. After one hour of equilibration, 
2.8 x 104 of RBMVEC were loaded on each well of the upper chamber. The CIM-plate 
was subsequently placed on a RTCA analyzer in a 37ºC incubator. The cellular 
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migration was recorded every 15min (100 Sweeps at 15min Interval) using the cellular 
index provided by the RTCA DP instrument (Roche). RBMVEC basal medium was 
used as negative control. Four independent reactions were assayed for each 
condition. 
 
Micro-deposition of Sema3A. Aortic explants from adult GFP-mice (see above) 
were plated on polycarbonate slides adjacent to micro-deposited Sema3A (100ng/μl) 
and vehicle controls using micropipettes. Samples were covered with growth factor 
reduce Matrigel as described above. Nascent vessels were visualized using 63X 
objectives by fluorescence microscopy (Nikon Eclipse E800). 
 
Morphometric analysis and live cell imaging. Rat brain microvascular endothelial 
cells (RBMVECs) incubated with Sema3A and RGC supernatants were photographed 
using a 40X air objective on a Leica DMI6000 microscope coupled to a Ultraview Vox 
spinning disc confocal unit (Perkin Elmer). The camera was a Hamamatsu Orca-R2. 
Cells were maintained at 37 degrees using an environment chamber system from 
Pathology Devices. Images were acquired each 2 min for 45 min and surface areas 
were calculated using the Image J software. 
 
Actin network visualization and RhoA pull down. RBMVECs were incubated for 1 
hour with RGC CM or Sema3A and cells were fixed with 4% PFA and permeabilized 
with 0,2% Triton X-100. Subsequently, cells were stained using rhodamine-phalloidin 
(0,15μM) for 30min and DAPI (0,1μg/mL) for an additional 5min. Actin network 
collapse was assessed by confocal microscopy (Zeiss LMS5). RhoA activity was 
determined using a RhoA pull down kit from Pierce Biotechnology following 
manufacturer instructions. Briefly, active RhoA (GTP-bound) fraction was isolated 
from 200μg of protein lysates from RBMVEC incubated with RGC CMs. Five μg of 
total RhoA was presented here as loading controls. 
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Statistical analysis. Data are presented as means ± s.e.m. Two-tailed independent 
Student’s t-tests was used to analyse data. Comparisons between groups were made 
using one-way analysis of variance followed by post-hoc Tukey’s multiple 
comparisons test among means. P< 0.05 was considered statistically significant. 
 
Results 
The expression pattern of Sema3A is temporally and geographically consistent with a 
role in both vaso-obliterative and vaso-proliferative phases of PRs. 
 
In humans, the initial retinal vascular degeneration observed in PRs yields pockets of 
non-perfused neuronal tissue resulting in local hypoxia. Similarly in mice, the OIR 
model (75% oxygen from P7-P12 and room air until P17) provokes a central 
avascular retinal region (Fig 1A; left and central panels). As the retina revascularizes, 
aberrant neo-vascularization peaks at P173,21 (Supplementary Fig 1) where vascular-
tufts protruding into the vitreous are found bordering the avascular zone (Fig 1A; 
centre and right panels). In accordance with a role in retinopathy, Sema3A levels in 
whole retina (determined by RT-PCR) surge 3-fold (p=0.0015) during the height of 
vascular obliteration immediately following exposure to high O2 concentrations at P8 
and persists during pre-retinal NV formation at P14 (p=0.0157) (Fig 1B). At P14, when 
pre-retinal NV commences (Supplementary Fig 1), this increase in Sema3A is 
precisely located to central avascular (A) zones in micro-dissected retinas (Fig 1C). 
Although, VEGF levels significantly increase in this avascular zone (Supplementary 
Fig 2), nascent vessels fail to enter. Moreover, Sema3A mRNA expression (by RT-
PCR) is markedly increased in OIR in the ganglion cell layer (GCL) (Fig 1D) 
(p=0.0075) isolated by laser capture micro-dissection (Fig 1F), while lesser 
expression was noted in the inner nuclear layer (INL) (Fig 1D). These findings are 
confirmed by immunohistochemical localization of Sema3A in the GCL of the central 
avascular retina in OIR (P14), specifically in retinal ganglion cells expressing Thy1.1 
(Fig 1E). Importantly, at P19 when physiological revascularization progresses after 
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the earlier peak of NV (Supplementary Fig 1)13,15, Sema3A levels decrease in the 
central avascular zones to values detected at the periphery (Fig 1C), consistent a 
revascularization of the retina (see below). Bordering the Sema3A rich avascular 
retina, Nrp-1 expression is increased in pathological pre-retinal vascular tufts. In 
contrast to Sema3A, which is mainly found within the avascular zone, Nrp-1 is 
increased in pre-retinal vascular tufts (P17) (Supplementary Fig 1B) that are present 
in the periphery of this central avascular zone (Fig 1G,H). Together, these data 
suggest that Sema3A generated by RGCs is induced during the vasoobliterative 
phase of PRs, and positioned to block subsequent desirable revascularization during 
the proliferative phase (Fig 7C).  
 
IL-1β in the ischemic core of the retina induces Sema3A expression  
 
During vascular injury, the neural retina mounts an inflammatory response to the 
insult. Accordingly, levels of various cytokines such as, IL-1β22,23, IL-623-25 and TNF-
α7,26 are increased in the vitreous fluid of patients with proliferative diabetic 
retinopathy, in the retina of diabetic rats and during the proliferative phase of ROP. 
We determined whether the induction of Sema3A in the ischemic core of the retina 
was dependent on inflammation. Retinal levels of key inflammatory mediators IL-6, 
TNF-α and IL-1β, were increased at P14 in OIR (Fig 2A) (p<0.05). Although cytokine 
signaling is inter-related, we focused on IL-1β, which was markedly elevated and 
largely confined to the avascular retina (Fig 2B) in regions of elevated Sema3A 
expression (Fig 1C). Stimulation of IL-1RI-expressing RGCs (Supplementary Fig 3A) 
with IL-1β induced a robust rise in Sema3A expression (Fig 2C). Importantly, the 
induction of Sema3A was only noted after prolonged exposure to IL-1β (starting at 8 
h), and therefore suggests that a sustained inflammatory stress is required to trigger 
the production of this cue. Concordant with RGCs being the main source of Sema3A, 
we localized IL-1RI in this neuronal population in retinal cross-sections (Fig 2D) and in 
retinal astrocytes (Supplementary Fig 3B). To ascertain the role of the inflammatory 
stimulus, specifically IL-1β, in the generation of Sema3A in OIR, we determined the 
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effects of IL-1 receptor antagonist (IL-1ra; Kineret) on Sema3A expression. IL-1ra 
administered twice daily starting at P10 fully inhibited the production of Sema3A in 
OIR at P14 (Fig 2E), further confirming a role for inflammatory stress in governing 
expression of this repulsive cue. 
 
RGC-derived Sema3A partakes in vasoobliteration, hinders vascular regeneration 
and contributes to pre-retinal neovascularization in OIR. 
 
Physiological and pathological retinal vascularization is orchestrated by the 
coordinated interplay of ECs, astrocytes, microglia2,27,28, and neurons such as RGCs3. 
Given the pivotal role of the latter in retinal vascular homeostasis3 and the relative 
abundant expression of Sema3A in RGCs (Fig 1D,E), we proceeded to knockdown 
Sema3A mRNA in these neurons using small hairpin interfering RNA (shRNA) 
encoded in lentivectors (Lv); this approach was favoured over the use of Sema3A 
transgenic mice which exhibit high mortality rates and confounding neuronal deficits29; 
surviving Sema3A transgenic pups are also small for gestational age30, which would 
independently alter their OIR phenotype18. Intraocular injection of Lv at P2 effectively 
infects ~70% of RGCs as determined 72 h post infection3 (GFP colocalization with 
RGC marker Thy1.1; Supplementary Fig 4A) and leads to a ~50% reduction (p<0.05) 
in retinal Sema3A, while the Sema3A levels in contralateral control eyes infected with 
Lv.shGFP are unaffected (Supplementary Fig 4B,C). Importantly, expression of 
related Semaphorins and VEGF remains unaltered, confirming specificity of the 
Lv.shSema3A (Supplementary Fig 4C,D).  
Mice injected with Lv.shSema3A exhibit 32% less O2-induced vaso-obliteration 
at P12, consistent with Sema3A’s pro-apoptotic properties in ECs31 (p<0.01) (Fig 3A; 
Supplementary Fig 5A). Moreover, prior and during the vaso-proliferative phase (P12-
P17) revascularization of the central avascular zone is accelerated by 3.7 folds in 
animals treated with Lv.shSema3A (p=0.02 linear reg) (Fig 3A). Of note, more rapid 
restoration of retinal vasculature is associated with less pre-retinal neovascularisation 
(Fig 3B; Supplementary Fig 5B), as expected21,32,33. These findings introduce a new 
neurovascular paradigm where stressed neurons express Sema3A and contribute to 
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promoting the degeneration of surrounding vasculature, which deviates nascent 
vessels away from the most severely ischemic areas, in an attempt to redistribute 
metabolic resources to areas deemed “more salvageable”34. 
 
Inhibition of RGC-derived Sema3A during proliferative retinopathy preserves neuro-
retinal function. 
 
Maintaining neural function in ischemic tissue requires preservation of local vascular 
supply. Accelerated post-ischemic revascularization is associated with improved 
neural recovery35,36. OIR is associated with sustained depression in retinal function37, 
primarily in the inner retina (reflected by bwave amplitude of the ERG)5. To assess 
the functional benefits of inhibition of RGC-derived Sema3A, we performed short-flash 
electroretinogram (ERG) analysis in 50 day-old OIR mice. We find that suppression of 
Sema3A (using Lv.shSema3A) in animals subjected to OIR preserves inner neuro-
retinal function asdemonstrated by enhanced scotopic (mixed cone-rod) b-wave 
amplitudes when compared to Lv.shGFP injected controls (p=0.0049) (Fig 4A,B). This 
Lv.shSema3A-induced improvement in amplitude was accompanied by 
renormalization of the delayed b-wave peak times (p=0.001) (Fig 4C). Outer retinal 
function as determined by a-wave amplitudes, is not significantly affected (Fig 4B). 
 
Sustained hypoxia in RGCs induces Sema3A and blocks endothelial cell growth. 
 
Given the inferred neurovascular cross-talk observed, we sought to decipher the 
cellular dynamics governing Sema3A expression and actions. We first explored 
Sema3A production using an in vitro model of RGCs38 exposed to hypoxia (2% O2)3. 
In response to hypoxia, VEGF mRNA rises promptly (within 6 h) as expected (Fig 5A) 
and is consistent with the initial attempt of VEGF to protect ischemic neurons and 
promote vascular re-growth. This is confirmed by increased proliferation of primary rat 
neuromicrovascular endothelial cells (RBMVEC) and vascular sprouting of aortic 
explants exposed to 12 h hypoxia RGC media; addition of rSema3A (800 ng/ml) to 
this VEGF-rich media abolished its proliferative effect (Fig 5B,C). By 24 h of hypoxia, 
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VEGF levels subside and are followed at 36 h and 48 h by sharp rises in Sema3A 
mRNA (p<0.0001) (Fig 5A), in line with hypoxia and/or oxidant stress-induced 
regulation of other semaphorins 39. Accordingly, conditioned media from hypoxic 
RGCs taken at 40 h reduces basal RBMVEC division by 70% (suggestive of cell 
death) (p<0.01) as well as vessel sprouting from aortic explants (Fig 5B,C); these 
effects are abolished by Sema3A knockdown in the hypoxic RGCs using 
Lv.shSema3A [~95% infection efficiency & 50% knockdown (Supplementary Fig 6A)] 
compared to Lv.shGFP controls. Taken together, our findings reveal that Sema3A is 
produced by hypoxic stress-injured neurons and support our hypothesis that these 
injured RGCs participate in hindering revascularization of ischemic retinal tissue.  
Revascularization of ischemic tissues begins with the selection at the vascular 
front of highly motile ECs known as tip cells that express a number of chemo-
sensitive receptors such as Sema3Aresponsive Nrp1, and are believed to follow 
guidance and growth cues with their elaborate filopodial extensions10. Accordingly, in 
control (as well as in Lv.shGFP-treated) mice subjected to OIR, tip cells at the retinal 
vascular front bordering the avascular zone rich in Sema3A exhibited mostly short 
and dystrophic filopodia (Fig 5D). Conversely, in mice with RGC knockdown of 
Sema3A, vascular filopodia are 3-fold more abundant (Fig 5D). These data 
underscore the role of neuron-derived Sema3A in stalling vascular regeneration of 
ischemic tissues. 
 
RGC-derived Sema3A repels nascent vessels. 
 
Aberrant vessel guidance as an etiology of disease has thus far not been considered; 
althoughSema3A has been reported to affect EC motility9, its role in guiding vessels 
remains elusive. We corroborated this influence on cell motility in a real-time 
migration assay demonstrating that hypoxic RGCs produce sufficient Sema3A to 
significantly impede EC movement and thus reduce rates of migration (P<0.05) (Fig 
6A). The effect of Sema3A in specifically deviating vessels is also observed as 
nascent vessels (from aortic explants of germ-line-GFP mice) steer away from micro-
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deposited Sema3A (Fig 6B,C).  
Steering endothelial tip cells towards desired trajectories requires dynamic 
cytoskeletal rearrangement involving actin polymerization, the formation of stress 
fibres and focal adhesion points, which together modulate cytoplasmic morphology 
and are required to instigate movement. In line, RGCderived Sema3A influences EC 
shape. Conditioned media from hypoxic RGCs (40 h) caused rapid endothelial cell 
deformation (assessed using live spinning-disk imaging) (Fig 6D) to a similar extent 
as that observed with rSema3A (Fig 6E, Supplementary Fig 6B). The effects on cell 
shape and motility translate into a loss of stress fibres (determined by F-actin staining 
with rhodamine-phalloidin) by hypoxia-inducing Sema3A (Fig 6F); these changes are 
abrogated by Sema3A knockdown in RGCs (Fig 6D,F).  
Actin alignment, cell shape and stress fibre formation is under the control of 
small GTPases, such as RhoA, which activate Rho Kinase leading to myosin light 
chain phosphorylation and in turn contributes to actomyosin contraction and cell 
motility. In line with the promotion of tip cell formation and subsequent growth of 
vessels, conditioned media from RGCs silenced of Sema3A, promotes RhoA 
activation in endothelial cells (as determined by RhoA-GTP pull-down; Supplementary 
Fig 6C). Altogether, these findings are consistent with changes in endothelial cell 
migration affected by Sema3A (Fig 6A-C), and by the tip cell phenotype observed at 
the vascular front of OIR mice (Fig 5D).  
The source of Sema3A release dictates the direction of the repulsive and anti-
angiogenic force acting upon tip cells. In OIR (as presented in Fig 1), Sema3A is 
produced by ischemic RGCs of the avascular zone under the superficial retinal 
vascular layer (Fig 7A) causing neovessels to steer away from the central zone 
towards the vitreous to form pathologic vascular tufts. Intravitreal injections of 
rSema3A (into the pre-retinal vitreous) following OIR (P14) prevent entry of 
neovessels in the vitreous body and hence decrease vascular tuft formation at P17 
(Fig 7B). Although a trend was noted, vaso-obliteration in rSema3A-treated retinas 
also tended to decrease, albeit not significantly (Fig 7B). Collectively, our data 
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suggest that regional production of Sema3A by markedly hypoxic RGCs participates 
in deviating neovessels away from the avascular ischemic retina thus hindering 
functional revascularization of avascular retinal zones, as depicted in the schematic 
diagram in Fig 7C. 
 
Discussion 
Neuronal metabolism is tightly coupled to vascular supply by regulating 
vasomotricity and in a more sustained manner through the release of a number of 
growth factors3. However the reasons why vessels fail to invade distinct zones of 
ischemic yet salvageable neural tissue are to date poorly understood. This study 
provides the first proof of concept for a neuronal factor implicated in microvascular 
degeneration, and identifies neuronal-derived Sema3A as a vascular repulsive cue 
that also actively participates in mediating the key features of PRs. Paradoxically, our 
findings uncover that hypoxic ischemia causes neurons to reverse their signaling 
machinery from VEGF production to expression of the vascular chemo-repellent and 
cytotoxic cue Sema3A at the expense of VEGF (Fig 5A). This sacrifice of injured 
neurons could be a mechanism to preserve the integrity of the remaining 
neurovascular network by shunting revascularization away from irreversibly damaged 
tissue (sustained loss of inner retinal function). In doing so, neurons mount a chemical 
barrier that deviates neovessels, isolating the damaged retina away from healthy 
regions. This novel mechanism involving Sema3A also provides an alternative 
explanation for the pathognomonic phenotype of ridge and tufts formation observed in 
ischemic PRs. 
However, the factors that regulate expression of Sema3A remain elusive. 
Although general hypoxia and/or oxidant stress have been shown to affect other 
semaphorins39,40, our study is the first to draw a direct link between the inflammatory 
stress present in ischemic neural tissue and the induction of semaphorins. Consistent 
with the theory of segregating damaged areas of tissue, the induction of Sema3A 
requires prolonged exposure to inflammatory cytokines (here notably IL-1β) - a 
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scenario akin to prolonged exposure to damaging ischemia. Our findings thus expose 
a new patho-physiological role for neuronal-derived Sema3A that extends beyond its 
previously reported anti-angiogenic properties.  
The paradigm presented herein may also apply to other areas of the eye and 
the central nervous system. Increased levels of repulsive guidance cues (including 
Sema3A) are released from choroidal neovascular retinal pigmented epithelium41. 
Guidance cues may therefore also contribute to diseases of the outer retina, such as 
age-related macular degeneration. Shortly after an ischemic stroke42, Sema3A is 
produced by injured cells43,44 and localizes to regions immediately adjacent to the 
infarct44. A similar pattern is observed after spinal cord injury, where neurons near the 
site of lesion increase production of Sema3A45. The timing of this increase 
corresponds to the early phases of the response to injury when vascular remodeling 
occurs and axonal sprouting is induced. However, besides direct effects of repulsive 
cues such as Semaphorins on cellular proliferation in models of tumourogenesis46,47, 
the involvement of guidance cues in pathological settings has not previously been 
explored. In light of the ubiquitous release of Sema3A by injured neurons elsewhere 
in the central nervous system, the present study suggests that modulation of this 
guidance cue could be harnessed as a therapeutic strategy to promote prompt 
revascularization of ischemic neural tissue. 
In line with our current mechanistic understanding of PRs, VEGF has been the 
most promising therapeutic target for ocular vasoproliferative diseases, albeit with 
concerns. Notwithstanding the contribution of excessive levels of VEGF in PRs, this 
growth factor also plays a pivotal protective role in the normal physiologic 
development and health of the retina48,49. Inhibiting VEGF may curb 
neovascularization but may also cause unwanted damage to neuronal networks; 
accordingly, the appropriate dose of anti-VEGF treatment remains a challenge50. 
Alternatively, inhibiting the repulsive forces that are only present during a pathological 
insult may prove to be a more selective therapeutic approach.  
Although mechanisms governing vascular degeneration and ensued pre-retinal 
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neovascularization in PRs have been studied13,51-55, there are currently no strategies 
to accelerate revascularization of the vasoobliterated area and consequently limit 
aberrant pre-retinal neovascularization. We propose that inhibition of neuronal-
derived Sema3A aids the physiological vascular regeneration of the retina by 
overriding the vaso-inhibitory status of the injured tissue and thus alleviates the 
hypoxic stress that is central to disease progression. Accordingly, inhibition of RGC-
derived Sema3A or upstream inflammatory mediators (notably IL-1β), while 
harnessing the growth potential of VEGF (Supplementary Fig 2 & 4) may force 
vessels to promptly revascularize injured neurons and improve retinal function. 
rSema3A may also curb pathological neovasculariation; however as is the case with 
anti-VEGF therapy, this approach would curtail beneficial rapid retinal 
revascularization 7. Thus modulation of RGC-derived Sema3A may be a preferable 
therapeutic modality to remedy PRs without directly sequestering growth factors such 
as VEGF that are essential for endothelial and neuronal homeostasis. Since Sema3A 
is also released by injured neurons elsewhere in the central nervous system9,44,45, the 
concept proposed herein may not only apply to ischemic retinopathies, but also to 
other pathologies such as cerebral infarct where vascular growth is a key determinant 
of outcome35,36. 
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Fig 1. Sema3A expression is consistent with a role in retinopathy. (A) Frozen 
cross section (left panel) and flat mount retinas (central panel) taken at P17 of OIR 
demonstrating the principal characteristics of PRs including avascular (A) and 
vascular (V) zones. Paraffin sections (right panel) demonstrating preretinal 
neovascular tufts (black arrows). (B) Real-time PCR on whole retinas taken at P8 and 
P14 demonstrates a ~3-fold increase in Sema3A during the vaso-obliterative and 
neovascular phases of PRs respectively (n=3). Values are gene copy number 
normalized to CyclophilinA standards ± s.e.m. **p=0.0015 and *p=0.0157 compared 
to Normoxia (Norm). (C) Micro-dissection of avascular regions of the OIR retina at 
P14 reveals a 3.5-fold induction in Sema3A protein levels in the avascular area (n=3). 
Values are shown relative to vascularized areas ± s.e.m. *p=0.0447 compared to 
vascularised zone (V). At P19 when physiological retinal re-vascularization is 
reinstated, Sema3A in the avascular retina returns to control levels. Levels of 
Sema3A in the peripheral (P) and central (C) retina of normoxic controls are 
comparable. (D) Laser Capture Microdissection on retinal layers (F, and Suppl Fig 
1B) demonstrates that Sema3A is primarily produced in the Ganglion Cell Layer 
(GCL) with lower expression in the inner nuclear layer (INL). Levels of Sema3A surge 
4.4-fold in the GCL at P14 following OIR (n=3). **p=0.0075 and *p=0.0143 relative to 
normoxia (Norm). (E) Confocal imaging of IHC on central avascular retinal cross-
sections (OIR P14) reveals a predominant expression of Sema3A by RGCs as 
confirmed by merging with RGC marker Thy1.1. (G) At P17, LCM and RT-PCR of 
normal vessels versus neovascular tufts revealed a 2.2-fold induction in Neuropilin-1 
(Nrp-1) in tufts (n=3). Values are gene copy number normalized to CyclophilinA 
standards ±s.e.m.***p=0.0007 compared to controls (Ctl). (H) Immunohistochemistry 
on flat-mount retinas confirms pronounced staining of Nrp-1 on lectin-stained neo-
vascular tufts (P17). Images are representative of 5 experiments. Scale bars: (A) 300 
μm (right panel), 500 μm (central panel) and 50 μm (right panel). (E) 25 μm, (F) 100 
μm and (H) 25 μm. 
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Relative contributions: Figure 1 
A) Immunohistohemistry, imaging and analysis performed by JS Joyal and K 
Zaniolo 
B) qPCR analysis performed by A Stahl and P Sapieha 
C) Western blot performed by N Sitaras 
D) and G) Laser-capture microdissection and qPCR analysis performed by A 
Stahl and P Sapieha 
E) Immunocytochemistry and imaging performed by N Sitaras and JS Joyal 
F) And H) Immunocytochemistry and imaging performed by JS Joyal and K 
Zaniolo 
Animal handling and sample collection: N Sitaras, JS Joyal, Z Shao and K Zaniolo 
Figure preparation: JS Joyal, N Sitaras, P Sapieha and S Chemtob 
Approximate Figure contribution: 25% 
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Fig 2. IL-1β in the ischemic avascular retina induces Sema3A expression. (A) 
Inflammatory cytokines IL-6, TNF-α and IL-1β are induced in OIR retinas, in particular 
IL-1β which was upregulated 6.8 fold compared to normoxia. n=3; p<0.01 compared 
to normoxia (Norm). (B) Micro-dissection of avascular (A) regions of the OIR retina 
reveals a marked induction in IL-1β (17 ΚDa) protein levels compared to the vascular 
regions (V) and the central (C) and peripheral (P) normoxic retina; higher molecular 
weight bands correspond to pro-IL-1β. n=3; p<0.01 compared to time 0. (C) RGC-5 
stimulated with IL-1β (0.5 ng/ml) elicit a delayed (8 h) but significant 4-fold increase in 
Sema3A (n=3-4). (D) Confocal imaging of IHC on retinal cross-sections (OIR P14) 
reveals a predominant expression of IL-1RI by RGCs as confirmed by merging with 
RGC marker Thy1.1. (E) Interleukin receptor (IL-1RI) antagonist IL-1ra (Kineret) 
abrogated the OIR-dependent induction of Sema3A compared to vehicle-treated 
normoxia and OIR controls. Values are fold-increase of control ±s.e.m. n=3; **p<0.01 
compared to normoxic vehicle (Veh). (D) Scale bar: 25μm. 
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Relative contributions: Figure 2 
A) qPCR analysis performed by N Sitaras 
B) Western blot analysis performed by N Sitaras 
C) In vitro experiment and qPCR analysis carried out by N Sitaras 
D) Immunocytochemistry and imaging performed by JS Joyal and T Zhu 
E) Kineret administration and qPCR analysis performed by N Sitaras and JC 
Rivera 
Animal handling and sample collection: N Sitaras, JS Joyal and JC Rivera 
Figure preparation: JS Joyal, N Sitaras, P Sapieha and S Chemtob 
Approximate Figure contribution: 60% 
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Fig 3. RGC-derived Sema3A partakes in vasoobliteration, hinders vascular 
regeneration andcontributes to pre-retinal neovascularization in OIR. (A) 
Representative photo-micrographs of Griffonia simplicifolia lectin stained flatmount 
retinas at P12 reveal that mice receiving an intravitreal injection of Lv.shSema3A 
show a 32% reduction in the area of vaso-obliteration compared to contralateral eyes 
receiving Lv.shGFP injections and non-injected eyes (basal) revealing the vaso-toxic 
properties of Sema3A in the first phase of OIR (n=13-15; additional quantification is 
presented in Supplementary Fig 4A). The inhibition of RGC-derived Sema3A 
significantly enhanced the rate of vascular regeneration secondary to OIR as 
determined at P12 (n=13-15), P14 (n=12-13) and P17 (n=15-18). Values are 
presented as rate change in vaso-obliterated area relative to Lv.shGFP treated 
controls ± s.e.m. p=0.02 by anova factoring for time and group. (B) At peak 
neovascularization (P17) lectin-stained flatmount retinas reveal that inhibition of 
Sema3A (n=9-12) significantly reduced areas of pathological neovascularization from 
9.3% to 4.5% as determined using the Swift NV quantification protocol 
(Supplementary Fig 4B). Values are presented as area of neovascularization 
relative to total retinal area ± s.e.m. ***p=0.0002 compared to control. Scale bars: (A) 
and (B) 500μm. 
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Relative contributions: Figure 3 
A) and B) Lentiviral preparations performed by N Sitaras, JS Joyal, D Hamel and 
C Beauséjour 
Intravitreal injections performed by N Sitaras, K Zaniolo and Z Shao 
Sample preparation performed by N Sitaras, K Zaniolo and Z Shao 
Imaging and calculation performed by N Sitaras, K Zaniolo, Z Shao and A 
Zabeida 
 
Animal handling and sample collection: N Sitaras, JS Joyal, Z Shao and K Zaniolo 
Figure preparation: JS Joyal, N Sitaras, P Sapieha and S Chemtob 
Approximate Figure contribution: 60% 
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Fig 4. Inhibition of RGC-derived Sema3A during proliferative retinopathy 
preserves neuro-retinal function. (A) Representative recordings of full field 
scotopic ERGs in response to progressively brighter flashes of white light ranging in 
intensity from -6.3 log cd.s/m-2 to 0.9 log cd.s/m-2 in 0.3 log-unit increments (Grass 
photostimulator, interstimulus interval: 10 sec, flash duration 20μs, average of 2-5 
flashes). (B) Lv.shSema3A-treated mice show a significant gain in inner-retinal 
scotopic (mixed conerod) b-wave response (418.2 μV; n=6) when compared to 
control contra-lateral Lv.shGFP μV (234.3; n=8) injected eyes. **p<0.01 and p<0.001 
compared to corresponding control. Similarly, knockdown of Sema3A enhances the 
response time to light stimulus as illustrated by a decreased peak times (56.4 ms) 
with respect to controls (67.1 ms). Inner retinal function determined by a-wave 
amplitudes and peak times was not significantly affected. 
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Relative contributions: Figure 4 
A) and B) Lentiviral preparations performed by N Sitaras, JS Joyal, D Hamel and 
C Beauséjour 
Intravitreal injections performed by N Sitaras, K Zaniolo and Z Shao 
Electroretinogram performed by A Polosa and M Djavari 
Analysis of data performed by JS Joyal, N Sitaras, P Lachapelle and P Sapieha 
 
Figure preparation: JS Joyal, N Sitaras, P Sapieha and S Chemtob 
Approximate Figure contribution: 10% 
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Fig 5. Sema3A produced by hypoxic RGCs prevents retinal endothelial cell 
growth. (A) VEGF and Sema3A release by cultured RGC-5 cells exposed to hypoxia 
(2%). In the initial 12 h after hypoxia, VEGF levels rapidly rise ~9-fold while Sema3A 
remains unaffected. Later as hypoxic exposure is prolonged, Sema3A levels rise (6-
fold at 36 h and 10-fold at 48 h). Values represent fold increase relative to time 0. 
**p<0.01 and ***p<0.0001 compared to corresponding time 0. (B) Neuro-
microvascular endothelial cells (EC) proliferation measured by thymidine 
incorporation. Incubation of EC with conditioned media (CM) from RGCs exposed to 
hypoxia for 12 h (high VEGF, low Sema3A) caused a 1.7- (vehicle) and 2.3- (non-
specific shRNA; LV.shGFP) fold increase in cell number within 24 h; this effect is 
abrogated by rSema3A (800 ng/ml). Conversely, ECs treated with CM from RGCs 
exposed to hypoxia for 40 h (low VEGF, high Sema3A), show a Sema3A-dependent 
reduction in EC division (5-fold diminution). Knockdown of Sema3A in hypoxia-
exposed RGCs using Lv.shSema3A prevents the noted drop in EC division compared 
to vehicle and Lv.shGFP treated RGCs. n=4-6; *p<0.05, **p<0.01 compared to 
vehicle during normoxia (Norm) at time 0. (C) Aortic sprouting more than doubled in 
explants grown in CM from vehicle- and LV.shGFP-treated RGCs exposed to 12 h 
hypoxia; this vascular growth was curbed by rSema3A (800 ng/ml). CM from RGCs 
exposed to 40 h hypoxia reduce their sprouting by ~60% compared to normoxic 
media controls. When Sema3A is knocked-down in RGCs, vascular sprouting is 
doubled compared to Lv.shGFP underscoring the inhibitory properties of Sema3A 
towards nascent vessels. Values are represented as fold change relative to controls. 
n=3-6; *p<0.05, **p<0.01 compared to vehicle during normoxia (Norm) at time 0. (D) 
Representative confocal images of the re-vascularization front (images on left) and 
high magnification of tip cells (images on right) at OIR P14. The number of filopodia 
(asterix) per tip cell is increased 3-fold in Lv.shSema3A animals, whereas contra-
lateral eyes treated with Lv.shGFP showed less filopodia and dystrophic tip cells. 
n=10; ***p<0.0001 compared to value for Lv.shGFP. Scale bars: (C) 1mm, (D) 50 μm 
(left) and 10 μm (right). 
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Relative contributions: Figure 5 
A) In vitro preparation and qPCR analysis performed by N Sitaras, JS Joyal and 
A Zabeida 
B) In vitro preparation and data analysis performed by N Sitaras, JS Joyal and K 
Zaniolo 
C) Aortic ring explant preparation performed by N Sitaras and JC Honoré 
Sample preparation, imaging and analysis performed by N Sitaras, JS Joyal 
and P Sapieha 
D) Lentiviral preparations performed by N Sitaras, JS Joyal, D Hamel and C 
Beauséjour  
Intravitreal injections performed by JS Joyal, Z Shao and K Zaniolo 
Immunocytochemistry and data analysis performed by JS Joyal, E Picard and 
P Sapieha 
 
Figure preparation: JS Joyal, N Sitaras, P Sapieha and S Chemtob 
Approximate Figure contribution: 30% 
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Fig 6. Sema3A produced by hypoxic RGCs repels nascent vessels. (A) Rates of 
RBMEC migration using a real-time cell analyzer. EC motility was significantly 
blocked by hypoxia-induced Sema3A (4.2 fold) and rescued by CM from hypoxic RGC 
where Sema3A was silenced (40 h). n=4; *p<0.05 compared to vehicle at 40 h of 
hypoxia. (B) Effect of rSema3A on EC migration rate (over 45 min). n=3; **p<0.01 
compared to vehicle (Veh). (C) Propensity of Sema3A to deviate (repel) nascent 
vessels was established using micro-deposited Sema3A adjacent to aortic explants 
from GFP-mice. Vascular sprouts invaded vehicle-coated regions but avoided 
Sema3A-coated zones. (D) RGC-derived Sema3A modulates EC cytoskeletal 
arrangements and morphology, as demonstrated by time-lapse morphometric 
analysis of RBMEC subjected to CM (Supplementary Fig 6B). ECs exposed for 45 
min to CM from hypoxic RGCs (40 h) contracted, while knock-down of Sema3A in the 
RGCs largely abrogated this effect. n=3; **p<0.01 compared to vehicle at 40 h of 
hypoxia. (E) rSema3A provokes a dose-dependent cellular contraction (22.5%), 
similar in magnitude to 40 h hypoxic CM presented in panel. n=3; **p<0.01compared 
to vehicle (Veh). (F) Actin stress fibers in ECs. Treatment of ECs with hypoxic CM 
from hypoxic retinas resulted in loss of actin stress fibres and collapse of the actin 
network (as determined by rhodamine-phalloidin staining [red]); knockdown of 
Sema3A in RGCs abrogated this effect. Hence, changes in actin are consistent with 
those on cell shape and movement (panels A-E). Images are 
representative of 4 experiments. Nuclei are stained with DAPI in blue. Scale bars: (C) 
20 μm, (F) 50 μm. 
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Relative contributions: Figure 6 
A) In vitro preparation performed by N Sitaras, F Binet and T Zhu 
EC Migration and analysis performed by F Binet, T Zhu, JS Joyal and T Zhu 
B) Same as A 
C) Aortic ring explant preparation performed by D Kunik, S Constantino and P 
Sapieha 
Sample preparation, imaging and analysis performed by JS Joyal, A Stahl and 
P Sapieha 
D) Lentiviral preparations performed by N Sitaras, JS Joyal, D Hamel and C 
Beauséjour 
Sample preparation, imaging and analysis performed by F Binet, JS Joyal, G 
Hickson and P Sapieha 
 
Figure preparation: JS Joyal, N Sitaras, P Sapieha and S Chemtob 
Approximate Figure contribution: 20% 
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Fig 7. Intravitreal delivery of rSema3A suppresses pre-retinal 
neovascularization in OIR. (A) 3D reconstructions of pathological neovessels and 
RGC-YFP at P17 following OIR. The spatial distribution of retinal neurons and vessels 
results in the repulsion of neo-vascular tufts towards the vitreous. (B) Intravitreal 
injection of rSema3A (100 ng; P14) halved the formation of pre-retinal vascular tufts 
at P17. n=7; **p=0.0012 compared to corresponding vehicle. (C) Schematic summary 
illustrates ischemic neurons in the avascular zones producing Sema3A secondary to 
inflammatory stress (IL-1β). Pathologic neo-vascular tufts are enriched in Neuropilin-1 
(Nrp-1). RGC-derived Sema3A impedes revascularization and repels neo-vessels 
away from the avascular neural-retina towards the vitreous (left). Whereas intravitreal 
rSema3A (injected) prevents pre-retinal invasion of pathological neovessels (right). 
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Relative contributions: Figure 6 
A) Sample preparation, imaging and analysis performed by JS Joyal, A Stahl and 
P Sapieha 
B) Intravitreal injections performed by JC Rivera and N Sitaras  
Sample preparation, imaging and analysis performed by N Sitaras, JS Joyal, 
JC Rivera and P Sapieha 
C) Schematic provided by P Sapieha 
 
 
Figure preparation: JS Joyal, N Sitaras, P Sapieha and S Chemtob 
Approximate Figure contribution: 30% 
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Microglia and IL-1β  in Ischemic Retinopathy elicit microvascular 
degeneration through neuronal Semaphorin3A 
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101.10  Allosteric modulator of IL-1R1 
RGC-CM Retinal ganglion cell conditioned medium 
 
Abstract 
Objective: Pro-inflammatory cytokines contribute to the development of retinal 
vasculopathies. However the role of these factors and the mechanisms by which they 
elicit their effects in retina are not known. We investigated whether activated microglia 
during early stages of ischemic retinopathy produces excessive interleukin-1β (IL-1β), 
which elicits retinal microvascular degeneration, not directly but rather by triggering 
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the release of the pro-apoptotic/repulsive factor Semaphorin3A (Sema3A) from 
neurons.  
Approach and results: Sprague Dawley rats subjected to retinopathy induced by 
hyperoxia (80% O2; O2-induced retinopathy [OIR]) exhibited retinal vaso-obliteration 
associated with microglial activation, NLRP3 upregulation, and IL-1β and Sema3A 
release; IL-1β was mostly generated by microglia. Intraperitoneal administration of IL-
1 receptor antagonists (IL-1Ra [Kineret], or rytvela [101.10]) decreased these effects 
and enhanced retinal revascularization; knockdown of Sema3A resulted in 
microvessel preservation and conversely, administration of IL-1β caused vaso-
obliteration. In vitro, IL-1β derived from activated primary microglial cells cultured 
under hyperoxia, stimulated the release of Sema3A in retinal ganglion cells (RGC-5), 
which in turn induced apoptosis of microvascular endothelium; antagonism of IL-1R 
decreased microglial activation and on RGC-5 abolished the release of Sema3A 
inhibiting ensuing endothelial cell apoptosis. IL-1β was not directly cytotoxic to 
endothelial cells.  
Conclusions: Our findings suggest that in the early stages of OIR retinal microglia 
are activated to produce IL-1β, which sustains the activation of microglia and induces 
microvascular injury through the release of Sema3A from adjacent neurons. 
Interference with IL-1 receptor or Sema3A actions preserves the microvascular bed in 
ischemic retinopathies and consequently decreases ensued pathological pre-retinal 
neovascularization. 
 
Introduction 
Ischemic vasoproliferative retinopathies characterized by a retinal 
microvascular degeneration followed by an abnormal intravitreal neovascularization 
have recently been associated with neuro-inflammatory responses1-3. Interleukin-1β 
(IL-1β), a major mediator of inflammation4-6, has generally been implicated in the 
development of vasoproliferative retinopathies such as in diabetes7 and choroidal 
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neovascularization8,9. Yet, IL-1β exerts neurotoxicity2,10,11, vascular repulsion1, 
capillary degeneration12, induction of neovascular tumor growth,13-15 and seems to 
modulate angiogenesis by directly interacting with vascular endothelial cells or by 
enhancing the production of pro-angiogenic factors in a paracrine manner6,16-18. In the 
eye, under ischemic conditions IL-1β is markedly increased in neutrophils recruited 
into the retina, endothelial and retinal glial cells19. Microglia are phagocytic sentinels 
in the central nervous system including the retina, and are also needed for neuronal 
homeostasis and innate immune defense20,21. However, under severe insults 
including hypoxic/ischemic injury, microglia become over-activated and function as a 
prominent source of cytotoxic oxidant stress and pro-inflammatory factors22-24. In this 
regard, microglial overactivation can contribute to the production of IL-1β, TNF-α, and 
IL-6 found in high concentrations in tissues of patients and animals with 
vasoproliferative retinopathy25-27, and have been linked to the development of 
ischemic retinopathies in humans28 and animal models27, 29, 30. 
IL-1β exerts its biological effects by interacting with the IL-1 receptor type I (IL-
1RI), which is composed of a ligand binding unit and a signaling unit named the 
accessory protein (IL-1RacP)4. This activity is modulated endogenously by the natural 
IL-1 receptor antagonist (IL-1Ra) - a 17.5-kDa protein that competes with IL-1 for its 
binding site on IL-1RI31,32. IL-1Ra is considered an important endogenous anti-
inflammatory cytokine that blocks all known actions of IL-1β. Previous studies have 
shown that recombinant IL-1Ra (Kineret) protects against IL-1β and excitotoxin-
induced neurotoxicity33. In vitro, the presence of IL-1Ra has been shown to transform 
amoeboid microglia into ramified cells34, and inhibit endothelial cell death induced by 
IL-1β by decreasing NFκB and caspase-3 activation7. IL-1Ra-deficient mice are 
susceptible to neuronal injury following cerebral ischemia35, and conversely 
recombinant IL-1Ra attenuates the neurotoxicity36. Intravitreal IL-1Ra also markedly 
reduces laser-induced choroidal neovascularization8.  
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Our laboratory recently highlighted the influence of neuron-derived signalling 
molecules on endothelial cell function in the retina1. These signals include classic 
neuronal guidance cues, particularly the class III Semaphorins, implicated among its 
functions in inducing apoptosis37,38. However, the specific interplay of microglia and 
neurons in the pathogenesis of ischemic retinopathies (such as of prematurity [and 
diabetes]), particularly as it applies to IL-1β, on the critical vascular degenerative 
component, which precedes the aberrant vasoproliferative phase, is not known. 
In this work we found in the oxygen-induced model of retinopathy of 
prematurity (OIR) that hyperoxia activates microglia in the retina to produce IL-1β, 
which sustains the activation of microglia and induces microvascular injury not directly, 
but through the release of proapoptotic/repulsive factor Sema3A from adjacent 
neurons. Administration of two distinct inhibitors of IL-1R (IL-1Ra, and an all-d 
[protease resistant] oligopeptide rytvela labeled 101.1039) abrogated microglial 
activation, IL-1β release and Sema3A expression in the retina and resulted in a 
significant decrease in vaso-obliteration and acceleration of revascularization of the 
avascular retina in OIR, as seen after knockdown of Sema3A. 
 
Materials and Methods 
Animal Care 
All experimental procedures were approved by the Animal Care Committee of the 
Hôpital Ste-Justine in accordance with guidelines established by the Canadian 
Council on Animal Care. 
 
Retinal vaso-obliteration model 
Since we focused on retinal vaso-obliteration we utilized a well-established model of 
retinopathy of prematurity–the oxygen-induced retinopathy model (OIR)-, 
characterized by exposing the animals to 80% O2 during the first days of birth, when 
vasculature is still immature, and susceptible to damage caused by hyperoxia leading 
to retinal vaso-obliteration, a hallmark of the initial phase of ischemic retinopathies in 
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humans1, 2; relevantly, this model mimicks the relative hyperoxia premature infants 
are exposed to relative to levels in utero. Hence, Sprague- Dawley albino rat pups 
were placed with their mothers in an 80% oxygen environment from P5 to P10, when 
normal retinal vasculature reaches the periphery. The ability of IL-1Ra or 101.10 to 
curb vaso-obliteration was tested in two different animal groups exposed to O2 from 
P5-P8 (first group) and P5-P10 (second group). Briefly, in each group the pups were 
randomly selected to receive twice daily 20 μl saline (vehicle), IL-1Ra (10 mg/kg) or 
101.10 (1.5 mg/kg) intraperitoneally from P5 to P8 in the first group and from P8 to 
P10 in the second group; pups were euthanized respectively on P8 and P10. Eyes 
were enucleated and retinas dissected. Vaso-obliteration was evaluated in retinal flat-
mounts. Control animals were maintained in room air (21% O2). All other conditions 
(e.g., light exposure, temperature, feeding, etc.) were similar for both treatment 
groups. 
 
Retinal neovascularization model 
Within 4 hours after birth, litters of Sprague-Dawley albino rats (Charles River, St. 
Constant, Québec, Canada) were placed with their mothers in an oxygen regulated 
environment (OxyCycler A820CV; BioSpherix Ltd., Redfield, NY) adjusted to alternate 
between 50% and 10% of oxygen every 24 hours for 14 days. At postnatal day 14 
(P14), pups were transferred to room air (21% O2) for 4 days40. Pups were randomly 
selected to receive twice daily 20 μl saline (vehicle), commercial interleukin-1 receptor 
antagonist Kineret® [(Amgen, Canada, Inc) by intraperitoneal injections (10 mg/kg) or 
twice daily the recently reported allosteric modulator of IL-1 receptor, labelled 101.10 
[(peptide sequence: rytvela; synthesized by Elim Biopharmaceuticals, Hayward, CA) 
by intraperitoneal injections (1.5 mg/kg) from birth to sacrifice39; the efficacy of doses 
used has previously been demonstrated39,41. This treatment protocol aimed at 
preventing vaso-obliteration (induced by high O2) and consequently 
neovascularisation. On day P18, rats were anaesthetized with isoflurane (2%) and 
sacrificed by decapitation. Eyes were enucleated and retinas dissected. 
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Neovascularization was evaluated in retinal flat-mounts stained with lectins. Control 
animals were maintained in room air (21% O2) throughout the 18 days. All other 
conditions (e.g., light exposure, temperature, feeding, etc.) were similar for both 
treatment groups. 
 
Retinal Flat-Mounts 
In all cases the eyes were enucleated and fixed in 4% paraformaldehyde for one hour 
at room temperature and then stored in PBS at 40C until used. The cornea and lens 
were removed and the retina was gently separated from the underlying choroid and 
sclera under a dissecting microscope. Then, the retinas were subjected to 100% cold 
methanol (-20°C) for 10 minutes, and incubated overnight at 40C in 1% Triton X-100-
1 mM CaCl2/phosphate-buffered saline (PBS) with the TRITC-conjugated lectin 
endothelial cell marker Bandeiraea simplicifolia (1:100; Sigma-Aldrich, St. Louis, MO). 
Retinas were washed in PBS and mounted on microscope slides (Bio Nuclear 
Diagnostics Inc, Toronto, ON) under cover slips with Fluoro-Gel® (Electron 
Microscopy Sciences, Hatfield, PA) as the mounting media. 
Retinas were photographed under an epifluorescence microscope (Nikon, Eclipse 
E800, Rockland, MA) using a digital camera (Nikon, DXM1200, Rockland, MA) and 
vascular density was calculated for the full retina surface by using the software 
AngioTool recently described42. AngioTool computes several morphological and 
spatial parameters including vascular density by assessing the variation in foreground 
and background pixel mass densities across an image42. Vascular density in study 
groups was normalized with that of untreated groups raised in 21% O2. Vaso-
obliterated areas were assessed as the retinal area devoid of vasculature over the 
total retinal area. Neovascularization was analyzed using the SWIFT-NV method43, 
that consists of a set of macros that was developed to quantify all the pixels 
represented by neovascular tufts and clusters, but not normal vessels in lectin-stained 
retinal whole mounts. 
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Retinal uptake of 101.10 in vivo.  
Pups were randomly selected to receive 40 μl of the peptide 101.10 labelled with 
fluorescein isothiocyanate (101.10-FITC), or FITC (alone; Sigma-Aldrich) as control 
by intraperitoneal injections (3 mg/kg) or enteral administration (5 mg/kg) in rats 
exposed to normoxia (21% O2) or hyperoxia (80% O2). Animals were euthanized 3 
hours after drug administration, and retinas were evaluated in retinal flat-mounts co-
stained with lectins and 4,6- diamidino-2- phenylindole, dihydrochloride (DAPI; 0.1 
μg/mL; Molecular Probes). 
 
Intravitreal injections of IL-1β  
On day P5, pup rats were anaesthetized with isoflurane (2%) and intravitreally 
injected into the left eye with 5ng/1μl of IL-1β, and sterile PBS was injected into the 
contralateral eye as control. Twenty-four hours after the administration of IL-1β, the 
animals were euthanized, the eyes were removed, and retinal flat-mounts stained by 
the lectin technique and vascular density evaluated using image J. 
 
Immunofluorescence in retinal cryosections 
Seventy two hours after exposure to hyperoxia, eyes of rats treated or not with IL-1Ra 
or 101.10 and their corresponding controls (n=3 in each group) were enucleated and 
fixed in 4% paraformaldehyde at room temperature for 4 hours, incubated in 30% 
sucrose overnight, and then frozen and cut. Sagittal cryosections were blocked in 
PBS containing 1% bovine serum albumin, 1% normal goat serum, 0.1% Triton X- 
100 and 0.05% Tween-20 for 1 h and double labeled overnight at 40C with a 1:300 
dilution of anti-IL-1β polyclonal (R&D Systems), 1:300 dilution of anti-IL-1RI polyclonal 
(Santa Cruz Biotechnology, inc), 1:200 of anti-Sema3A polyclonal (Abcam, Inc) or a 
1:100 dilution of the anti-IL-1β monoclonal antibodies and antibodies for cell-specific 
proteins: microglia [Iba-1, 1:500; Wako Chemicals USA, Inc], astrocytes [GFAP, 
1:500; Dako, Carpinteria, CA], neurons [NeuN, 1:100, Chemicon] and endothelium 
[anti-CD31, 1:100 Immunologicals Direct). The primary antibodies were labeled for 2 
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h with Alexa-594-conjugated goat anti-rabbit or anti-mouse IgG, or Alexa-488 goat 
anti-rabbit or anti-mouse IgG obtained from Molecular Probes (Eugene, OR) and used 
at dilutions of 1:1000 (anti-rabbit) or 1:500 (anti-mouse), respectively. Incubation with 
isotype antibody was used as control. Labeled retinas were examined with a laser 
scanning confocal microscope (Zeiss LSM 510). 
 
Primary cultures of retinal microglia cells 
Microglial cells were isolated from retinas of rats (6 days old) according to the method 
described previously2,44. Briefly, the eyes were enucleated, and the retinas were 
collected in ice- cold 0.01 M PBS. They were soaked in Dulbecco’s modified Eagle’s 
medium/F12 (1:1) (DMEM; Invitrogen, CA, USA) supplemented with 100 U/ml 
penicillin and 100 μg/ml streptomycin, and then washed in Hank’s balanced salt 
solution, cut into small pieces, and digested with 0.5% trypsin for 30 min at 370 C. 
Then DMEM/F12 (1:1) with 10% fetal bovine serum (FBS; Hyclone, Logan, UT, USA) 
was added to terminate trypsinization, the retinal pieces were manually dissociated by 
trituration and centrifuged. The supernatant was eliminated and the cell pellet was 
resuspended in DMEM/F12 (1:1) + 10% FBS supplemented with 10 ng/ml 
recombinant murine granulocyte–macrophage colony-stimulating factor (rmGM-CSF, 
PreproTech, Rocky Hill, NJ, USA) and allowed to grow at 370 C in 5% CO2 in 75-cm2 
flasks at a density of 1X106 cells/mm2. All cultures were maintained in a humidified 
CO2 incubator (Sanyo Biomedical) and fed every 2 days. After 2 weeks, microglia 
were harvested by shaking the flasks at 200 rpm for 4 h in an orbital shaker at 370 C. 
The cell suspension was centrifuged at 1000 rpm for 5 min, and the cell pellet was 
resuspended in DMEM/F12 (1:1) + 10% FBS. The purity of the microglia in the 
cultures was determined by immunostaining the cells with Ionized Calcium Binding 
Adaptor Molecule-1 (Iba-1), Glial Fibrillar Acidic Protein (GFAP), or Neuronal Nuclei 
(NeuN), as specific markers for microglia, astrocytes and neurons, respectively. The 
percentage of microglial cells was about 97%, which was established after 2 weeks. 
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Microglia activation in vitro and quantification in vivo  
To study whether IL-1β regulates the activation of microglia, isolated retinal microglial 
cells (150, 000 cells/well) were treated with IL-1β (0.5 ng/ml) in presence or absence 
of IL-1Ra or 101.10. After 24 hours, the mRNA expression of IL-1β and Iba-1 was 
analyzed by qPCR. For microglia quantification, retinal flat-mounts stained with an 
anti-Iba-1 polyclonal antibody were used. Four representative fields in the central 
(vasoobliterated) zone were randomly selected in each retina. Activated microglial 
cells were recognized by their short and thick processes and their increased 
immunoreactive staining of Iba-1 (as well as IL-1β)45,46. The average number of Iba-1 
positive cells from the four fields for each retina was calculated by using Image J. The 
mean and standard error of these averages from at least 4 retinas in each group was 
calculated. 
 
Preparation of microglia-conditioned media (MGCM) 
To study the effects of hyperoxia on expression of IL-1β, microglial cells (250, 000 
cells) were cultured in plates of 25 cm2 (Sarstedt, Inc, Newton, NC, USA) with 
DMEM/F12 (1:1) + 10% FBS. After 24 hours the cells were starved with DMEM/F12 
(1:1) free of FBS for 24 hours. Then the cells were exposed to hyperoxia (80% 
oxygen and 20% nitrogen; Hyp-MGCM) in a modular incubator chamber (Billups-
Rothenberg, Inc) and maintained in a humidified CO2 incubator at 370 C for 4, 12, 
and 24 h. Microglial cells in matching controls (Nor-MGCM) were incubated at 370 C 
in an incubator with 95% air and 5% CO2 and collected at the same time points. 
 
Reverse transcription and quantitative real-time PCR analysis. 
Eyes were enucleated and retinas were rapidly dissected and processed for RNA 
using TRizol (Invitrogen). Total cellular RNA was isolated by acidic phenol/chloroform 
extraction followed by treatment with DNase I (Roche Diagnostics, Mannheim, 
Germany) to remove any contaminating genomic DNA; 500 ng of RNA was reverse 
transcribed into cDNA with Moloney murine leukemia virus reverse transcriptase 
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(Promega, Madison, WI) in 25μL of reaction mixture. PCR primers targeting for IL-1β; 
(5'-CATCTTTGAAGAAGAGCCCG-3' and 5'- GGGATTTTGTCGTTGCTTGT-3'), 
Sema3A; (5'-GAGTCCCTTATCCACGACCA-3' and 5'- 
AATGCTTTCTCCGCTCTGAA-3'), VEGF; (5'-CAATGATGAAGCCCTGGAGT-
3'and 5'- AATGCTTTCTCCGCTCTGAA-3'), Iba-1; (5'-
AGAGGTGTCCAGTGGCTCCGA-3' and 5'- GTCCTCGGTCCCACCGTGTT-3'), 
ICAM1; (5'-TGCAGCCGGAAAGCAGATGGT3' and 5'- 
CACGATCACGAAGCCCGCAAT-3'), IL1Ra; (5-'TCTGTTGGCTAACCCAATCC3' and 
5'- ACTTGGGGGATTGTCAAGTG-3'), Caspase-1; (5'-
AAGGCACGAGACCTGTGCGAT-3' and 5'- ACCACTCGGTCCAGGAAATGCG-3'), 
TNF-α; (5'-CTATGTGCTCCTCACCCACA-3' and 5'- TGGAAGACTCCTCCCAGGTA-
3'), IL-1R1; (5'-TGAATGTGGCTGAAGAGCAC-3' and 5'- 
CGTGACGTTGCAGATCAGTT-3'), NLRP3; (5'-TGCATGCCGTATCTGGTTGT-3'
 and 5'- ACGGCGTTAGCAGAAATCCA-3') were designed using Primer Bank 
and NCBI Primer Blast software. Quantitative analysis of gene expression was 
generated using an ABI Prism 7700 Sequence Detection System and the SYBR 
Green Master mix kit (BioRad) and gene expression was calculated relative to 18S 
universal primer pair (Ambion) expression using the ΔcT method. 
 
Western Blot 
Retinal samples were obtained as described above. Three retinas from different 
animals per sample (n=3 samples per group) were collected in tubes (Precellys 
Lysing Kit, 0.5 ml, MEDICORP, Montreal, CA) containing 100 μl lyses buffer and 
proteases inhibitors and then homogenized in a tissue homogenizer (Precellys®24 
Cat. 03119.200.RD000) at 5000 rpm- 3x15seg. The samples were then centrifuged at 
10,000 rpm during 10 minutes at 40C and the supernatant was collected. 50 μg of 
protein was loaded on an SDS-PAGE gel and electroblotted onto a PVDF membrane. 
After blocking, the membranes were incubated overnight with 1:200 rabbit antibody to 
VEGF-A (sc-152; Santa Cruz Biotechnology), 1:1000 rabbit antibody to Sema3A 
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(ab23393; Abcam), 1:200 goat antibody to rat IL-1β (MAB501; R&D), 1:500 rabbit 
antibody to IL-1R (sc-689; Santa Cruz Biotechnology) and 1:1000 mouse antibody to 
β-actin (sc-47778; Santa Cruz Biotechnology). After washing, membranes were 
incubated with 1:5000 horseradish peroxidase conjugated anti-rabbit, anti-goat or 
anti-mouse secondary antibodies (Amersham) for one hour at room temperature. 
 
MTT assay 
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assays were 
performed to assess endothelial or microglia cell viability. Briefly, rat brain 
microvascular endothelial cells (RBMVEC, Cell Applications, Inc, 1.8 × 105 cells) 
were seeded in 48-well plates and treated for 24 h with recombinant rat IL-1β (500 
pg/mL; 400-01B; PeproTech), recombinant Sema3A (R&D Systems), normoxic or 
hyperoxic microglia-conditioned media (Norm-MGCM or Hyp-MGCM), Norm-MG-
RGC-CM or Hyp-MG-RGC-CM or with normoxic or hyperoxic endothelial-RGC-
conditioned media (Nor-EC-RG-CM or Hyp-EC-CM) in presence or absence of IL-1Ra 
or 101.10. To analyze microglia cells viability, the cells were cultured in 6-well plates 
(2.4 x 105) and exposed to hyperoxia (80% O2) or normoxia (21% O2) in presence or 
absence of N- acetylcysteine (NAC; 8 mM). After treatment in both types of cultures, 
the medium was removed and MTT (5 mg/mL, 30 μl/well) was added followed by 
incubation at 37°C for 4 h. Afterwards, supernatants were carefully removed, and 
DMSO (30 μl/well, Sigma-Aldrich, St. Louis, MO) was added to the cells. After 
insoluble crystals were completely dissolved, absorbance at 590 nm was measured 
using microplate reader (Awareness Technology, Inc). Cell viability was expressed as 
a percentage of optical density relative to control. 
 
TUNEL assay 
Retinal ganglion cell line (RGC-5, 2.5 × 104 cells) was kindly provided by Neeraj 
Agarwal (University of North Texas Health Science Center, Fort Worth, TX). RGC-5 
supernatant (RGC- CM) was collected after 24 hours of stimulation with Hyp-MGCM, 
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Norm-MGCM or directly with pure recombinant rat IL-1β (0.5 ng/ml) in presence or 
absence of IL-1Ra or 101.10. Hyp-MG- RGC-CM, Norm-MG-RGC-CM or RGC-
CM+IL-1β was centrifuged to remove debris and filtered with 0.2-μm filters (Millipore). 
To eliminate the Sema3A present in the RGC-CM, the collected medium was filtered 
with a Centricon (10000 MWCO, Millipore). The concentrated medium was discarded 
and the filtered media was immu-neutralized with a polyclonal anti-Sema3A antibody 
(2μg/ml, Abcam) in the RBMVEC assay. RBMVEC (1.8 × 105 cells) were seeded in 
48-well plates and treated for 24 h with Hyp-MG-RGC-CM, Norm-MG-RGC-CM or IL-
1β-RGC-CM. After the treatment, the medium was removed and TUNEL assay was 
performed with an in situ cell- death detection kit (ApopTag® Plus, Chemicon 
International.) according to the manufacturer’s instructions. After TUNEL staining, the 
samples were counterstained with 4,6-diamidino-2- phenylindole, dihydrochloride 
(DAPI; 0.1 μg/mL; Molecular Probes). 
 
Immunofluorescence in RBMVEC cells 
After the treatment with Norm-MG-RGC-CM or Hyp-MG-RGC-CM for 24 hours, the 
medium was removed and rat brain microvascular endothelial cells (RBMVEC, Cell 
Applications, Inc) were washed two times with PBS, fixed with 4% paraformaldehyde 
for 10 minutes and incubated with a 1:500 dilution of activated caspase-3 polyclonal 
antibodies (Cell Signaling Technology) or a 1:300 dilution of the anti-β-actin 
monoclonal antibodies (Santa Cruz Biotechnology, Inc). The primary antibodies were 
labelled for 2 h with Alexa-488 goat anti-rabbit (1:1000) or Alexa-594-conjugated goat 
anti-mouse (1:500). RBMVEC cell were co-stained with DAPI (0.1 μg/mL; Molecular 
Probes) and examined with a laser scanning confocal microscope (Zeiss LSM 510). 
 
ELISA 
Conditioned media from microglial cells exposed to hypoxic or hyperoxic conditions in 
presence or absence of N-acetyl cysteine (NAC; Sigma-Aldrich) was collected and 
concentrated in Ultrafree-4 centrifugal filter unit (10,000 NMWL, Millipore) at 3,500 
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rpm for 10 minutes at 40C. The concentrated media (5 times) was collected and 
analyzed by ELISA according to the manual instructions (Rat IL-1β/1L-1F2 
immunoassay R&D Systems, Inc, Cat. RLB00) to determine the IL-1β concentration in 
each condition. 
 
Internalization of 101.10 in HEK cells 
HEK-BlueTM IL-33/IL-1β cells (InvivoGen) designed to detect bioactive IL-1β 
(generated by stable transfection of the IL1-RL1 gene) and HEK293 cells (ATCC®) 
that do not express the IL-1RI were used. Both cell types were cultured following the 
manufacturer’s protocols. Briefly, HEK-BlueTMIL-1β and HEK-293 cells were cultured 
in 24 well plates at densities of approximately 50,000 cells/well in 500 μl of complete 
growth medium consisting of DMEM supplemented with 4.5 g/l glucose, 10% FBS, 50 
U/ml penicillin, 50 mg/ml streptomycin, 100 mg/ml NormocinTM and 2 mM L-
glutamine for HEK-BlueTM IL-1β cells or ATCC-formulated Eagle's Minimum 
Essential Medium, supplemented with 10% fetal bovine serum [FBS], 100 U/ml 
penicillin, and 100 μg/ml streptomycin for HEK 293 cells. All cultures were maintained 
in a humidified incubator at 5% CO2 and 37 °C. After overnight incubation, the cells 
were starved with Eagle's Medium or DMEM free of FBS for 4 hours. Then the cells 
were stimulated with human recombinant IL-1β (50 ng/ml/well) and incubated with 
101.10-FITC or FITC alone (control) for 3, 6 and 9 hours. After incubation the cells 
were washed three times with PBS, fixed with 4% paraformaldehyde, stained with 
DAPI. Microphotographs showing the uptakes 101.10- FITC were made by confocal 
microscopy. 
 
IL-1β stimulation in RAW-Blue mouse macrophage and HEK blue cells  
Transfection with siRNA macrophages was performed as follows. Twenty micrograms 
of siRNA complex was mixed with 8 ml of 1mg/ml polyethylenimine solution 
(Polyscience Inc.) for 30 minutes and added to RAW-Blue mouse macrophages 
(Invivogen). The following day cells were treated with mIL-1β (50 ng/ml) at 37°C for 4 
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hours. HEK blue and 293 cells were treated 
with human recombinant IL-1β in presence or absence of 1x106 M of IL-1Ra or 
101.10. After treatment, the cells were collected in TRIzol (Invitrogen) and total RNA 
was isolated. 500 ng of RNA was combined to qScript cDNA SuperMix (Quanta 
Bioscience) and cDNA synthesis was performed following the manufacturer’s protocol. 
Quantitative real-time PCR was performed on MxPro3000 (Stratagene) using iTaq 
SYBR Green SuperMix with ROX (Bio-Rad). siRNA primers and qPCR primers were 
synthesized by Alpha DNA and sequences were: siRNA: simIL-
1RF557AGUAACCGUAACUGUUATT; simIL-1R-
R557UAACACAGUUACGGUUACUTT; simIL-
1RF1794GAAAGACCACAGUCUGCAATT ; mIL1RF:AACCTTTGACCTGGGCTGTC ; 
mIL1bF: AGATGAAGGGCTGCTTCCAAA ; expression levels were normalized 
against 18S rRNA endogenous control levels in each sample and calculated relative 
to control vehicle-treated cells. simIL1RR1794UUGCAGACUGUGGUCUUUCTT; 
mIL1RR :CAGAGGATGGGCTCTTCTTCAA ; mIL-
1bR:GGAAGGTCCACGGGAAAGAC ; mRNA expression levels were normalized 
against 18S rRNA endogenous control levels in each sample and calculated relative 
to control vehicle-treated cells. 
 
Lentivirus production 
Lentiviral vectors (HIV-1 derived) were prepared as we previously reported1 by 
transfecting HEK293T cells with a vector plasmid containing the small hairpin RNA 
(shRNA) against Sema3A or green fluorescent protein together with the third 
generation packaging plasmids pV-SVG, pMDL, and pREV (Open Biosystems). 
 
Intravitreal injections of lentivirus 
P2 rat pups were anesthetized with 3.0% isoflurane and injected intravitreally with 1 
μL of lentivirus using a 10-μL Hamilton syringe fitted with a 50-gauge glass capillary 
tip. Approximately 500 ng/μL of lentivirus shGFP or containing shSema3A was 
injected. From P5 to P8 the animals were exposed to hyperoxia (80% oxygen). At P8, 
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the animals were sacrificed and vaso-obliteration was assessed in retinal flat-mounts. 
 
Statistical Analysis 
Results are expressed as mean ± SEM. Two-tailed independent Student t tests was 
used to analyze data. Comparisons between groups were made using 1-way ANOVA 
followed by the post hoc Bonferroni’s multiple comparison test. Statistical significance 
was set at p<0.05. 
 
Results 
Oxygen-induced retinopathy (OIR) triggers early production of IL-1β and other 
inflammatory mediators in the retina; inhibition of IL-1β activity decreases 
inflammation and retinal vaso-obliteration  
 
Animals were subjected to OIR as described40. At postnatal day 6 (P6) 
following exposure to hyperoxia (80% O2) for 20 hours there was an increase in the 
retinal mRNA expression of the proinflammatory cytokine, IL-1β (4.1-fold; p<0.001), 
the microglial marker, Iba-1 (2.6-fold; p<0.01), and the cytotoxic factor, Sema3A (2.1-
fold; p<0.05), as well as other inflammatory mediators such as TNF-α (2.1-fold; 
p<0.01) and ICAM-1 (1.5-fold; p<0.05), compared to the normoxic retinas (Fig. 1); 
interestingly, the major inflammasome protein NOD-like receptor family pyrin domain 
containing-3 (NLRP3) was also increased in retina of P6 and P8 hyperoxia-exposed 
pups (Supplemental Fig. IA). mRNA expression of endogenous IL-1Ra did not 
significantly increase, and that of Caspase-1 and VEGF also remained unchanged 
(Fig. 1). IL-1Ra and 101.10 (started at P5) significantly attenuated hyperoxia-induced 
changes in IL-1β, TNF-α, ICAM-1, Iba-1, and Sema3A.  
At P8, 72 h after exposure to high oxygen IL-1β and Iba-1 mRNA expression 
was greater than values in normoxia, albeit lower than at P6 (Fig. 1); IL-1Ra 
decreased further to below normoxia values. In contrast, Caspase-1, ICAM-1 and 
VEGF mRNA increased relative to values at P5; while TNF-α and Sema3A remained 
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steady. Western blot analysis confirmed the hyperoxia-induced increase in IL-1β and 
Sema3A, while VEGF expression decreased (Supplemental Fig. IB). IL-R antagonists 
generally decreased values for all parameters except IL-1Ra and VEGF (Fig. 1 and 
Supplemental Fig. IB).  
 At P10, 120 h after exposure to hyperoxia the mRNA expression of all 
inflammatory and apoptotic factors subsided, while that of the anti-inflammatory IL-
1Ra and of the cytoprotective VEGF increased relative to changes at P8 (during this 
vaso-obliterative phase). 
Both antagonists of IL-1R prevented retinal vaso-obliteration and tended to 
renormalize vascular density of animals subjected to hyperoxia (Fig. 2). Moreover, 
pups treated with both IL-1R antagonist starting at P8 (3 days after exposure to 
hyperoxia which leads to vaso-obliteration) till P10 exhibited a significant increment in 
normal revascularization (compared with the vehicle-treated rats) (Fig. 2G), as noted 
by a gradual decrease in vaso-obliteration; this was further substantiated by a lack of 
increase in VEGF by P10 (Fig. 1). In control normoxic pups IL-1Ra and 101.10 did not 
affect developmental retinal vascular density (Supplemental Fig. II), consistent with 
absence of inflammation under normal conditions. Hence, the overall decreased 
vaso-obliteration by IL-1R inhibitors tended to abolish the hypoxia-driven surge in 
VEGF (Fig. 1H). Thus as anticipated, treatments with inhibitors of the IL-1 receptor 
consequently diminished ensued aberrant pre-retinal neovascularization 
(Supplemental Fig. IIIA). Additional evidence to substantiate cytotoxic effects of IL-1β 
on retinal microvasculature was demonstrated by intravitreal injection of IL-1β in 
normoxia-raised pups (P5), which resulted 24 h later in a loss of microvasculature 
(Supplemental Fig. IIIB).  
To ascertain actions of the all-d peptide 101.10 in retina, its local distribution 
was studied. 101.10 was conjugated to FITC and fluorescence detected by 
microscopy in retinas of injected animals. 101.10 localized principally in microglial and 
endothelial cells in normoxia-raised rats (Supplemental Figure IV). Animals exposed 
to hyperoxic conditions exhibited a significant increase in vascular and perivascular 
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fluorescence; FITC alone (not conjugated to 101.10) was negligibly detected in retina. 
Hence, 101.10 distributes in retina – more so during hyperoxia when IL-1R (to which 
101.10 binds39) expression increases (Supplemental Figure ID). To determine the 
need for IL-1R expression for uptake of 101.10, HEK-Blue cells (that express 
constitutively IL1-R) and HEK293 cells devoid of IL-1R were stimulated with 1L-1β (0-
9 h) in presence of 101.10-FITC; 101.10-FITC internalization was only observed in IL-
1R-expressing cells, indicative of the need for IL-1R for cell uptake (Supplemental Fig. 
V).  
Together these results reveal that hyperoxia induces an early increase in the 
expression of inflammatory mediators in the retina, and show that exogenous IL-1Ra 
and 101.10 comparably reduce the expression of these inflammatory components, 
and in turn protect the retina from retinal vascular degeneration allowing for an 
accelerated normal vascular regrowth and preventing against ensued pre-retinal 
neovascularization. 
 
Hyperoxia leads to activation of microglia, which in turn is the main generator of IL-1β 
in retina 
 
Increased Iba-1 mRNA expression in hyperoxic rats (Fig. 1B) was suggestive 
of microglial activation. We elaborated on this observation by examining microglial 
Iba-1 immunoreactivity and morphology in situ. IL-1β was mostly found in the inner 
retina of hyperoxic rats (at P8), largely confined to microglia (Iba-1 immunopositive; a 
calcium-binding protein expressed by activated microglial cells) (Fig. 3); baseline 
immunoreactivity (under normoxic conditions) was very weak (Fig. 3). Both 
exogenous IL-1Ra and 101.10 reduced intensity of IL-1β immunoreactivity in 
hyperoxic rats (Fig. 3). A slight localization of IL-1β was found on endothelium (CD31 
immunopositive; Supplemental Fig. VI), but hardly on retinal ganglion cells (NeuN 
immunopositive) and astrocytes (GFAP immunopositive; Supplemental Fig. VI). IL-1RI 
expression was increased by hyperoxia (at P8), and found throughout all layers of the 
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retina, consistent with its ubiquitous distribution (Supplemental Fig. VII); no 
immunoreactivity to isotype control antibody was detected. 
Upon closer examination one noted overall increased Iba-1 immunoreactive 
cells in retinas of hyperoxic rats compared to normoxic ones (Fig. 3). Retinal microglia 
from normoxic rats possessed thin processes that branched as they extended from 
the cell soma (Fig. 3), characteristic of resting microglia. Microglia in retinas of 
hyperoxic rats were hypertrophied often with amoeboid shape, had fewer processes, 
which were thicker and shorter, consistent with differentiation into an activated 
phagocyte (Fig. 3). Treatment with inhibitors of IL-1R, IL-1Ra or 101.10, renormalized 
the number of activated microglia as well as their morphology which was more 
branched out similar to that in normoxic animals (Fig. 3); these observations along 
with those showing decreased Iba-1 mRNA in IL-1R inhibitor-treated animals (Fig. 1) 
suggested that IL-1β participates in the activation of microglia.  
 
IL-1β is released from microglial cells exposed to hyperoxia in vitro  
 
Microglia is activated and IL-1β is released during the hyperoxia-induced vaso-
obliteration in OIR (Figs. 1 and 3). To confirm microglia as a prominent source of IL-
1β under hyperoxic conditions, primary retinal microglial cells from pup rats at P6 
were isolated and cultured (Fig. 4). Nearly all (>98%) of the isolated DAPI-positive 
cells from retinas of rats were immunopositive for the microglial specific marker Iba-1 
(Fig. 4A) as well as lectin Bandeiraea simplicifolia (Fig. 4B); cells were 
immunonegative for macroglial marker glial fibrillary acidic protein (GFAP; Fig. 4C) 
and for neural marker NeuN (Fig. 4D). Exposure of microglial cells to hyperoxia (80% 
O2) (compared to normoxia [21%]) for 4-24 hours revealed a time-dependent robust 
increase in IL-1β mRNA expression (in cells) and protein (in cell media) (Fig. 4E and 
F), which was not due to an increase in viable microglial cells (Supplemental Fig. 
VIIIA).  
Since hyperoxia results in oxidant stress in retina of young developing 
subjects41 we determined its role in inducing IL-1β. The antioxidant glutathione 
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precursor N-acetyl cysteine markedly prevented hyperoxia-induced microglial 
activation as attested by diminished Iba-1, NLRP3 and IL-1β expression 
(Supplemental Fig. VIIIB-E).  
We also verified in isolated microglia if IL-1β controls activation of microglia 
and stimulates further generation of IL-1β, as inferred in vivo using the inhibitors of IL-
1R (Fig. 1). Indeed, stimulation of microglial cells with IL-1β induced Iba-1 and IL-1β 
(mRNA) expression, and this effect was abrogated by inhibitors of IL-1R (Fig. 4G). 
This auto-amplification of IL-1β expression by exogenous IL-1β was reproduced in IL-
1RI-expressing HEK cells as well as in raw-blue mouse macrophages (Supplemental 
Fig. IXA,B). Essentially, stimulation with exogenous IL-1β induced an increase in IL-
1β mRNA in IL-1RI-expressing HEK cells; this effect was abrogated by IL-RI 
antagonists; no induction of IL-1β was observed in IL-1RI-devoid HEK293 cells 
(Supplemental Fig. IXA). A similar pattern of response was observed in raw-blue 
mouse macrophages (Supplemental Fig. IXB). 
  
Activation of microglia is cytotoxic to endothelial cells through IL-1β-dependent 
induction of Semaphorin 3A in retinal ganglion cells 
 
Since microglial activation and increased IL-1β are associated with vaso-
obliteration during hyperoxia in vivo (Figs. 2-4), we next investigated in vitro if 
conditioned media from activated microglia in culture (which contains IL-1β [Fig. 4F]) 
or if IL-1β is directly cytotoxic to retinal microvascular endothelial cells. Neither 
conditioned media from hyperoxia-exposed microglia nor exogenous IL-1β were 
directly cytotoxic to retinal microvascular cells (Fig. 4H,I). Interestingly, IL-1β has 
been reported to induce the release of the endothelial pro-apoptotic and repulsive cue 
Sema3A from RGC1. We first confirmed the contribution of Sema3A in vaso-
obliteration as seen upon exposure to hyperoxia (when IL-1β levels are high [Fig. 1]). 
We started by showing that exposure to hyperoxia induced an increase in Sema3A 
expression specifically in RGC and that this increase was abolished by IL-1R 
antagonists (Supplemental Fig. X). We then determined the role of Sema3A on vaso-
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obliteration using shRNA encoded in lentiviral vectors (Lv) as we previously reported1. 
Rat pups were injected at P1 with Lv.shSema3A and the contralateral (control) eye 
with Lv.shGFP; the shSema3a- but not the shGFP-encoded lentivirus knocked down 
Sema3A expression (Fig. 5). As anticipated, Lv.shSema3A but not Lv.shGFP (control) 
attenuated the OIR-associated vaso-obliteration at P8 (Fig. 5).  
We further explored the link between IL-1β and Sema3A. IL-1β induced a time-
dependent increase in Sema3A mRNA expression in cultured RGC, which was 
significantly attenuated by inhibitors of IL-1R (Fig. 6A); similar changes were seen on 
the protein by Western blot (Supplemental Fig. IE). In addition, RGC stimulated with 
conditioned media from hyperoxia-exposed (24 h) microglia (containing IL-1β [Fig. 
4F]) triggered endothelial cell apoptosis as attested by activated caspase-3 
(Supplemental Fig. XI) and TUNEL positivity (Fig. 6); similar results were observed 
with recombinant IL-1β (Fig. 7). Inhibitors of IL-1RI as well as anti-Sema3A antibody 
protected the endothelial cells (Fig. 6B,C and Fig. 7), and conversely application of 
Sema3A to endothelial cells triggered death (Fig. 7; Supplemental Fig. XIIA); 
apoptotic effects of Sema3A were unrelated to VEGF expression (Supplemental Fig 
XIIB) as reported38. In contrast, hyperoxia-exposed endothelial cells did not exhibit 
augmented IL-1β formation, and treatment of RGC with conditioned media from 
hyperoxia-exposed endothelium did not cause endothelial cytotoxicity (Supplemental 
Fig. XIIC,D). Together with in vivo evidence that IL-1R inhibitors prevent the early 
hyperoxia-induced surge in Sema3A (Fig. 1C, and Supplemental Fig. X), the present 
findings strongly support an IL-1β-induced Sema3A expression and in turn endothelial 
cell death, consistent with Sema3A-dependent impaired vascular sprouting. Our 
results provide evidence for a role for IL-1β, (largely) from sustained activated 
microglia (Figs. 3 and 4), in contributing significantly to hyperoxia-induced vaso-
obliteration through a mechanism involving the pro-apoptotic factor, Sema3A.  
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Discussion 
A number of studies have proposed a role for inflammatory mediators in 
ischemic retinopathies. In this context, the major proinflammatory cytokine IL-1β has 
been suggested to contribute to the development of proliferative diabetic retinopathy 
in humans as well as in animal models7,12,25,42 choroidal neovascularization and 
retinal degeneration8,9; its role in retinopathy of prematurity has never been 
specifically evaluated. On one hand, IL-1β is primarily associated with 
angiogenesis.8,9,18,43 Whereas, on the other hand, IL-1β has also been linked to retinal 
vascular degeneration44; this latter aspect remains unexplained. Although microglia 
are thought to contribute significantly to the generation of cytokines in neural 
tissue,2,45 their involvement in retinovascular degeneration is elusive; along these 
lines, microglia (nonactivated) are reported to participate in normal developmental 
angiogenesis.46 In this study, we show that retinal microglia are overactivated during 
the vaso-obliteration phase of ischemic retinopathies, and serve as an important 
source of IL-1β, which induces vascular degeneration not directly but rather by 
stimulating the generation of proapoptotic/repulsive cue Sema3A from adjacent 
neurons. Inhibitors of the IL-R, notably exogenous recombinant IL-1Ra and the IL-1R 
modulator 101.10,39 decreased microglial activation and IL-1β release, and in turn 
Sema3A expression, consequently diminishing vaso-obliteration, enhancing 
revascularization and, thus, attenuating resultant pathological preretinal 
neovascularization in the established model of OIR. 
A major feature in this study applies to the pivotal role of microglia not only in 
generating IL-1β, but also through this cytokine in orchestrating neurovascular 
degeneration through the release of Sema3A. Although microglia are known to be in 
intimate contact with neovascular tufts29,30 because they guide the proliferating 
vascular bed,46 mechanisms for their role in vascular degeneration is vague. We 
found that in response to hyperoxic stress, microglia are activated and release IL-1β 
(in vivo and in vitro), which in turn induces its endothelial cytotoxic effects via RGC-
derived Sema3A; our findings do not fully exclude a contribution of cytokines by other 
	   127	  
retinal cells.19 Consistent with these findings, hyperoxic stress is tightly intertwined 
with inflammation47 through receptors activated by products of peroxidation, such as 
CD36,48 TLR4, and stimulation of the inflammasome49; this oxidant stress41 seems to 
explain the generation of IL-1β during hyperoxia as observed here and by others.50 
Conversely, we found that interfering with IL-1R actions preserved retinal vasculature, 
enhanced revascularization, and, as a result, prevented preretinal neovascularization. 
In this context, we observed that it is not so much the number of microglia that 
changes with the stress stimulus (hyperoxia) but rather their activation. These 
observations are consistent with microglial activation in human diabetic retinopathy28 
as well as in experimental ischemic retinopathies.30 Interestingly, we also found that 
IL-1β maintains activation of microglia, and inhibition (or downregulation) of IL-1R 
prevents increased Iba-1 in microglia and IL1β expression in different cell types. 
Along these lines, inhibition of microglial activation (using minocycline) has been 
found to diminish cytokine release and reduce progression of ischemic retinopathy27; 
whereas exogenous IL-1Ra reduces intercellular adhesion molecule-1 expression and 
reinstates microglial ramification (resting condition)34; microglial activation is also 
reduced in IL-1R1 null mice subjected to hypoxic/ischemic insults.51 Together our 
observations, supported by other reports, suggest an autoactivation of microglia 
through IL-1β. 
In the present work, we uncover a new mechanism for IL-1β in inducing retinal 
microvascular degeneration, specifically by stimulating RGCs to produce the 
proapoptotic/repulsive factor Sema3A. By 20 hours of hyperoxia, microglia were 
activated through an IL-1β–dependent process, resulting in release of IL-1β (along 
with other inflammatory markers) and (consequently) in Sema3A; this in vivo induction 
in IL-1β expression could be reproduced and better characterized in vitro on cultured 
microglia exposed to hyperoxia; in turn, IL-1β was also shown to induce Sema3A in 
isolated RGCs. Consequently, Sema3A was responsible for microvascular endothelial 
cell death (in vitro and in vivo); hence, inhibition of IL-1R or of Sema3A (anti- Sema3A, 
or through silencing shRNA-Sema3A) exerted a relative preservation of retinal 
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endothelium. By 120 hours of hyperoxia (at P10), retinal vascular degeneration was 
found to be pronounced, resulting in a relatively hypoxic inner retina, which triggers 
an increase in VEGF expression in an attempt to reestablish O2 supply; this does not 
exclude a direct role for IL-1β in inducing VEGF expression52–54; however, there was 
a general suppression of inflammatory markers at P10 (compared with P8), which 
may be attributable to the relative increase in IL-1Ra. Interestingly, one also notes at 
P10 unaltered levels of Sema3A (compared with normoxia), consistent with a rate of 
vaso-obliteration, which decreases from P8-P10 compared with P5-P8. Inhibition of 
IL-1R prevents the early (P8) rise in Sema3A, which contributes to vaso-obliteration, 
and facilitates revascularization; re-establishment of the O2 supply to the retina 
suppresses a hypoxia-driven surge in VEGF at P10. A schematic model depicting our 
overall observations is presented in Figure 8. 
A new aspect conveyed in this study applies to the efficacy of the IL-1R 
modulator 101.10 in ischemic retinopathies. This small stable peptide was as effective 
as recombinant IL-1Ra. Recombinant IL-1Ra is approved for rheumatoid arthritis, but 
exhibits certain drawbacks, such as pain at the site of administration, need for 
injection (rather than oral administration), and increased risk for infections. The 
allosteric modulator of IL-1R 101.10 may offer certain advantages, including possibly 
through its pharmacological selectivity diminish certain adverse effects such as the 
risk for infections.39 101.10 may represent a prototype for a new class of small 
(molecule) inhibitors of IL-1R, which so far are all large molecules requiring parenteral 
administration.55 
In summary, we hereby present a critical role for IL-1β in contributing to the 
early (and consequently as well to the late) phase of OIR, by activating microglia that 
are major contributors in IL-1β generation; on one hand, IL-1β sustains microglial 
activation, and on the other induces adjacent RGCs to produce Sema3A. The latter 
causes microvascular degeneration contributing to the early vaso-obliteration 
detected in ischemic retinopathies, which predisposes to subsequent preretinal 
neovascularization. Distinct inhibitors of IL-1R, notably recombinant IL-1Ra and the 
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modulator 101.10, prevent hyperoxia-induced microglial activation, the surge in IL-1β 
formation, retinal vaso-obliteration and, consequently, preretinal neovascularization. 
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Significance  
IL-1β is a major pro-inflammatory cytokine that is vasoproliferative for 
endothelium from tumors and choroid. Although it is detected in high levels in retina in 
ischemic retinopathies such as that associated with diabetes (and prematurity), its 
role in the corresponding vasculopathy is unknown. We found in ischemic 
retinopathies, that the majority of IL-1β arises from activated microglia and 
participates in its auto-activation. IL-1β was cytotoxic to retinal vasculature. However, 
this effect was not direct but rather occurs through a complex process involving 
activation of neurons to produce Semaphorin 3A, which in turn induces apoptosis of 
retinal microvascular endothelium. Inhibition of IL-1β (using IL-1Ra [Kineret], or a 
novel allosteric modulator d-peptide rytvela) or of Semaphorin 3A preserves retinal 
microvascuture and prevents ensuing aberrant intra-vitreal neovascularization – a 
predisposition to blindness. IL-1β is thus an important target which so far has 
attracted little attention for ischemic retinopathies; approved inhibitors may yield 
clinical benefits.  
 
 
 
 
Specific contributions from the candidate 
The contribution of IL-1β and microglia in Ischemic Retinopathies (IRs) is not 
so well defined; elevated levels of both cytokine and cell in the retina have been 
documented in the literature in patients with DR and ROP and they appear to have a 
causal role in exacerbating IRs. Dr. JC Rivera and Dr. S Chemtob initially set out to 
explore how microglia and IL-1β effectively contribution to the pathogenesis of IRs. In 
the previous study, published in Blood, we crudely outlined the contribution of 
inflammation and IL-1β in the induction of Sema3A expression; my contribution in this 
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study was determining the precise interaction between microglia cells and neurons in 
producing Sema3A (via IL-1β), which, in turn, cause vascular decay. 
Precisely, I contributed to the development of the project through planning, 
designing and performing the experiments. I partook in gathering and analyzing data, 
and preparing figures for the manuscript. Finally I contributed to scripting and editing 
the manuscript.  
Dr. JS Joyal, Dr. P Hardy, Dr. F Sennlaub and Dr. W Lubell provided expert 
opinion in the study. 
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Figure 1. Hyperoxia triggers the production of inflammatory mediators and 
other factors in the retina. Quantitative RT-PCR analysis on whole retinas from 
animals exposed to hyperoxia (80% O2) for 20 hours (HypP6) and from P5 to P8 
(HypP8) or P5 to P10 (HypP10) treated intraperitoneally with vehicle, IL-1Ra or 
101.10; normoxic control values were set at 1. An increment in the retinal mRNA 
expression of IL-1β, Iba-1, Sema3A, TNF-α and ICAM-1, was seen 20 hours after 
exposure to hyperoxia (80%) (at P6) compared to the normoxic retinas. By P8 and 
P10 the mRNA expression of IL-1β, Iba-1 and Sema3A gradually decreased 
compared to values at P6. IL-1R inhibitors decreased IL-1β, Iba-1 and Sema3A 
values at P6 and P8. Values are mean ± SEM of 3-4 experiments. The fold changes 
were normalized to 18S as internal control. Significant differences (p value) in the 
mRNA levels between vehicle and IL-1Ra or 101.10 treatments are shown in the 
graphs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   139	  
Relative contributions: Figure 1 
A) through H) Drug administration, sample preparation performed by JC Rivera 
and JC Honoré 
qPCR and analysis performed by N Sitaras and JC Rivera  
 
Animal handling and sample collection: JC Rivera and N Sitaras 
Figure preparation: JC Rivera, N Sitaras and S Chemtob 
Approximate Figure contribution: 50% 
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Figure 2. Inhibition of IL-1β activity decreases retinal vaso-obliteration and 
promotes revascularization. Representative images of flat-mounted retinas labeled 
with Griffonia simplicifolia lectin to examine vascularization at P8 (A) and at P10 (D); 
the central outline delimits the vasoobliterated (VO) region. In the top panels (A-C) rat 
pups (n=5-6 per group) were treated with vehicle or IL-1R antagonists, and 
maintained in hyperoxia (80% oxygen) from P5 to P8; one notes a 26% central 
capillary dropout area (white areas) and 44% decrease in vascular density in controls 
(compared to pups exposed to 21% oxygen). Whereas IL-1Ra and 101.10 treatments 
significantly reduced the capillary dropout areas to ∼10% (B;  #*p<0.05 versus 
hyperoxia [vehicle-treated], and increased vascular density to ∼85% [C;. &p=0.001 vs 
normoxia,  #*p<0.05 versus hyperoxia [vehicle]). In lower panels (D-G) rat pups (n=5-
6) were maintained in hyperoxia (80% oxygen) from P5 to P10 (D) and treated with 
vehicle or IL-1R antagonists from P8 (when vaso-obliteration was already present) 
until P10. In vehicle-treated animals there was a 29% central capillary dropout area 
and 48% reduction in vascular density compared to the control. Treatment with both 
antagonists of IL-1R (starting at P8 and ending at P10, see arrows in Fig. G) reduced 
significantly the central capillary dropout area to ∼13% (E; #*p<0.05 versus hyperoxia 
[vehicle]), and increased vascular density to ∼78% (F), and promoted 
revascularization as noted by decrease in vaso-obliteration between P8 and P10 (G;  
&p<0.001 vs normoxia,   #p<0.01 and *p<0.001versus hyperoxia [vehicle]). 
 
 
 
 
 
 
 
 
	   142	  
Relative contributions: Figure 2 
A) through G) Drug administration, sample preparation performed by JC Rivera, N 
Sitaras and JC Honoré 
Imaging and analysis performed by JC Rivera and N Sitaras 
 
Animal handling and sample collection: JC Rivera 
Figure preparation: JC Rivera and S Chemtob 
Approximate Figure contribution: <10% 
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Figure 3. Hyperoxia-induced generation of IL-1β is largely produced by 
activated microglia in the retina. (Left panels) Representative confocal images 
showing immunoreactivity of IL-1β (green) and Iba-1 (red) merged with DAPI (blue 
and yellow) in retinal cryosections from 8-day-old rats (n=3 per group) after 3 days in 
normoxia (21% O2) or hyperoxia (80% O2). Co-staining of IL-1β with Iba-1 was 
detected mainly on activated microglial cells localized in the nerve fiber layer (NFL) or 
the ganglion cell layer (GCL) in retinas from hyperoxic pups treated with vehicle. 
Retinas from hyperoxic rat pups treated with IL-1Ra or 101.10 reveal a decrement in 
IL-1β staining and a resting microglia phenotype (Iba-1 labeling) similar to the 
normoxic animals in the outer nuclear layer (ONL) and GCL. Scale bar = 50 μm. 
(Right panels) Quantitative analysis of the number of Iba-1 immunopositive cells in 
retinal flat-mounts (n=3-4 per group) from pups exposed to normoxia (21% O2) or 
hyperoxia (80% O2) from P5 until P8 and treated with vehicle, IL-1Ra or 101.10; 
&p<0.01 vs normoxia, #* p<0.01 vs hyperoxia. Representative photomicrographs from 
retinal flat-mounts stained with Iba-1 (white) showed a predominant labeling of 
ramified, non-activated microglia in animals exposed to normoxic conditions, whereas 
a large number of amoeboid/activated cells were present in retinas under hyperoxic 
conditions. Hyperoxic animals receiving IL-1Ra or 101.10 administrations displayed a 
reverse phenotype of microglia with long protrusions typical of resting microglia. Scale 
bar = 50 μm. 
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Relative contributions: Figure 3 
Drug administration performed by JC Rivera, N Sitaras and JC Honoré 
Imaging and analysis performed by JC Rivera and N Sitaras 
 
Animal handling and sample collection: JC Rivera 
Figure preparation: JC Rivera and S Chemtob 
Approximate Figure contribution: <10% 
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Figure 4. IL-1β is released from microglial cells exposed to hyperoxia in vitro. 
Representative retinal microglial cultures isolated from 6 days old rats, and 
characterized by double immunostaining for the classic microglial markers Iba-1 (A), 
and lectin (B); cultures (n=4) were immune-negative for the specific astrocyte marker 
glial fibrillary acidic protein (GFAP, C) and the specific neural marker neuronal nuclei 
(NeuN, D). Scale bar = 50 µm. mRNA and protein expression of IL-1β were evaluated 
respectively by qRT-PCR on cell culture lysates (E) or by ELISA in the conditioned 
media (F) from primary microglia cells (n=3-4 per condition) exposed to 21% and 80% 
of oxygen levels for 4, 12 and 24 hours.*p<0.001 vs 21% O2. Microglial cell cultures 
(n=4) exposed to IL-1β (0.5 ng/ml) resulted in an increment in mRNA expression for 
Iba-1 and IL-1β, that was significantly suppressed with both IL-1R antagonists 
treatment (G). & p<0.001 vs control and *# p<0.001 vs IL-1β treatment. No changes 
were observed in cell viability evaluated by MTT reduction assay on neuro-
microvascular endothelial cells (RBMVEC; n=3) treated with hyperoxic (80% O2) 
microglial media (H) or IL-1β protein (I; 0.5 ng/ml), in absence (vehicle) or presence of 
IL-1Ra or 101.10 for 24 hours. Conditioned media from microglial cells exposed to 
normoxia (21%) or PBS (vehicle) were used as controls.  
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Relative contributions: Figure 4 
A) through D) Microglial isolation, expansion and characterization performed by 
JC Rivera and C Quiniou 
E) and F) In vitro assay and qPCR analysis performed by JC Rivera, N Sitaras, B 
Noueihed and A Madaan 
H) and I) In vitro assay and analysis performed by JC Rivera, N Sitaras, B 
Noueihed and A Madaan 
 
Animal handling and sample collection: JC Rivera  
Figure preparation: JC Rivera, N Sitaras, B Noueihed and S Chemtob 
Approximate Figure contribution: 30% 
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Figure 5. Sema3A contributes to vaso-obliteration in rat pups exposed to 
hyperoxia. Representative photomicrographs of Griffonia simplicifolia lectin-stained 
flat-mount retinas at P8 reveal that rat pups (n=4-5) receiving an intravitreal injection 
of Lv.shSema3A show a 36 % reduction in the area of vaso-obliteration (central 
outline) compared with contra-lateral eyes receiving Lv.shGFP injections and 
noninjected eyes (control). Specificity of shSema3A was confirmed by qRT-PCR, 
where Sema3A expression was diminished (vs Lv.shGFP). n=3; ***p<0.01 compared 
to corresponding Lv.shGFP. Values in the histogram are presented as the rate 
change in vaso-obliterated areas relative to Lv.shGFP-treated controls ± SEM. 
***p<0.01 vs Lv.shGFP.  
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Relative contributions: Figure 5 
Lentiviral preparation performed by N Sitaras and D Hamel 
Intravitreal injections performed by JC Rivera and N Sitaras  
Immunohistochemistry, imaging and analysis performed by JC Rivera and N 
Sitaras 
 
Animal handling and sample collection: JC Rivera and N Sitaras 
Figure preparation: JC Rivera, N Sitaras and S Chemtob 
Approximate Figure contribution: 40% 
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Figure 6. Activation of microglia is cytotoxic to endothelial cells through IL-1β-
dependent generation of Semaphorin 3A by retinal ganglion cells. (A) RGC-5 
stimulated with IL-1β (0.5 ng/ml; n=3) elicited an increase in Sema3A expression (at 
12, 18 and 24 hours), that was suppressed by IL-1Ra or 101.10. &p<0.001 vs 0 hours, 
#*p<0.001 vs IL-1β effect. Representative photomicrographs of apoptotic cells (C; 
green nuclei) detected by TUNEL on RBMVEC treated for 48 hours with conditioned 
medium from RGC-5 cells which were previously stimulated with normoxia- (21% O2; 
Norm-MG-RGC-CM) or hyperoxia-exposed (80% O2) media from microglia untreated 
(vehicle; Hyp-MG-RGC-CM) or treated with IL-1Ra or 101.10. Co-localization of 
RBMVECs nucleus stained with DAPI (blue) and TUNEL staining were merged with 
phase contrast. Scale bar = 50μm. (B) Histogram compiles percent TUNEL-positive 
cells determined in three different fields for each group (n=3) and normalized to the 
control (Normoxia). &p=0.01 vs Norm-MG-RGC-CM, #* p<0.05 vs Hyp-MG-RGC-CM-
vehicle.  
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Relative contributions: Figure 6 
A) In vitro assay and qPCR analysis performed by JC Rivera, N Sitaras and B 
Noueihed 
B) In vitro assay and TUNEL analysis performed by JC Rivera, N Sitaras  
C)  Immunocytochemistry, imaging and analysis performed by JC Rivera  
 
Figure preparation: JC Rivera, N Sitaras and S Chemtob 
Approximate Figure contribution: 20% 
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Figure 7. Endothelial apoptotic effects of RGC-conditioned media containing 
Sema3A.  obtained by stimulation of RGC-5 with IL-1β is abolished by the 
immunoneutralization of Sema3A or by blocking the activation of the IL-1 
receptor. Representative micrographs of apoptotic neuro-microvascular endothelial 
cells (RBMVEC) detected by TUNEL (green nuclei) 24 h after treatment of RGC-5 
stimulated or not with IL-1β (RGC-CM), recombinant Sema3A (Sema3A) or 
conditioned media from RGC-5 cells previously stimulated with IL-1β (0.5 ng/ml) in 
absence (RGC-CM+IL-1β) or presence of IL-1R antagonists (RGC-CM+IL-1β+IL-1Ra 
and RGC-CM+IL-1β+101.10), or RGC-CM+IL-1β immu-neutralized with a polyclonal 
anti-Sema3A antibody (2µg/ml, RGC-CM+anti-Sema3A). Cells were counter-stained 
with DAPI (blue) to detect nuclei. Scale bar = 100μm. Histogram compiles the 
percentage of TUNEL-positive cells determined in three different fields for each group 
(n=3) and normalized to the control (RGC-CM). $#p=0.05 vs Norm-RGC Medium, *** 
p<0.05 vs RGC-CM+IL-1β. 
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Relative contributions: Figure 7 
In vitro assay performed by JC Rivera and N Sitaras  
Immunocytochemistry, imaging and TUNEL analysis performed by JC Rivera 
and N Sitaras 
 
Figure preparation: JC Rivera and S Chemtob 
Approximate Figure contribution: 10% 
 
	   158	  
 
 
 
 
 
 
 
	   159	  
Figure 8. Microglia activation contribute to vascular regression in ROP through 
IL-1β-dependent stimulation of Semaphorin 3A in retinal ganglion cells: 
Inhibition of IL-1β activity decreases retinal vaso-obliteration and promotes 
revascularization. Microglial cells maintain the neuronal homeostasis and 
immunological integrity of the healthy retina. Hyperoxia as seen in OIR and 
retinopathy of prematurity activates microglia, which become a prominent source of 
pro-inflammatory auto-activating interleukin-1β (IL-1β). IL-1β then stimulates in a 
paracrine manner the production of Sema3A from adjacent retinal ganglion cells, and 
in turn induces endothelial cell death. Pre-treatment with IL-1R blockers prevent this 
cascade, retinal vaso-obliteration, and subsequent pre-retinal neovascularization. 	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Relative contributions: Figure 8 
Schematic provided by JC Rivera 
 
Figure preparation: JC Rivera, N Sitaras and S Chemtob 
Approximate Figure contribution: <10% 	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Abstract 
Background: Ischemic retinopathies (IRs) are characterized by sequential 
vasoobliteration followed by abnormal intra-vitreal neovascularization predisposing to 
retinal detachment and blindness. IRs are associated with robust inflammation 
leading to generation of IL-1β, which causes vascular degeneration and impairs 
retinal revascularization. Yet, revascularization of the retina occurs in subjects with 
IRs. Because inflammation leads to activation of proteases involved in formation of 
vasculature, we hypothesized that PAR2 may modulate deleterious effects of IL-1β. 
Methodology and Results: PAR2 - detected mostly in retinal ganglion cells – was 
upregulated in Oxygen-induced retinopathy (OIR). Surprisingly, OIR-induced 
vasoobliteration and neovascularization were unaltered in PAR2-knockout mice, 
suggesting compensatory mechanisms. We therefore conditionally knocked down 
retinal PAR2 with shRNA-PAR2-encoded lentivirus. PAR2 knockdown interfered with 
normal revascularization, resulting in pronounced intra-vitreal neovascularization; 
conversely PAR2 agonist peptide (SLIGRL) accelerated normal revascularization. In 
vitro and in vivo exploration of mechanisms revealed that IL-1β induced PAR2 
expression, which in turn, downregulated IL-1RI through ERK1/2-dependent process. 
Significance: Collectively, our findings unveil an important mechanism, by which IL-
1β regulates its own endothelial cytotoxic actions by augmenting PAR2 expression to 
repress sequentially IL-1RI and Sema3A expression. Timely activation of PAR2 may 
be a promising therapeutic avenue in IRs. 
Key Words: 
Ischemic retinopathies, inflammation, revascularization, protease-activated receptor 2, 
inteleukin-1 beta, Semaphorin 3A 
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Introduction 
 Ischemic retinopathies, such as retinopathy of prematurity (ROP) and in some 
circumstances diabetic retinopathy (DR), are the main causes of severe visual 
impairment in children and working class population in industrialized countries1, 2. 
Ischemic retinopathies are biphasic diseases characterized by a degeneration of the 
retinal vascular bed, resulting in tissue hypoxia that leads to an anarchic, deregulated 
vessel proliferation into the vitreous, which in severe instances can result in retinal 
detachment and blindness3. Importantly, the vascular decay-induced retinal ischemia 
can also cause neuronal dysfunction and loss4. Therefore, therapeutic interventions 
that help accelerate alleviate ischemic stress of the neural retina would be desirable 
to prevent these adverse neuronal consequences in patients suffering from Ischemic 
retinopathies.  
 In Ischemic retinopathies, oxidative stress elicits sustained inflammation 
associated with a release of inflammatory cytokines5-8, notably interleukin-1b (IL-1b), 
which participates in recruiting and activating inflammatory cells in the retina8-10. We 
recently showed in a murine model of oxygen-induced retinopathy (OIR) that 
hyperoxia-activated microglia through an autocrine feedback loop to secrete IL-1b. IL-
1b in turn induces in a paracrine manner the release of the pro-apoptotic repulsive 
cue Semaphorin3A (Sema3A) from neighbouring retinal ganglion cells (RGC), which 
contributes to vaso-obliteration8 and hinders normal revascularization11. This self-
sustained and potentially unrelenting destructive inflammatory cascade, if kept 
unchecked, could result in severe obliteration of the microvascular network of the 
retina; however, this is not the case as revascularization eventually does occur, albeit 
slowly (over several days)12. Simple homologous downregulation of IL-1RI by its own 
natural ligand, however, is usually not the case; in fact, the contrary often happens13, 
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14. It is thus reasonable to postulate the existence of alternate intrinsic regulatory 
mechanism that counteracts the self-sustained and potentially harmful IL-1b-induced 
inflammatory cascade. 
 Inflammation is associated with the release and activation of various proteases 
involved in ensued vascularization15. A number of these proteases activate a class of 
G protein-coupled receptors (GPCR) the Protease-activated receptors (PARs), 
through cleavage of their N-terminus thus revealing their tethered ligand, which can 
subsequently bind to the second extracellular loop of the PARs to elicit intracellular 
signaling16. Of the four members of the PAR family, PAR1 through 416, PAR2 is 
recognized for its marked pro-angiogenic properties in the retina17, 18. Interestingly, 
PAR2 is robustly activated by IL-1b in different cell types, including neurons and 
endothelial cells19-22; and IL-1b-mediated inflammation can further induce the 
expression of various proteases, which can cleave and activate PAR223. This may 
appear rather counterintuitive as amplified IL-1b increases endothelial cell death in 
OIR8, 11. We therefore hypothesize that in OIR PAR2 exerts its angiogenic properties 
by countering the cytotoxic actions of IL-1b. 
 Using a mouse model of OIR24, which mimics the cardinal features of ischemic 
retinopathies, we uncover a new mechanism of action for PAR2 in retinal 
revascularization. By conditionally knocking down PAR2 (utilizing a lentiviral-encoded 
shRNA), we hereby show that IL-1b regulates neuronal PAR2 expression, which in 
turn reduces oxygen-induced vaso-obliteration and enhances desirable 
revascularization of the retina. The effect of PAR2 is mediated (in large part) by 
downregulating IL-1RI specifically in RGCs, which in turn diminishes Sema3A release, 
to facilitate revascularization. Our findings unveil a novel property for PAR2 in 
modulating inflammation, which in the context of ischemic retinopathies limits the 
vaso-obliterative effects of amplified IL-1b, allowing desirable revascularization and 
consequently reducing pathological intra-vitreal neovascularization.  
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Materials and Methods 
Animals 
Adult C57BL6/J mice and PAR2 transgenic mice (B6.Cg-F2rl1tm1Mslb) were purchased 
from Jackson laboratories (Bar Harbour, Maine, USA). PAR2 transgenic mice were 
genotyped as described by Jackson Laboratories. Adoptive CD-1 lactating females 
were purchased from Charles Rivers Laboratories (Sainte-Hyacinthe, Canada) to tend 
to hyperoxia-exposed mice pups. All experiments were conducted in accordance with 
ARVO statement regarding use of animals in ophthalmic and vision research and 
were approved by Maisonneuve-Rosemont and Sainte-Justine research center animal 
care committees.  
Oxygen-induced retinopathy (OIR) 
Mice pups were exposed from postnatal day 7 (P7) to P12 to 75 % oxygen using 
BioSpherix oxycycler. Vasoobliteration (VO) and neovascularization (NV) were 
assessed in hyperoxia-exposed mice pups at P12 and P17, respectively, as 
described previously24, 25. Concisely, mice pups were fully anesthetized in 3 % 
isoflurane in oxygen and decapitated using a guillotine. Eyes were enucleated and 
fixed in 4 % paraformaldehyde solution for 1 h at room temperature. Retinas were 
dissected and stained overnight at 4ºC with fluorescein-labeled GSL 1, isolectin B4 
(Vector Labs; 1:100). Lectin-stained retinas were whole-mounted onto Superfrost/Plus 
microscope slides (Fisher Scientific) with the photoreceptor side down and imbedded 
in Fluoro-gel (Electron Microscopy Sciences) and imaged at 10x using a Zeiss 
AxioObserver.Z1. Images were merged into a single file using the MosiaX option in 
the AxioVision 4.6.5 software (Zeiss). Quantification of VO and NV was assessed 
using the SWIFT_NV methods as previously described26. Commercial interleukin-1 
receptor inhibitor Kineret® (Amgen Canada Inc.) was administered intraperitoneally 
from P7 to P8 at 20mg/kg/day. 
Preparation of lentiviral particles 
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Third generation Lentivirus (HIV-1) was prepared by as previously described27. p24 
ELISA kit (Clontech) was used to quantify lentiviral titers for Lv. shGFP (8.5 ng/mL), 
Lv. shPAR2 (9.6 ng/mL) and Lv. GFP (15.0 ng/mL). 
Intravitreal injections 
Animals were anesthetized in 3 % isolfurane in oxygen and injected intravitreally 
either at P3 with 1.0 uL of lentiviral particles (described above) or at P7 with 10 mmol 
of Kineret® or P7 and P9 or P12 and P14 with 100 mmol of NH2-SLIGRL (Elim 
Biopharm) using a Hamilton syringe equipped with 50 gauge glass capillary.  
Immunohistochemistry 
Eyes were enucleated from mice pups and fixed in 4 % paraformaldehyde at room 
temperature for 2 h and saturated overnight at 4ºC in a 30 % sucrose solution prior to 
embedding in OCT compound (TissueTek®). Coronal sections of 10 mm were 
sectioned using a Cryostat (Leica). Sections were subsequently washed with PBS, 
blocked and permeabilized for 1 h at room temperature and subsequently incubated 
with fluorescein-labeled GSL 1, isolectin B4 (Vector Labs; 1:100) for retinal 
vasculature. Antibodies to rabbit bIII-tubulin (ECM Biosciences; 1:1000), mouse bIII-
tubulin (Sigma; 1:1500), mouse PAR2 (Invitrogen; 1:500), rat CD31 (BD Biosciences; 
1:100), rabbit IL-1RI (Santa Cruz Biotechnology; 1:400), rabbit Sema3A (Abcam, 
1:500) or rabbit VEGF (Santa Cruz Biotechnology; 1:200), while fluoresceinated 
secondary antibodies (goat anti-mouse IgG Alexa Fluor 488, 594 and/or 647 and goat 
anti-rabbit IgG Alexa Fluor 488, 594 and/or 647; Invitrogen) were used for localization 
studies according to manufacturers’ recommendations. Samples were visualized 
using 30x or 60x objectives with an IX81 confocal microscope (Olympus), and images 
were obtained with Fluoview 3.1 software (Olympus). 
Laser-capture microdissection 
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Eyes were enucleated and immediately embedded in OCT compound and snap 
frozen in liquid nitrogen and subsequently cut into 16 mm coronal sections onto 
MembraneSlide 1.0 PEN nuclease free slides (Zeiss). To visualize vessels, sections 
were prepared as previously described11. Retinal sections were laser-microdissected 
(LCM) with the Zeiss (Observer.Z1) Palm Microbeam LCM microscope system. 
Isolated retinal RNA was transcribed into cDNA for quantitative real-time PCR 
analysis (see Reverse Transcription PCR).  
Western Blot  
Eyes were enucleated and retinas dissected and placed into commercial RIPA buffer 
(Cell Signalling) and homogenized using Precellys 24 homogenizer. Samples were 
centrifuged and 30 μg of pooled retinal lysate from two different animals was loaded 
on an SDS-PAGE gel and subsequently electro-blotted onto either PVDF or 
nitrocellulose membrane (BioRad). After blocking, the membranes were blotted with 
1:400 mouse antibody to PAR2 (35-2300, Invitrogen), 1:1000 mouse antibody to b-
actin (Santa Cruz Biotechnology), 1:200 rabbit antibody to VEGF (SantaCruz 
Biotechnology), 1:400 rabbit antibody to IL-1RI (sc-689; Santa Cruz Biotechnology), 
1:400 goat antibody to IL-1b (R&D Systems), 1:1000 rabbit antibody to Sema3A 
(Abcam), 1:500 rabbit antibody to total (Cell Signaling) or phosphorylated IRAK1 
(Sigma), 1:1000	   rabbit	   or	   mouse	   antibody	   to	   total	   and	   phosphorylated	   ERK1/2	   (Cell	  Signaling),	   1:1000	   rabbit	   antibody	   to	   total	   and	   phosphorylated	   p38	   (Cell	   Signaling)	   or	  1:1000	   rabbit	   or	  mouse	   antibody	   to	   total	   and	   phosphorylated	   c-­‐jun	  N-­‐terminal	   kinase	  [JNK]	   (Cell	   Signaling). After washing, membranes were incubated with 1:5000 
horseradish peroxidase-conjugated (HRP) anti-mouse or 1:2000 HRP anti-goat or -
rabbit secondary antibodies (Millipore). Membranes were imaged with LAS-3000 
imager and bands were assessed using densitometry plugins in Multi Gauge 4.0 
software (FujiFilm). 
Reverse-transcription PCR and quantitative real-time PCR 
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Freshly dissected whole retina or laser-capture microdissected samples were 
processed using RiboZol (AMRESCO) as described by manufacturer’s instructions. 
Genomic DNA was removed using DNAse I (Invitrogen). Approximately 1 mg of total 
RNA was reverse-transcribed into cDNA using iScript RT Supermix (BioRad) as 
described by manufacturer’s instructions. cDNA was analysed by Quantitative real-
time PCR using iQTM SYBR® Green Supermix (BioRad) with primers targeting mouse 
PAR2 (Fwd 5’-TGACCACGGTCTTTCTTCCG-3’ and Rev 5’-
TCAGGGGGAACCAGATGACA), rat PAR2 (Fwd 5’-TGGGAGGTATCACCCTTCTG-3’ 
and Rev 5’-GGGGAACCAGATGACAGAGA-3’), mouse Sema3A (Fwd 5’-
GCTCCTGCTCCGTAGCCTGC-3’ and Rev 5’-TCGGCGTTGCTTTCGGTCCC-3’), 
mouse VEGF-A (Fwd 5’-GCCCTGAGTCAAGAGGACAG-3’ and Rev 5’-
CTCCTAGGCCCCTCAGAAGT-3’), mouse and rat IL-1RI (Fwd 5’-
TGAATGTGGCTGAAGAGCAC-3’ and Rev 5’-CGTGACGTTGCAGACAGTT-3’) and 
mouse IL-1b (Fwd 5’-CTGGTACATCAGCACCTCACA-3’ and Rev 5’-
GAGCTCCTTAACATGCCCTG-3’) (designed using Primer3TM [NCBI]; see 
Supplemental Table 1). Quantitative gene expression analysis was assessed using 
ABI 7500 Real-Time PCR system (Applied Biosystems) and compared to control 
genes cyclophilin A (Fwd 5’-CAGACGCCACTGTCGCTTT-3’ and Rev 5’-
TGTCTTTGGAACTTTGTCTGCAA-3’) or 18S primers (Ambion) using the DDCT 
quantification. 
Preparation of stable cell lines 
Neeraj Agarwal of the University of North Texas Health Science Center at Fort Worth 
kindly provided the RGC-5 cell line and was prepared as previously described28. 
Undifferentiated RGC-5 were incubated overnight with lentiviral particles containing 
shRNA. Next day, media was changed and incubated for 48h prior to selection with 5 
ug/mL puromycin (Sigma) for 7 days. Cells were differentiated thereafter with 1 mM 
staurosporine (Sigma). 
Stimulation of RGC-5 and RBMVEC 
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Rat brain microvascular endothelial cells (RBMVEC) were obtained from Cederlane 
Laboratories (Cell Applications; cat #: R840-05a) and used between passages 2 – 7. 
RGC-5 were cultured in DMEM (Invitrogen) supplemented with 10 % FBS (Cell 
Applications) and 1 % penicillin/streptomycin (Cell Applications) at 37ºC and 5 % CO2 
while RBMVEC were cultured as described by manufacturer’s instructions. Cells were 
starved 4 h prior to treatment with 1.0 or 10.0 ng/mL of recombinant murine IL-1b 
(PeproTech) or 0, 40 or 100 mM SLIGRL-NH2. Commercial	   inhibitors	   for	   ERK1/2	  (U0126),	  JNK	  (SP600125)	  and	  p38	  (SB203580)	  were	  purchased	  from	  Sigma	  and	  used	  at	  10	  µM	  approximately	  60	  min	  prior	  to	  SLIGRL-­‐NH2	  treatment.	  	  
Preparation of RGC-5 conditioned media (CM) 
Terminally differentiated RGC-5 were seeded (106 cells) and starved 4 h prior to 
treatment with 0 or 100 mM NH2-SLIGRL and exposed to 5.0 ng/mL of recombinant 
murine IL-1b (PeproTech). Supernatants were collected 24 h later, centrifuged briefly 
and filtered through 0.22 mm filters (Millipore) and distributed for proliferation assays 
(see below). 
Cell survival assay 
Approximately 104 RBMVEC cells/well were seeded in 24-well plates and starved 4 h 
prior to exposure to RGC-5 CM. Neutralizing antibody to Sema3A was used at 2 
mg/mL (Abcam). After 24 h, 50 mL of a 5 mg/mL solution of Thiazolyl Blue 
Tetrazolium bromide (Sigma) was added and cells incubated for 2-3 h. Supernatants 
were aspirated and cells were lysed and resuspended in acidified isopropanol. 
Duplicate absorbance readings were taken at 565 nm using Infinite® M1000 Pro plate 
reader (TECAN). 
Aortic explant microvascular growth assay  
Aortae were isolated from adult PAR2 null mice, sectioned into 1 mm rings and 
placed into growth-factor reduced Matrigel (BD Biosciences) in 24-well plates. Rings 
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were cultured in supplemented Endothelial Basal Medium (Lonza) 4-5 days prior to a 
48 h exposure to RGC-5 CM. Treated rings were photomicrographed using 
AxioObserver (Zeiss) and microvascular growth assessed using Image Pro 4.5 
(Media Cybernetics, USA). Neutralizing antibody to mouse VEGF164 was used at 
concentrations of 20 mg/mL (R&D Systems) 
Statistical analysis 
Results are presented as mean ± s.e.m. for all studies. One-way or two-way analysis 
of variance with significance α=0.05 or higher were used for processing data. 
Bonferroni post-hoc analysis was used for calculating significance between groups. 
Two-tailed student t-tests were used to test for significance between two means. 
 
Results 
Neuronal PAR2 expression augments during oxygen-induced retinopathy (OIR) 
Retinas from C57BL/6 mice subjected to 75% oxygen for 5 days (P7 to P12)24 
were analyzed at different time points during OIR. During the early phases of vaso-
obliteration (at P8) protein levels of PAR2 surged ~3-fold compared to normoxic 
controls (Figure 1A,B), and relative to values at P5 (normalized vs. P5). PAR2 
expression in retina remained high during the hyperoxic phase at P12 (Figure 1A,B); 
by P17, PAR2 levels were comparable to normoxic controls.  
Immunofluorescence analysis on sagittal sections from P8 and P12 normoxic 
retinas demonstrates preferential distribution of PAR2 in βIII-tubulin positive RGCs 
(Figure 1C and Supplementary Figure 1A, upper panels) and robustly increases in 
these cells during OIR (Figure 1C and Supplementary Figure 1A, lower panels). PAR2 
also slightly co-localized with retinal endothelial cells at P8 (CD31-positive) 
[Supplementary Figure 1B]. Laser-capture microdissection of retinal tissue followed 
by qPCR analysis revealed significantly higher PAR2 mRNA in the ganglion cell layer 
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(GCL) relative to microdissected vessels (Figure 1D and Supplementary Figure 2A 
and B), particularly in OIR-subjected animals (~3.5-fold increase, p<0.001). Low 
levels of PAR2 mRNA were also detected in the INL likely owing to the invading blood 
vessels that protrude into these layers in retinas from P8 mice pups (supplementary 
Figure 2A and B); in OIR, the vasoobliteration leads to disappearance of PAR2 
expression in these layers. At P17, PAR2 expression remained localized to the retinal 
endothelium in both room air and hyperoxia-raised mice retina. Altogether, our data 
demonstrate that PAR2 increases sharply during the early phases of OIR and that this 
expression is localized preferentially to the RGCs. 
PAR2 protects the retina from oxygen-induced vaso-obliteration and induces retinal 
revascularization  
To explore the role of PAR2 in OIR, we exposed transgenic mice lacking PAR2 
gene (PAR2-/-) to 75 % O2 from P7 until P12. As previously reported17, mice lacking 
PAR2 gene surprisingly showed no changes in vaso-obliteration or pre-retinal 
neovascularization compared to age-matched wild-type mice (supplementary Figure 
3A, B and C). Because, compensatory mechanisms are regularly reported with germ 
cell line gene modulation,29 and signaling redundancies exist between different 
PARs16 (as reported in PAR2 transgenic mice30), we attempted to circumvent this 
drawback, by conditional knockdown of PAR2 using lentiviral (Lv.) constructs bearing 
shRNAs targeting PAR2 (Lv. shPAR2) injected intravitreally in C57BL/6 mice pups at 
P3; lentiviral vectors show high tropism for RGCs (see co-localization of GFP 
[encoded in Lv] with bIII-tubulin, supplementary Figure 3D and references11, 28, 31, 32). 
In wildtype mice Lv. shPAR2 successfully down-regulates retinal PAR2 expression by 
P7 compared to contralateral eyes injected with control Lv. shGFP (supplementary 
Figure 3E). PAR2 knockdown caused a significant reduction in the rate of 
revascularization between P12 and P17 (by 20.9%, p<0.001) [Figure 2C] resulting in 
augmented retinal vaso-obliteration at these corresponding ages [Figure 2A and 2B, 
upper panels]. Consequently, Lv. shPAR2 treated animals exhibited increased 
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aberrant pre-retinal neovascularization at P17 compared to control Lv. shGFP 
injected pups (Figure 2B); Lv. shPAR2 was ineffective in PAR2-/- pups (supplementary 
Figure 4A and B), consistent with the specificity of the shPAR2.  
We next proceeded to evaluate the effects of exogenous PAR2 stimulation with 
PAR2 activating peptide (PAR2-AP), SLIGRL (corresponding to tethered ligand),33 
injected intravitreally. Since expression of PAR-2 increased robustly at P8 and P12, 
we administered SLIGRL via intravitreal injection during early (P7) and late (P12) 
hyperoxic exposure. Administration of SLIGRL at P7 caused a significant reduction in 
vaso-obliteration at P12 compared to vehicle-injected animals [Figure 2A, lower 
panels]; a successive injection at P9 further diminished vaso-obliteration [Figure 2A, 
lower right panel]. Likewise, intravitreal injections of SLIGRL after the hyperoxic 
exposure (P7-P12) at P12 and P14 reduced dose-dependently the size of the 
avascular area measured at P17 [Figure 2B, lower panels], which reflected into an 
accelerated rate of revascularization between P12 and P17 [Figure 2C]. Consequently 
and as expected, SLIGRL treatment diminished pathological pre-retinal 
neovascularization at P17 (Figure 2B; lower histogram). PAR2-/- mice were 
unresponsive to SLIGRL (Supplementary Figure 4A and B). Collectively, these data 
indicate that PAR2 enhances the integrity of the inflammation-challenged8,11 retinal 
vascular bed during hyperoxic stress by promoting normal revascularization, which in 
turn reduces undesirable aberrant pre-retinal neovascularization.  
IL-1β induces PAR2 expression in neuronal and endothelial cells 
Oxidative stress and inflammation are intimately intertwined34. Accordingly, 
augmented levels of inflammatory cytokines, such as IL-1β, IL-6 and TNF-α are found 
in the vitreous of patients with ischemic retinopathies and corresponding animal 
models5-8, 11. Of relevance, IL-1β has been shown to increase PAR2 expression in 
cultured endothelial cells20, chondrocytes21, synovial cells19 and neuronal cells22. We 
explored the relationship between IL-1β and PAR2 in vivo in OIR. IL-1β  levels were 
increased during hyperoxia, particularly at P8 (Figure 3A), corresponding to the peak 
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of PAR2 expression in OIR. (Figures 1A, 3B). Pre-treatment of hyperoxia-exposed 
mice with IL-1 receptor antagonist (IL-1Ra) Anakinra (Kineret®), reduced IL-1β mRNA 
expression (supplementary Figure 5) as reported8, and significantly lowered PAR2 
mRNA levels at P8 (Figure 3B), suggesting that IL-1β may regulate PAR2 expression 
in vivo. 
In vivo findings were ascertained in vitro. Cultured mouse retinal neuronal cells 
(RGC-5) and RBMVEC displayed dose-dependent increases in PAR2 mRNA 
expression upon treatment with recombinant murine IL-1b [rmIL-1b] (Figure 3C and 
D); these effects were abolished by IL-1Ra (Figure 3E and F). PAR2 mRNA increased 
within 2-4 h after stimulation with IL-1b, but was not sustained thereafter; whereas 
increased PAR2 protein translation was detected by 6-12 h in both cells, but remained 
sustained at 24 h only in RGC-5 (Figure 3G and H), consistent with changes in PAR2 
expression in micro-dissected retinas of animals subjected or not to OIR (Figure 1D). 
Hence, IL-1b upregulates PAR2 expression in retinal ganglion neurons in a sustained 
manner but yields a limited and transient response in vascular endothelial cells. 
PAR2 is involved in negative feedback regulation of IL-1 response 
Chronic inflammation can be detrimental to the nascent vessels, either directly 
via cytokine or chemokine signaling35-39 or indirectly through inflammatory cell 
activation9, 10, 40. Previous studies from our laboratory reveal that in OIR IL-1β - 
predominantly generated by microglia - interferes with normal revascularization of the 
retina by eliciting paracrine release of the pro-apoptotic endothelial repulsive cue 
Sema3A, from RGCs.8,11 On the other hand, we hereby show that IL-1β  upregulates 
PAR2 (Figure 3), which enhances normal revascularization of the retina (Figure 2C). 
We therefore set out to determine how PAR2 promotes retinal revascularization in 
OIR, by examining its modulation of IL-1 signaling. We determined IL-1β and IL-1RI 
expression in retinas from P9 C57BL/6 mouse pups exposed to OIR and injected 
intravitreally with SLIGRL or Lv.shPAR2. Both IL-1β and IL-1RI expression increased 
in vehicle-injected retinas of animals exposed to hyperoxia. SLIGRL attenuated the 
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OIR-provoked increase in IL-1RI expression predominantly localized on βIII-tubulin 
positive RGCs (Figure 4A,B); normoxic animals treated with SLIGRL also exhibited 
moderate reductions in IL-1RI (Supplementary Figure 6A,B). Conversely Lv.shPAR2 
further augmented IL-1RI expression in OIR (Figure 4A); whereas SLIGRL and 
Lv.shPAR2 had no effect on IL-1β (Figure 4A).  
To determine whether inhibition of IL-1 and stimulation of PAR2 acted 
synergistically in enhancing revascularization, wildtype mice subjected to OIR were 
treated with either IL-1Ra, SLIGRL or both. The effects on vaso-obliteration were 
comparable (Figure 4C), suggesting that PAR2 stimulation did not induce any 
additional mechanism to that through IL-1RI suppression to enhance retinal 
revascularization in OIR; as anticipated, PAR2-null mice were only responsive to IL-
1Ra (Supplementary Figure 6C). 
PAR2 stimulation reduces IL-1RI expression in retinal neurons via JNK and 
downstream ERK1/2 signalling 
 To elucidate signaling pathways by which PAR2 regulates IL-1RI expression, 
we first corroborated our in vivo observations on cultured cells. In RGC-5 cells, 
SLIGRL reproduced its in vivo effects, as it time- and dose-dependently suppressed 
IL-1RI mRNA expression (Figure 5A; Supplementary Figure 7A); a similar profile was 
observed for IL-1RI protein (Figure 5B); this reduction was abrogated in cells 
previously infected with Lv.shPAR2 (Figure 5A,B and Supplementary Figure 7B). 
Interestingly, in RBMVEC IL-1RI mRNA increased 1 h after stimulation with SLIGRL 
and IL-1RI protein increased by 2 h following SLIGRL stimulation only 
(Supplementary Figure 7C), suggesting distinct pathways in different cell types. In 
addition in RGC-5 cells, IL-1 induced IRAK-1 phosphorylation as expected 
(Supplementary Figure 6D); this effect was attenuated by pre-treatment with SLIGRL, 
which suppresses IL-1RI (Figure 4); RGC-5 cells infected with Lv.shPAR2 were 
unresponsive to SLIGRL (Figure 5A,B).  
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 PAR2 stimulation results in activation of several downstream effectors 
including Ca2+ transients and MAPK signaling16, 41,42. RGC-5 cells treated with 
SLIGRL exhibited a time-dependent increase in MAPK signaling including ERK1/2, c-
jun N-terminal kinase (JNK) and p38 phosphorylation (Figure 5C). Inhibition of p38 
using SB203580 did not affect SLIGRL-dependent suppression of IL-1RI mRNA; 
however, pre-treatment with MEK1/2 inhibitor, U0125, or JNK inhibitor, SP600125, 
prevented SLIGRL-induced IL-1RI mRNA suppression (Figure 5D). Western blot 
analysis demonstrate that the JNK inhibitor, SP600125, effectively abolished ERK1/2 
phosphorylation while the MEK1/2 inhibitor, U0125 had no effect on JNK 
phosphorylation indicating that PAR2 stimulation suppresses IL-1RI in RGCs by 
signaling downstream first via JNK and subsequently via ERK1/2 pathway. RBMVEC 
cells stimulated with MET kinase inhibitor, PD98059, did not abolish SLIGRL-induced 
IL-1RI upregulation further supporting distinct signaling pathways in different cells 
types (Supplemental Figure 7E and F).  
PAR2 activation inhibits IL-1β-mediated Sema3A release and ensuing endothelial cell 
death and promotes angiogenesis by concomitant VEGF release 
 OIR-induced increase in IL-1β leads to Sema3A release and ensuing 
endothelial cell death resulting in increased vaso-obliteration8,11 and hindered normal 
revascularization11. Since PAR2 negatively regulates IL-1 signaling (Figures 4 and 5), 
we proceeded to investigate if this was associated with suppressed Sema3A 
expression. OIR-induced Sema3A expression was indeed suppressed by PAR2 
stimulation with SLIGRL (Figure 6A,B); as expected, Lv.shPAR2 increased Sema3A 
levels compared to Lv.shGFP. Concomitantly, VEGF levels increased sharply in 
RGCs upon SLIGRL stimulation (Supplementary Figure 8A,B), facilitating 
angiogenesis (Supplementary Figure 8C,D). 
 To ascertain in vivo findings, we stimulated RGC-5 cells with IL-1β and 
measured Sema3A in presence or absence of SLIGRL. Sema3a mRNA was markedly 
induced by IL-1β (Figure 6C), and this effect was abrogated by SLIGRL, which was 
	   176	  
ineffective in Lv.shPAR2-infected cells (Figure 6D); importantly, SLIGRL in absence of 
IL-1β did not affect Sema3a expression. 
 Next, we determined the functional role of PAR2 in angiogenesis by treating 
RBMVEC to assess cell survival, using conditioned media (CM) from RGC-5 cells 
stimulated with IL-1β in the presence or not of SLIGRL. Endothelial cell death 
triggered by IL-1β stimulation of RGC-5 cells was Sema3A-dependent, as this was 
abrogated using a neutralizing antibody to Sema3A (Figure 6E). IL-1β-induced 
endothelial cell death was also abolished by PAR2 stimulation (Figure 6F). Similarly, 
CM from PAR2 stimulated RGC-5 cells elicited aortic explant vascular sprouting 
(Figure 6G) due to concomitant VEGF release from these cells (Supplementary 
Figure 8C,D); whereas CM from IL-1β stimulated RGC-5 cells diminished aortic 
explant vascular sprouting, and this effect was abolished by co-treatment of RGC-5 
with SLIGRL (Figure 6G). Altogether these data demonstrate that the actions of PAR2 
in the retina negatively modulate IL-1β actions, and thus prevent IL-1β-induced 
Sema3A release while maintaining elevated levels of VEGF; these effects dampen 
endothelial cell death during oxygen-induced vaso-obliteration and augment desirable 
revascularization through retino-vascular proliferation.  
 
Discussion 
Sustained inflammation is an established cause of vessel network injury5-10, 35, 
43. Resident microglia cells, a dominant source of inflammatory IL-1β, are auto-
activated by this cytokine, which contributes to exacerbating vaso-obliteration in 
ischemic retinopathies8. Despite this auto-amplified inflammation, vasoobliteration 
eventually ceases to progress and instead – as seen in some patients – normal 
retinal revascularization takes place,12, 44 suggesting the presence of an intrinsic 
regulatory mechanism. In this study, we demonstrate that neuronal PAR2 acts as an 
important regulatory mediator for dampening IL-1β-induced vessel degeneration and 
prompts preferential revascularization of vaso-obliterated retinal tissue. In this context 
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rapid IL-1β release induces PAR2 expression, which in turn negatively regulates IL-
1β signaling by downregulating its receptor IL-1RI; this system essentially counteracts 
the otherwise homologous upregulation of IL-1RI by its natural ligand13, 14. These 
events occur in IL-1RI- and PAR2-expressing RGCs where the pro-apoptotic Sema3A 
is produced8,11, to limit its formation, while concomitantly enhancing secretion of 
VEGF to allow nascent vessels to invade and perfuse the ischemic vaso-obliterated 
regions, as depicted  in the schema in Figure 7.  
 There is growing evidence to show that neurons play a crucial role in the 
formation of retinal vessel network. For instance, mice pups lacking retinal ganglion 
cells (brn3bZ-dta/+; six3-cre mice) are devoid of an inner retinal capillary network28. In 
OIR, neurons appear to contribute beneficially early in disease by releasing pro-
angiogenic signals such as GPR91, VEGF and Netrin1 in attempts to counteract 
ischemic stress11, 28, 31; however, if unchecked, sustained hypoxia and inflammation 
can result in suppression of VEGF and secretion of vaso-repulsive cue Sema3A, as 
well as activation of endoplasmic reticulum stress pathways that translates to an 
IRE1-a-dependent cleavage of Netrin1 mRNA8,11, 31; this results in diversion of 
metabolic stores away from perishing tissue11. On the other hand, we hereby show 
that amplified IL-1β rapidly signals an increase in PAR2 expression on RGCs in an 
attempt to regulate and overcome excessive vascular decay elicited by Sema3A, and 
reestablish normal revascularization by inducing expression of VEGF (independently 
of HIF-1a45). PAR2 exerts these beneficial effects by suppressing IL-1RI expression in 
RGCs, which in turn limits IL-1β-regulated Sema3A release, despite high IL-1β retinal 
levels during OIR. Altogether this study highlights a central role for neurons in 
governing retino-vascular network integrity in ischemic retinopathies, and more 
specifically uncovers an important regulatory mechanism in PAR2 that avoids 
excessive vascular decay and reestablishes normal retinal revascularization in these 
conditions.  
 PAR2 is ubiquitously expressed in various organs and can have distinct 
cellular functions depending on the cell type where it is expressed46, 47. Herein, we 
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show that PAR2 in the retina is most prominently localized on RGCs and to a lesser 
extent on endothelium, where it exhibits functionally distinct cellular processes. Tissue 
Factor, which is expressed on endothelium (but not on neurons), has been shown 
when constitutively activated to robustly stimulate angiogenesis of the vascular plexus 
during development via PAR218; however in OIR, endothelial PAR2 activation by 
Tissue Factor fails to curb oxygen-induced vaso-obliteration and subsequent 
pathological neovascularization17. Correspondingly, we show that endothelial PAR2 
activation increases IL-1RI (and IL-1β20) expression, which may potentiate vascular 
injury, and does so seemingly via distinct intracellular signaling pathways. Neuronal 
PAR2, on the other hand, dampens oxygen-induced endothelial cell death by 
inhibiting IL-1β-mediated Sema3A release while maintaining elevated levels of VEGF 
in the retina, thus allowing normal growth of intra-retinal neovessels (and 
consequently avoid extra-retinal neovessel formation). In the brain as well as other 
organs, a similar dichotomy is apparent. PAR2 activation can have opposing effects 
depending on the tissue or cell where it is expressed48, 49. For instance, experimental 
models of neurodegenerative disorders demonstrate that PAR2 in glial cells evoke 
distinct cellular mechanisms from neuronal PAR2 to initiate neuroprotection22, 50-53. 
Hence targeting PAR2 on specific cell populations may selectively modulate 
downstream effectors in an attempt to limit pathological processes. 
 Importantly, this study also highlights the drawback associated with embryonic 
gene deletion. As previously reported17, OIR-induced vaso-obliteration and 
neovascularization were unaltered in mice having embryonic deletion of PAR2. Herein, 
we show that PAR2 mice, whereupon they are exposed to OIR, not only demonstrate 
comparable vascular phenotypes but also show similar molecular signatures 
compared to PAR2-intact mice. This indicates that embryonic gene deletion may – in 
some circumstances – unobtrusively induce compensatory mechanisms that may 
guise the native function of genes under investigation. 
Overall our findings uncover an important unprecedented physiologic 
mechanism induced by inflammation to limit vascular injury. In this process, the major 
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pro-inflammatory IL-1β induces PAR2 expression, which in turn suppresses IL-1RI to 
curb IL-1β-triggered Sema3A-dependent vasoobliteration and prompt desirable 
revascularization of the hypoxic retina, thus preventing aberrant pre-retinal 
neovascularization in ischemic retinopathies. We hereby identify PAR2 as an 
important physiologic mediator that regulates the inflammatory hypoxic-ischemic 
retinal environment in ischemic retinopathies, thus allowing for normal vascular 
regeneration of the retina. To date considerable attention has been focused on 
inhibiting pathological neovascularization54-57, whereby anti-VEGF administration is 
currently accepted as a possible treatment regime for patients suffering from ischemic 
retinopathies58. However, there are no clinical treatments that prompt desirable 
revascularization in an effort to reduce ischemic stress that is crucial to neuro-retinal 
dysfunction and pre-retinal neovascularization. The current study offers an approach 
for alleviating ischemic stress using PAR2 agonists. 
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Specific contributions from the candidate 
In this study, we focused on a discrepancy that we observed in the previous 
Chapter, which is that of the autocrine, autostimulatory activation of microglia in the 
retina in IRs. IL-1β propagates this cycle and concomitantly induces Sema3A-
mediated vascular decay. Bearing this in mind, I theorized the possibility of a intrinsic 
regulatory mechanism by which the retina (and more specifically, retinal ganglion 
cells) controls the exacerbated vascular degeneration precipitated by IL-1β and 
activated microglia. Since IL-1β also induces the expression of various proteases, 
which sequentially activates protease-activated receptors (PARs), we turned our 
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attention to PAR2 as a potential candidate–due to its previously described pro-
angiogenic effects in the retina. 
Precisely, I contributed enormously to the development of the project, which 
include planning, designing, optimizing and performing the majority of the 
experiments. I was chiefly involved in gathering and analyzing data. Dr. S Chemtob 
and myself prepared the figures with the aid of Dr. JC Rivera. Finally I scripted, 
proofed and finalized the entire manuscript. Dr. S Chemtob, Dr. JC Rivera and Dr. JS 
Joyal aided in editing and proofing the finalized version of the manuscript.  
Dr. P Hardy and Dr. P Sapieha provided expert opinion in the study. 
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Figure 1. Neuronal PAR2 increases in mice retina during Oxygen-induced 
retinopathy (OIR). (A) Western Blot analysis of C57BL/6 mice whole retina at 
different time points of OIR24 showing increases of PAR2 at P8 and P12 compared to 
room-air raised mice retinas (n=2 retinas per time point). (B) Densitometry 
quantification of A. Values are normalized to P5 retinas. (*=p<0.05, n=3 independent 
experiments). (C) Immunohistochemical analysis on retinal coronal sections from P8, 
P12 and P17 C57BL/6 mice pups exposed for 24h in either 21 or 75 % O2. PAR2 
(green) immunohistochemistry increases substantially in βIII-tubulin-expressing retinal 
ganglion cells (red) during OIR at P8 and P12 similar to what is seen in A. At P17, 
PAR2 immunoreactivity in OIR mice retina was similar to normoxia-raised animals. 
Nuclei are counterstained with DAPI (blue) and vessels with CD31 (magenta). NFL, 
nerve fiber layer; GCL, ganglion cell layer; IPL, inner plexiform layer; INL; inner 
nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer. Scale bar = 50 
μm. Original magnification 300x. (D) Laser-capture microdissected retinas from P8 
pups exposed to 21 or 75 % O2 (OIR). Real-time quantitative PCR (qPCR) on 
microdissected retinal layers demonstrate robust expression of PAR2 mRNA in GCL, 
which increases specifically in this layer following 24h exposure to high oxygen 
(***=p<0.001, n=4 retinas). 
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Relative contributions: Figure 1 
A) Western Blot analysis performed by N Sitaras and M Bien-Aimé 
B) Immunohistochemistry, imaging and analysis performed by N Sitaras and JC 
Rivera 
C)  Laser capture microdissection and qPCR analysis performed by N Sitaras 
and M Bien-Aimé 
 
Animal handling and sample collection: N Sitaras 
Figure preparation: N Sitaras, JC Rivera and S Chemtob 
Approximate Figure contribution: 75% 
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Figure 2. Modulation of PAR2 activity during OIR affects vaso-obliteration and 
neovascularization. (A) Representative photomicrographs from isolectin B4-stained 
retinal flatmounts from P12 C57BL/6 mice pups exposed to hyperoxia from P7 to 
P1224. Original magnification 100x. Vaso-obliterated (VO) areas are outlined with solid 
black line. Pups injected intravitreally with lentiviral (Lv.) particles containing shRNA 
versus PAR2 (~9.6 ng) show significant increases in VO compared to vehicle or 
control Lv. shGFP (~8.5 ng) injected animals. Mice pups injected intravitreally with 
PAR2 agonist peptide (PAR2-AP), SLIGRL-NH2 (100μmol), however, display 
significant decrease in VO. Quantification of VO areas is shown in graph (*=p<0.05, 
***p<0.001, n=6-12 retinas). (B) Photomicrographs of P17 C57BL/6 mice pups 
exposed to OIR and injected intravitreally with Lv. shPAR2 demonstrate increased VO 
and neovascularization (NV) compared to control vehicle or Lv. shGFP treated 
animals, while, SLIGRL-treated mice pups demonstrate significant decreases in 
avascular area and NV. VO and NV areas are outlined with solid black lines and 
white-hashed lines, respectively. Quantification of avascular areas and NV areas by 
SWIFT_NV26 are shown in graphs (**=p<0.01, ***p<0.001, n=6-12 retinas). (C) 
Calculated rate of revascularization from P12 to P17 of mice pup retinas following 
hyperoxic exposure previously injected with modulators of PAR2 activity. Change in 
VO was calculated for each group using VO at P12 as starting value (100%). 
Samples at P17 were compared relative to singly injected vehicle-treated animals. Lv. 
shPAR2 treatment translated to a retard in revascularization potential whereas 
administration of SLIGRL accelerated this process (*=p<0.05, ***p<0.001, n=18-23 
retinas). 
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Relative contributions: Figure 2 
A) through C) Lentiviral preparations performed by N Sitaras and D Hamel  
Intravitreal injections performed by N Sitaras, JC Rivera, K Zaniolo and Z 
Shao 
Immunohistochemistry, imaging and analysis performed by N Sitaras, JC 
Rivera and K Zaniolo 
 
Animal handling and sample collection: N Sitaras, K Zaniolo and Z Shao 
Figure preparation: N Sitaras and S Chemtob 
Approximate Figure contribution: 75% 
 
	   193	   
	   194	  
Figure 3. Increased expression of IL-1β in the retina during OIR stimulates 
PAR2 expression. (A) Western blot analysis of IL-1β in whole retina from mice pups 
at various time points of OIR showing increase in P8 compared to room-air raised 
C57BL/6 mice pups (n=2 retinas per time point). Densitometry quantification at right. 
Values are normalized to P5 retinas. (*=p<0.05, n=3 independent experiments). (B) 
Real-time qPCR analysis of whole retina from P8 C57BL/6 mice pups showing an 
increase in PAR2 mRNA upon exposure to hyperoxia for 24h. Animals treated 
intraperitoneally with IL-1 receptor antagonist (IL-1Ra; Kineret®) display significantly 
less PAR2 mRNA (***=p<0.001, n=3, pool of 2 retinas per n). IL-1β stimulated 
cultured (C) retinal neurons (RGC-5) and (D) rat brain microvascular endothelial cells 
(RBMVEC) display time- and dose-dependent increases in PAR2 mRNA as analyzed 
by qPCR analysis (**=p<0.01, ***=p<0.001, n=4-8). Administration of IL-1Ra 
abrogated IL-1β dependent increases in PAR2 mRNA in both (E) RGC-5 and (F) 
RBMVEC as determined by qPCR analysis (*=p<0.05, ***=p<0.001, n=6-8). (G) RGC-
5 cells stimulated with IL-1β displayed time-dependent increase in PAR2 protein 
levels. Densitometry quantification at right (*=p<0.05, **=p<0.01, n=2 independent 
experiments). (H) RBMVEC cells stimulated with IL-1β displayed an increase in PAR2 
protein levels at 12h only. Densitometry quantification at right (*=p<0.05, n=2 
independent experiments).  
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Relative contributions: Figure 3 
A) Western blot analysis performed by N Sitaras and M Bien-Aimé 
B) Kineret administration and qPCR analysis performed by N Sitaras  
C) though H) In vitro experiments and Western blot/qPCR analysis performed by 
N Sitaras, M Bien Aimé and B Noueihed 
 
Animal handling and sample collection: N Sitaras, M Bien Aimé and B Noueihed 
Figure preparation: N Sitaras and S Chemtob 
Approximate Figure contribution: 60% 
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Figure 4. PAR2 activation results in downregulation of IL-1RI in vivo. (A) 
Western Blot analysis of IL-1β and IL-1RI in P9 C57BL/6 mice whole retina exposed 
to OIR and injected with vehicle, SLIGRL (100 μM), Lv. shGFP or Lv. shPAR2 (n=2 
retinas per group). Increases in IL-1β and IL-1RI were observed in OIR exposed 
retinas; however, treatment with SLIGRL significantly reduced IL-1RI expression but 
not IL-1β. Conversely, administration of Lv. shPAR2 increased IL-1RI levels while IL-
1β levels remained the same. Densitometry quantification at right (*=p<0.05, n=3 
independent experiments). (B) Immunohistochemical analysis of P9 C57BL/6 mice 
retinas exposed to OIR (middle panels) displayed significant immuno-reactivity to IL-
1RI (green) localized primarily in the ganglion cell layer (βIII-tubulin; red) compared to 
normoxic-exposed retinas (upper panels). SLIGRL administration reversed this 
process (lower panels). Nuclei are counterstained with DAPI (blue) and vessels with 
isolection B4 (magenta). NFL, nerve fiber layer; GCL, ganglion cell layer; IPL, inner 
plexiform layer; INL; inner nuclear layer; OPL, outer plexiform layer; ONL, outer 
nuclear layer. Scale bar = 50 μm. Original magnification 300x. (C) Representative 
images from isolectin B4-stained retinal flatmounts from P12 C57BL/6 mice pups 
exposed to OIR and injected intravitreally with either SLIGRL (100 μM) or IL-1Ra (10 
μM) or both. Original magnification 100x. VO areas are outlined with solid blue lines. 
Individually, administration of PAR-2 agonist and IL-1RI antagonist successfully 
inhibited hyperoxia-induced vaso-obliteration (*=p<0.05, ***=p<0.001, n=6-8 retinas); 
however, there was no additive effect from co-administration of both SLIGRL and IL-
1Ra. 
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Relative contributions: Figure 4 
A) Western blot analysis performed by N Sitaras and M Bien-Aimé 
B) and C) Intravitreal injections performed by N Sitaras and JC Rivera 
Immunohistochemistry, imaging and analysis performed by N Sitaras and JC 
Rivera  
 
Animal handling and sample collection: N Sitaras and JC Rivera 
Figure preparation: N Sitaras, JC Rivera and S Chemtob 
Approximate Figure contribution: 75% 
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Figure 5. JNK activates downstream ERK1/2, which is required for PAR2-
dependent inhibition IL-1RI in retinal neurons. (A) PAR2-expressing RGC-5 
exhibit dose-dependent decreases in IL-1RI mRNA following 1h stimulation with 
SLIGRL (*=p<0.05, ***p<0.001, n=6-10); RGC-5 infected with Lv. shPAR2 abrogated 
effect. Lv. shGFP-infected served as control RGC-5 (***=p<0.001, n=10-14). (B) 
RGC-5 cells show effective decrease in IL-1RI protein levels following SLIGRL 
treatment; Lv. shPAR2 did not respond to SLIGRL treatment. Densitometry 
quantification below (*=p<0.05, n=2 independent experiments). (C) Administration of 
SLIGRL activates various MAPK signaling pathways. (D) RGC-5 cells pre-treated with 
either MEK1/2 inhibitor (U0125) or JNK inhibitor (SP600125) but not p38 inhibitor 
(SB203580), abrogated the SLIGRL-dependent decreases in IL-1RI mRNA in RGC-5 
(**=p<0.01, ***=p<0.001, n=6). (E) Activation of MAPK by SLIGRL in RGC-5 is 
abolished using specific inhibitors to MEK1/2 (U0125), p38 (SB203580) and JNK 
(SP600125); inhibition of JNK also translated to a downstream inhibition of ERK1/2 
phosphorylation. JNK phosphorylation was not affected by MEK1/2 inhibitor. 
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Relative contributions: Figure 5 
A) and D) In vitro preparation and qPCR analysis performed by N Sitaras and M 
Bien-Aimé 
B) C) and E) In vitro preparation and Western blot analysis performed by B 
Noueihed, M Bien-Aimé, S Omri and N Sitaras 
 
Figure preparation: N Sitaras, B Noueihed and S Chemtob 
Approximate Figure contribution: 40% 
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Figure 6. Activation of PAR2 abolishes IL-1b-mediated Semaa3A release, 
reducing endothelial cell death and promoting vascular sprouting. (A) Western 
Blot analysis of Sema3A in P9 C57BL/6 mice whole retinas exposed to OIR and 
injected intravitreally. OIR exposure augmented Sema3A expression in P9 vehicle 
injected animals; however, OIR retinas treated with SLIGRL reduced Sema3A levels 
significantly compared to vehicle-injected eyes (n=2 retinas per group). Densitometry 
quantification at right (*=p<0.05, n=3 independent experiments). Conversely, Lv. 
shPAR2 treatment augmented Sema3A levels compared to Lv. shGFP-injected 
retinas. (B) Immunohistochemical analysis on P9 C57BL/6 mice retina exposed to 
hyperoxia demonstrated significant immunoreactivity to Sema3A particularly in the 
ganglion cell layer. Treatment with SLIGRL, however, significantly reduced Sema3A 
levels in this layer. NFL, nerve fiber layer; GCL, ganglion cell layer; IPL, inner 
plexiform layer; INL; inner nuclear layer; OPL, outer plexiform layer; ONL, outer 
nuclear layer. Scale bar = 50 μm. Original magnification 300x. (C) RGC-5 cells 
stimulated with IL-1β exhibit time-dependent increases in Sema3a mRNA 
(***=p<0.001, n=6). (D) Control Lv. shGFP-infected RGC-5 stimulated with SLIGRL 
abrogated IL-1b-dependent increases in Sema3a mRNA after 24h; however, this 
effect was abolished in Lv. shPAR2-infected RGC-5 (*=p<0.05, **=p<0.01, 
***=p<0.001, n=7-8). (E) MTT cell survival assay on RBMVEC exposed to CM from 
RGC-5 cells stimulated with IL-1β demonstrated significant reduction in EC survival. 
Treatment with an antibody to Sema3A abrogated this effect (***=p<0.001, n=5-6). (F) 
Similar experiment as in E. but using CM from Lv. shGFP- or Lv. shPAR2-infected 
RGC-5 stimulated with either IL-1β or SLIGRL, or both. IL-1β-stimulated CM 
significantly reduced endothelial cell survival, while CM from Lv. shGFP RGC-5 co-
stimulated with SLIGRL and IL-1β reversed this effect. Lv. shPAR2 RGC-5 co-
stimulated with SLIGRL and IL-1β did not salvage the IL-1β-induced endothelial cell 
death (***=p<0.001, n=6). (G) Aortic explants exposed to the same CM as in F. 
Explants treated with CM from SLIGRL-stimulated RGC-5 displayed increased 
sprouting whereas explants exposed to CM from IL-1β-stimulated RGC-5 exhibited 
diminished sprouting growth. CM from Lv. shGFP RGC-5 co-stimulated with SLIGRL 
and IL-1β, however, translated to normal aortic sprouting angiogenesis whereas CM 
from Lv. shPAR2 RGC-5 did not. Quantification of aortic vascular sprouting at right 
(*=p<0.05, **=p<0.01, ***=p<0.001, n=6-9).  
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Relative contributions: Figure 6 
A) Western blot analysis performed by N Sitaras and M Bien-Aimé 
B) Intravitreal injections performed by N Sitaras 
Immunohistochemistry, imaging and analysis performed by N Sitaras and JC 
Rivera 
C) In vitro preparations and qPCR performed by N Sitaras, JS Joyal, M Bien-Aimé 
and S Omri 
D) In vitro preparations and EC survival assay performed by N Sitaras 
E) Aortic explant preparations, imaging and analysis performed by N Sitaras 
 
 
Animal handling and sample collection: N Sitaras and JC Rivera 
Figure preparation: N Sitaras, JC Rivera and S Chemtob 
Approximate Figure contribution: 75% 
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Figure 7. PAR2 on retinal ganglion cells enhances revascularization by 
suppressing IL-1RI. Augmented levels of secreted IL-1β stimulate rapid production 
of PAR2 to counteract the hyperoxic stress. However, exhaustive inflammation 
causes RGCs to suspend PAR2 production and instead induces Sema3A production, 
which leads to vaso-obliteration and contributes to pathological pre-retinal 
neovascularization (left panel). Conversely, timely activation of PAR2 – using peptide 
agonist, SLIGRL – abrogates this process by suppressing IL-1RI via JNK and 
ERK1/2-dependent processes in RGCs to blunt Sema3A production and 
concomitantly stimulate VEGF production to augment the revascularization process of 
the ischemic retina (right panel). 
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Relative contributions: Figure 7 
Schematic provided by JC Rivera and N Sitaras 
 
Figure preparation: N Sitaras, JC Rivera and S Chemtob 
Approximate Figure contribution: 25% 	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Final Discussion 
The studies presented herein highlight several novel topics that are central to 
understanding the pathogenesis of Ischemic Retinopathies (IRs) with particular focus 
on developing new treatments for these sight-threatening diseases. The concept of 
vascular repulsion is highlighted as having a causal role in repelling nascent vessels 
away from the ischemic regions and instead towards the vitreous as seen in patients 
suffering from IRs. The source of these vaso-repulsive cues originates from the 
underlying RGCs, which interact with surrounding microglia to release vaso-
modulatory factors. This tripartite cross-communication between neurons, vessels 
and immune cells is emphasized in these studies supporting the concept of 
neurovascular coupling and inflammation in ischemic diseases. The last concept 
covered herein is the varying functions of certain genes, which appear to be divergent 
depending on the cell type in which they are expressed. These concepts are 
discussed in detail below. 
Current treatments for IRs focus on the latter stages of the disease, namely, 
pathological neovessel formation2,3; retinal ischemia, however––that provokes the 
formation of neovessels––imparts critical biochemical changes in retina that often 
result in observable reductions in vision health and function4,260. Herein, we 
demonstrate that timely revascularization of the retina can: 1) considerably diminish 
vessel loss early on in efforts to reduce retinal ischemia that affects retinal function, 2) 
reinstate the vascular network by maintaining neovessels on the surface of the retina 
and 3) significantly reducing misguidance of vessels toward the vitreous. As such, 
stimulating revascularization either by targeting specifically Netrin1, Sema3A or its 
upstream regulator, IL-1RI (via inhibition of IL-1β or activation of PAR2), may be 
potential therapeutic avenues in preventing pathological signatures of IRs.  
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The importance of balancing vascular guidance cues in IRs: lessons from 
Sema3A and Netrin1 
 Vessels require both attractive and repulsive cues to properly guide 
them towards their non-perfuse targets. An imbalance in these factors can cause 
vascular defects68, as seen in patients suffering from IRs. Herein, we show that during 
the initial phases of retinal ischemia, neurons secrete high amounts of VEGF, to 
stimulate angiogenesis in efforts to reinstate metabolic homeostasis. While this 
initially attracts vessels towards these avascular areas, severely ischemic neurons 
reverse their signaling machinery from VEGF production to that of vaso-repulsive 
Sema3A. Thus, while the levels of VEGF are high, the presence of Sema3A in 
severely ischemic zones repels nascent vessels away from these areas (via Nrp1). 
Similarly, another study showed that Sema3E released by the underlying RGCs is 
enriched in the avascular zone during retinal ischemia and, despite high levels of 
VEGF, also repel vessels from these zones (via PlexD1 signaling on ECs)261. 
Interestingly, this study demonstrated that Sema3E ensures that vessels do not dive 
prematurely into the retina towards the photoreceptors261, which likely accounts for 
why pathological neovessels are always found protruding into vitreous of DR and 
ROP patients and not into the retina. 
Inhibiting Sema3A (either directly or indirectly) prevents abhorrent vessel 
growth and allows vessels to invade the ischemic regions enriched with VEGF. This 
can be seen at high magnification in the retina of animals treated with Sema3A 
inhibitor by the increased number of intact filopodia on tip cells projecting into the 
avascular zones. Consequently, the retinal vasculature of these mice looks ‘normal’ 
compared to untreated retina. A similar scenario is observed upon inhibition of 
Sema3E261. Essentially, tipping the balance between repulsive and attractive cues 
may reduce pathological vessel formation in efforts to ameliorate disease outcome. 
Similar strategies are exercised in various types of cancer, whereby treatment with 
class 3 semaphorins results in significant reduction of tumor growth and 
angiogenesis262,263. This is because various tumor cells increase production of VEGF 
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(or other growth factors)126 while simultaneously suppressing class 3 
semaphorins264,265, which are known for their anti-tumor capacities (Sema3A, 3B or 
3F)185.  
Netrin1 is a guidance molecules that can have varying effects in 
angiogenesis144,266. This is usually dependent on the netrin receptor present on the 
receptive cell, although Unc5b is the only reported endothelial Netrin1 receptor165. In 
a parallel study (Appendix 4), we unexpectedly found c-Myc-tagged Netrin1 on 
microglia/macrophages. Binding of Netrin1 to its receptor Adenosine A2B receptor on 
microglia/macrophages increased VEGF secretion, which translated to an increase in 
angiogenesis and accelerated revascularization of the ischemic retina. These 
important findings may account for the pro-angiogenic effects of Netrin1 observed in a 
mouse model of hindlimb ischemia107 whereby macrophages are known to play a vital 
role in tissue repair267. Moreover, this study further demonstrates the importance of 
neuronal guidance cues in shaping vascular phenotypes whereby Netrin1 counteracts 
the ischemia-challenged retina following vascular injury. Interestingly, and in similar 
fashion as in VEGF mRNA suppression in ischemic RGCs, Netrin1 levels becomes 
suppressed upon exposure to long periods of hypoxia. Reduction in Netrin1 was 
mediated by the unfolded-protein response (UPR), a protective cellular pathway 
initiated by endoplasmic-reticulum (ER) stress, which was significantly increased in 
ischemic mice retina. We show that neuronal-derived Netrin1 mRNA is cleaved by 
inositol-requiring kinase 1 alpha (IRE-1α) following activation of the UPR pathway. 
This data shows that ER stress and UPR pathways may be an important in changing 
the balance between repulsive and attractive molecules in IRs. Whether or not VEGF 
is a substrate for IRE-1α-mediated RNAse in neurons has yet to be determined; 
however, one study discovered that VEGF degradation was enhanced upon inhibition 
of UPR pathways in retinal and choroidal ECs268, indicating that other cellular 
pathways may be involved in regulating VEGF in severely hypoxic RGCs. Elucidating 
these intracellular pathways may be important for understanding the 
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pathophysiological mechanisms by which ischemic neurons deviate from their pro-
angiogenic phenotype. 
   
Neurovascular interactions in IRs: RGCs, microglia and vessels 
In the retina, increased neuronal activity increases metabolic demand for 
nutrients and oxygen, which is satiated by the formation of an intricate vascular 
network. Glial cells which also make up the neurovascular unit were thought to 
precipitate the formation of the vascular network94; however, recent evidence 
demonstrates that RGCs impart a significant role in retinal vascular development. For 
instance, genetic ablation of retinal ganglion cells in mice (brn3bZ-dta/+; six3-cre mice) 
are completely devoid of an inner retinal capillary network129. Another study 
demonstrated that Math5 knockout mice, having 95% reduction in RGCs, also have 
an abhorrent and disorganized retinal vasculature269. Moreover, cell specific genetic 
deletion of VEGF, HIF-1α or HIF-2α in retinal astrocytes did not incur any 
perturbations in vascular development in mice270 whereas genetic deletion of HIF-1α 
in neurons caused abnormal vascular phenotypes271,272. Indeed, while astrocytes are 
necessary for providing the essential framework required for normal development of 
the retinal vasculature, it appears that RGCs play a more definitive role in providing 
necessary factors for stimulating vessel growth and development.  
The relative contributions of neurovascular coupling in IRs, however, have only 
recently begun to come to light. In our studies, we demonstrate the neurons initially 
produce factors to counteract the ensuing oxidant/ischemic stress. PAR2 is rapidly 
upregulated on RGCs during the early phases of vascular dropout in mice retina to 
shut down exhaustive IL-1β signaling, which causes Sema3A-mediated vessel 
degeneration. Netrin1 is also secreted early on by RGCs, in response to ensuing 
stress, to counteract vessel loss. Other neuronally-derived molecules appear to 
precipitate the same effect. Neuronal-derived sirtuin1 is upregulated during OIR and 
was shown promote revascularization in attempts to counteract ischemic stress273. 
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Another study previously published by our lab demonstrated that ischemic neurons 
rapidly produce succinate, which induces expression of pro-angiogenic factors via 
GPR91 on RGCs to promote retinal angiogenesis129. On the other hand, persistent 
ischemia, if left unchecked, can induce Sema3A (and Sema3E261) which reproduce 
the cardinal features of IRs by repelling neovessels. Also, suppression of key vascular 
guidance molecules Netrin1 (by ER stress) and VEGF also results in delayed 
revascularization of avascular areas. A similar scenario is observed following stroke, 
whereby ischemic neurons secrete molecules to attract (or repel) growing 
neovessels274,275.   Thus, harnessing the inherent angiogenic potential of neurons 
may provide novel therapeutic avenues in effort to reduce retinal ischemia and the 
subsequent pathological neovessel formation, which are central to the pathogenesis 
of IRs. 
Glia are support cells in the retina (and CNS) that form part of the 
neurovascular unit226. While the relative contributions of astrocytes appear to be 
dispensable in formation of the retinal vascular network270, microglial cells appear to 
play a more central role in angiogenesis. During retinal development microglia are in 
close proximity to endothelial tip cells, which secrete factors that control neovessel 
formation118,137. Later microglia help maintain retinal homeostasis and form part of the 
innate immune response in the retina226. In retinal vasculopathies, however, microglia 
have a more disparaging role. In DR patients, microglia are associated with various 
vascular perturbations (microaneurysms, neovessel tufts)84 and animal models of DR 
show that microglia increase cytokine production and inflammation89. In ROP, the role 
of microglia is less clear. Our study (Chapter 2) shows a direct causal role for 
microglia in ROP whereby they become activated during hyperoxia and release IL-1β 
in an autocrine and auto-stimulatory fashion. This induces paracrine release of 
Sema3A from proximal RGCs translating to microvascular decay and exacerbating 
pathological neovessel formation. Inhibition of IL-1β (via inhibition of IL-1RI) reversed 
these effects, which corroborates with the studies in diabetic mice showing a marked 
reduction in retinal inflammation following inhibition of microglia activation89.  
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However, upon binding Netrin1, microglia (and possibly marcophages) can 
induce revascularization (Annex 4), which challenges the initial studies in the 
literature and herein (Chapter 2) demonstrating the detrimental effects of microglia. 
This discrepancy can be described by the dynamics of microglial activity; resting 
microglia cells upon activation have the ability, depending on their environment, to 
adopt two functionally distinct phenotypes33,34: either pro-inflammatory, or ‘M1’, or 
anti-inflammatory, or ‘M2’. While each microglia ‘type’ carries distinct molecular and 
phenotypical signatures, these polarized states are quite dynamic and likely 
interchangeable276,277. The same is true for macrophages232,278. Thus, Netrin1 may be 
polarizing what appear to be M1 microglia/macrophages in IRs towards a M2 
phenotype, which promote anti-inflammation and repair. A similar observation has 
been shown in a cardiac ischemia reperfusion model whereby Netrin1 attenuates 
myocardial injury following activation of macrophages279. In this regard, Netrin1 may 
yet have a therapeutic benefit in ischemic diseases by specifically modulating the 
inherent phenotypes of invading macrophages / activated microglia. 
While these two studies present the dual role of microglia in IRs, they also 
underline the importance of neurovascular cross-talk involving not only vessels and 
neurons, but glia too. The evidence herein shows that in retinal diseases, as well as 
other ischemic diseases in the CNS, this tripartite of cells continuously interact and do 
so in a highly dynamic and intimate fashion.  
 
IL-1ß and inflammation in IRs 
Inflammation plays an integral part of tissue’s response to injury and foreign 
invasion. In pre-term infants, inflammation is known to exacerbate the severity of 
ROP207 while in DR patients, increased levels of systemic pro-inflammatory cytokines 
(as a result of diabetes) precede the onset of retinal capillary dropout and contribute 
to the subsequent pathological neovascularization4,89. Elevated levels of inflammatory 
markers have been reported in the vitreous of IRs patients63,83,280 and animals40,209; 
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among these, IL-1β has generally been proposed as having an impact in the 
pathogenesis of IRs63,281; however, despite its known prototypical pro-inflammatory 
properties211,282,283, the specific contributions of this important cytokine in modulating 
vascular phenotypes in IRs is not so well defined. In some cases, IL-1β has shown to 
stimulate angiogenesis directly213,284. In our studies, we demonstrate the inverse 
whereby elevated IL-1β expression contributes to both EC decay and vascular 
repulsion via induction of Sema3A from proximal RGCs. Importantly, we also 
demonstrate that IL-1β regulates its own activity in the retina by induction of PAR2 in 
RGCs; this intrinsic regulatory mechanism shuts down IL-1RI specifically in RGCs to 
prevent further exacerbation of vascular pathogenesis perpetuated by IL-1β adding to 
its already complex self-regulatory mechanisms211,283. 
IL-1β is ubiquitously expressed in various organs and its expression reported 
in various cell types, particularly inflammatory cells211,283. Although, while IL-1β 
expression has been reported in IRs patients63 and animals281, the major source of its 
expression remains ill defined. Herein, we demonstrate that resident microglia–upon 
activation by hyperoxia (and hypoxia [data not shown])–contribute largely to the 
augmented production of IL-1β in the retina in an autocrine and autostimulatory 
fashion. This unrelenting cytokine production thus perpetuates a continuous cycle of 
microglial auto-activation exacerbating retinal inflammation. Moreover, increased 
microglia number in the superficial plexus is likely associated with increased 
expression of ICAM-1, which is typically upregulated by IL-1β in retinal ECs220. 
Evidence of this can be seen in OIR animals treated with IL-1RI inhibitors whereby 
fewer microglia were detected in these layers compared to vehicle treated OIR 
animals. This indicates that microglial cells not only secrete IL-1β paracrinely in 
efforts to stimulate its own an auto-activation but it also contributes to their migration 
within the retina in IRs.  
IL-1β mRNA is translated into a 33-kDa full length protein which includes a 16-
kDa N-terminal pro-piece283. Activation of IL-1β requires proteolytic cleavage of its 
pro-piece generating a 17-kDa mature IL-1β protein283. This intracellular processing is 
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dependent on caspase-1, which itself is regulated by adaptor (Apoptosis-associated 
speck-like protein containing CARD, ASC) and regulatory proteins (NOD-like receptor 
proteins, NLRPs) together forming a signaling complex known as the 
inflammasome285. While this protein complex has important biological processes and 
contributes significantly to the innate and adaptive immune response285, the data 
surrounding its contribution to IRs are only beginning to be unraveled209,212. In chapter 
3, we briefly underline the importance of the NLRP3 inflammasome (the most 
important isotype described in the retina286) in generating microglial-derived IL-1β in 
the retina, which offers insight into its contribution in modulating vascular phenotypes 
in IRs. However, NLRP3 is found in other cells including retinal-pigmented epithelium 
(RPE)287,288 and infiltrating macrophages215 indicating that it may have alternative 
functions in the retina and in IRs.  
While these studies offer a more formal understanding of the role of the 
prototypic IL-1β in IRs, further studies on its activation (with particular focus on the 
NLRP3 inflammasome) will be necessary for highlighting its fine-tuned regulation in 
ischemic retinal vasculopathies.  
 
Same protein, different roles: Lessons from PAR2 and Netrin1 
Genes that are ubiquitously expressed in different organs can have functionally 
distinct roles depending on the tissue that they are expressed. While some of the 
downstream signaling effectors can be similar, the final readout can vary significantly. 
Netrins was first identified to bind to DCC on commissural neurons and generating an 
attractive response for growing axon terminals160. It was later discovered that Netrins 
can bind to many other receptors, including Unc5 (a-d), Neogenin (part of the DCC 
family of Netrin receptors)144, Adenosine A2B receptor (AA2B)289 and possibly other 
unidentified receptors. Heterodimerization between two Netrin recetpors has also 
been described164.  
	   216	  
Binding of Netrin1 to DCC typically generates attraction action whereas binding 
to Unc5b mediates repulsion on neurons144. In endothelial cells, Unc5b is the only 
receptor for Netrin1 expressed in tip cells144,266; however, this action results in 
repulsion, quite different than the response that we see in the retina. Rather then 
repelling vessels and contributing to vessel misguidance and pre-retinal 
neovascularization, Netrin1 generates the exact opposite. This is because it signals 
via a different receptor and yields a diverse vascular response in macrophages. 
Although not described in this study, Netrin1 has the ability to signal on macrophages 
in efforts to attract or retain them in atherosclerotic plaques290 and in adipose tissue291. 
Thus, Netrin1 maybe be promoting migration from circulation into the retina to perform 
its pro-angiogenic functions. Intriguingly, Netrin1 signals macrophage retention in 
atherosclerotic plaques and adipose tissue via Unc5b receptor290,291, while in the 
retina this effect is mediated by AA2BR. Moreover, Netrin1/Unc5b signaling 
propagates inflammation and cytotoxicity in these models while in our study 
Netrin1/AA2BR incites protection, supporting the fact that Netrin1 has diverse 
functions depending on the receptor. 
While the explanation for Netrin1 functional differences can be explained by 
the varying receptor expression on the target cell, the justification for PAR2 functional 
differences is not so clearly defined. Herein, we show that PAR2 in the retina is most 
prominently localized on RGCs and to a lesser extent on endothelium, where it 
exhibits functionally distinct cellular processes. Neuronal PAR2 appears to be 
mediating protective capacities by secreting pro-angiogenic cues (VEGF) to stimulate 
vessel growth, which also simultaneously function as neuroprotectants to counteract 
ischemic stress292. Furthermore, PAR2 dampens IL-1RI in efforts to curb neuronal 
inflammation, which have degenerative consequences on the retinal vasculature (via 
Sema3A) and on neurons themselves293. Thus, PAR2 on RGCs functions as an 
intrinsic regulatory mechanism for preventing exhaustive inflammation while 
simultaneously secreting pro-vascular modulators. Endothelial PAR2 appears to have 
prolific properties during development; activation of PAR2, via TF-FVII signaling or 
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agonist peptide induction, stimulates endothelial cell growth133,225,294, presumably via 
VEGF and TNF-α/Tie2133. During pathological processes, however, endothelial PAR2 
function appears deleterious. We show that PAR2 activation increases IL-1RI 
expression, which may potentiate vascular injury by exacerbating IL-1 signaling. 
Notably, PAR2 stimulates IL-1β on ECs295, which can in turn increase ICAM-1 
expression and thus inflammatory cell adhesion89, supporting this hypothesis.  
In the brain, PAR2 can also have dichotomous roles during injury. In various 
animal of brain injury, PAR2 activity on neurons and astrocytes has neuroprotective 
functions296. Neuronal/astrocyte PAR2 protect against brain injury following transient 
middle carotid artery occlusion297, inhibits demyelination in a mouse model of 
experimental autoimmune encephalomyelitis298 and protects against β-amyloid 
neurotoxicity in Alzheimer’s Disease299. On the other hand, PAR2 on 
macrophages/microglia causes an upregulation of pro-inflammatory cytokines TNF-α, 
iNOS, IL-6, IL-12p40, IL-1β, IFN-inducible protein 10, MCP-1, and macrophage 
inflammatory protein 1α (MIP-1α)298, which translates to increased neuronal cell 
demyelination. Conversely, PAR2 deficiency in macrophages/microglia results in 
increased anti-inflammatory IL-10 expression298 and protects neurons. Essentially, 
native PAR2 on neurons serves as a neuroprotective factor in the retina and brain, 
while EC and microglial/macrophage activity precipitates neurodegeneration. The 
reasoning why a paracellular dichotomy exists in the same tissue, however, remains a 
mystery. 
Besides Netrin1 and PAR2, there are a plethora of genes that appear to have 
multiple functionalities. This work offers but one example of how evolutionary 
conserved molecules can diverge in their effector activation and read-out function in 
the cell that harbours their expression. This may be critical when developing 
therapeutic intervention for molecules that possess a variety of functions, such as 
VEGF, which imparts neuroprotective properties292. 
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Conclusions 
Vessel guidance is an important process required to ensure vessels reach their 
appropriate target to satisfy oxygen and nutrient demand while avoiding expenditure 
of metabolic stores on irrigating areas that do not require it. For this purpose attractive 
and repulsive signals exist, to function as intermediaries between the neurons and 
vessels. Having arisen later in evolution than nerves, vessels amalgamated the use of 
conserved neuronal guidance cues that help axons reach their target and do so in a 
highly concerted and regulated manner during vascular development. However, the 
interactions between neurons and vessels in ischemic retinal diseases are not fully 
understood. The studies presented herein demonstrate the important contribution of 
neuronal-derived vaso-modulatory cues (VEGF, Sema3A, Netrin1) in shaping 
vascular phenotypes in the neurovascular unit when under stress. Moreover, we 
identify important regulatory factors (IL-1β, PAR2, IRE1-α) that modulate expression 
of these vaso-modulatory cues, which may be attractive candidates for therapeutic 
intervention for ischemic retinal diseases. 
This work also supports the hypothesis that ischemic neurons shunt vessels 
away from perishing tissue by secreting vascular repulsive cues (and inhibiting vaso-
chemotactic molecules) in efforts to redirect metabolic stores to more salvageable 
parts of the retina. Although, while some explanations can be offered (ER stress and 
the UPR), there are yet unidentified, inherent mechanisms by which ischemic neurons 
(specifically RGCs) proverbially ‘switch’ from a pro-vascular phenotype to one that is 
vaso-repulsive. Understanding the pathophysiological mechanisms by which neurons 
react to ischemic stress will aid in our understanding of how these cells interact during 
ischemic stress. 
The current methods for treating IRs rely specifically on anti-angiogenic 
treatments, which aim at curbing retinal edema and vitreous hemorrhaging as well as 
pathological neovessel formation; however, these advents have variable success in 
IRs2,4,92. Moreover, these treatments do not address the underlying issue central to 
disease progression; namely, vessel loss and retinal ischemia. Exogenously 
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modifying the vascular response (possibly from neurons) in efforts to stimulate 
revascularization of ischemic tissue may present therapeutic avenues for treating IRs 
in the future.  
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Appendix 1 
Supplementary Figures Joyal JS, Sitaras N, et al. Blood 2011 
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Supplementary Figure 1. Timeline of revascularization in OIR and depiction of 
laser-capture microdissection. (A) Representative photo-micrographs of Griffonia 
simplicifolia lectin-stained retinal flatmounts illustrate the progression of vascular 
growth following the initial vaso-obliteration in response to oxygen exposure from P7-
12. At P12, immediately after exposure to hyperoxia, retinas present maximal 
vascular loss. As the retina attempts to revascularize, there is an initial delay in 
regrowth followed by misdirected preretinal vascular tuft formation that peaks at P17. 
Subsequently at P19-21, vessels enter the avascular retina, as the pre-retinal 
neovascularization regresses. By P23, the vaso-obliterated zone is fully 
revascularized. (B) Representative retinal cross-section of lectin-stained normal 
vessels before lasercapture, compared to (pre-retinal) vascular tufts. Dotted lines 
represent the laser dissection. 
 
 
 
 
 
Relative contributions: Suppl Figure 1 
A) Immunohistochemistry, imaging and analysis performed by N Sitaras, JS Joyal, 
K Zaniolo and Z Shao 
B) Immunohistochemistry, imaging and analysis performed by JS Joyal, A Stahl 
and P Sapieha 
 
Animal handling and sample collection: N Sitaras, JS Joyal, K Zaniolo and Z Shao 
Figure preparation: JS Joyal, N Sitaras, P Sapieha and S Chemtob 
Approximate Figure contribution: 40% 
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Supplementary Figure 2. VEGF is upregulated in the central avascular region of 
the OIR retina. Micro-dissection of avascular (A) and vascularized (V) areas of 
retinas from mice (P14) subjected to OIR, reveals a ~3-fold induction in VEGF protein 
(by Western blotting) specifically in the avascular center during pathological 
neovascularization (n=4). There is no significant difference in VEGF expression 
between peripheral (P) and central (C) normoxic retina at P14. Values are shown 
relative to peripheral and vascularized retinas ± s.e.m. *p=0.019 compared to 
corresponding vascularized area (V). 
 
 
 
 
 
Relative contributions: Suppl Figure 2 
Western blot analysis performed by N Sitaras and A Zabeida 
 
Animal handling and sample collection: N Sitaras, JS Joyal, K Zaniolo and Z Shao 
Figure preparation: JS Joyal, N Sitaras, P Sapieha and S Chemtob 
Approximate Figure contribution: 75% 
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Supplementary Figure 3. Expression of IL-1R1 in RGC-5 and astrocytes. (A) 
Protein expression of IL- 1R1 in unstimulated rat RGC-5 (by Western blot); human Tf-
1 cells were used as positive control (n=3). (B) Confocal immunohistochemical 
imaging of retinal cross-sections from P14 mice subjected to OIR reveals expression 
of IL-1R in astrocytes (GFAP positive); note merged images. n=3. Scale bar: 25 μm. 
 
 
 
 
Relative contributions: Suppl Figure 3 
A) In vitro preparation and Western blot analysis performed by N Sitaras 
B) Immunohistochemistry, imaging and analysis performed by T Zhu  
 
Animal handling and sample collection: N Sitaras, JS Joyal, K Zaniolo and Z Shao 
Figure preparation: JS Joyal, N Sitaras, P Sapieha and S Chemtob 
Approximate Figure contribution: 40% 
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Supplementary Figure 4. Intravitreal injection of Lentivirus efficiently infects 
RGCs. (A) LV vectors containing a GFP transgene under a CMV promoter (Lv.GFP) 
were injected intravitreally into mouse pups at P2 and infected ~70% of RGCs as 
detected by co-localization with the RGC-specific marker Thy1.1. at P14 (n=3). (B) 
Intravitreal injections of Lv.shSema3A at P2 resulted in a ~38% reduction at P8 (n=3, 
*p=0.043) and ~54% reduction at P14 (n=3, *p=0.034) of Sema3A protein, relative to 
values for corresponding Lv.shGFP. (C, D) Specificity of shSema3A was confirmed as 
neither VEGF nor other related Semaphorins such as Sema3D, Sema3E or Sema3F 
were downregulated. n=3; ***p<0.005 compared to corresponding Lv.shGFP. Scale 
bar (A) 50 μm. 
 
 
 
 
Relative contributions: Suppl Figure 4 
Lentiviral preparation performed by N Sitaras, JS Joyal, D Hamel and C 
Beauséjour 
Intravitreal injections performed by N Sitaras, K Zaniolo and Z Shao 
A) Immunohistochemistry, imaging and analysis performed by JS Joyal, K Zaniolo 
and P Sapieha 
B) Sample preparation and Western blot analysis performed by N Sitaras and A 
Zabeida 
C) Sample preparation and qPCR analysis performed by N Sitaras and A 
Zabeida 
 
Animal handling and sample collection: N Sitaras, JS Joyal, K Zaniolo and Z Shao 
Figure preparation: JS Joyal, N Sitaras, P Sapieha and S Chemtob 
Approximate Figure contribution: 40% 
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Supplementary Figure 5. Lv.shSema3A protects against vaso-obliteration and 
neovascularization. (A) Lectin-stained retinal flatmounts reveal that Lv.shSema3A 
treated retinas present significantly less vasoobliteration (67% relative to controls). 
n=13-15, **p=0.01 compared to control. (B) Neovascular areas shown in Figure 3B 
were quantified using Swift NV1; representative quantification masks are presented. 
 
 
 
 
 
 
Relative contributions: Suppl Figure 5 
Lentiviral preparation performed by N Sitaras, JS Joyal, D Hamel and C 
Beauséjour 
Intravitreal injections performed by N Sitaras, K Zaniolo and Z Shao 
D) Immunohistochemistry, imaging and analysis performed by N Sitaras, JS Joyal, 
K Zaniolo and P Sapieha 
 
Animal handling and sample collection: N Sitaras, JS Joyal, K Zaniolo and Z Shao 
Figure preparation: JS Joyal, N Sitaras, P Sapieha and S Chemtob 
Approximate Figure contribution: 40% 
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Supplementary Figure 6. In vitro assessment of RGC–derived Sema3A. (A) 
Lentivirus efficiently infects cultured RGCs and shSema3A reduces Sema3A 
expression by ~50%. n=3; ***p<0.01 compared to control. (B) Time lapse images (0 
to 45 min) of EC contraction upon stimulation with rSema3A (1 μg/ml) or vehicle 
(control). (C) Pull-down of activated RhoA-GTP reveals that this permissive player in 
cytoskeletal growth and remodelling becomes activated when RGC-derived Sema3A 
is knocked down in CM. 	  	  	  	  
Relative contributions: Suppl Figure 6 
Lentiviral preparation performed by N Sitaras, JS Joyal, D Hamel and C 
Beauséjour 
In vitro preparations performed by N Sitaras, F Binet and JS Joyal 
A) Immunocytochemistry, imaging and analysis performed by N Sitaras, JS Joyal, 
and F Binet 
qPCR analysis performed by N Sitaras and A Zabeida 
B) Live imaging and analysis performed by F Binet, G Hickson and P Sapieha 
C) Pull down assay and Western blot analysis performed by F Binet 
 
Figure preparation: F Binet, JS Joyal, N Sitaras, P Sapieha and S Chemtob 
Approximate Figure contribution: 20% 	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Appendix 2 
Supplementary Figures for Rivera JC, Sitaras N et al. Arterioscler 
Thromb Vasc Biol 2013 
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Supplemental Figure 1. NLRP3 inflammasome expression in the retina and 
protein detection of different mediators induced by hyperoxia. Measurement by 
quantitative PCR of the mRNA expression of NLRP3 inflammasome in retinas (n=3) 
from rat pups exposed to normoxia (21% O2) or hyperoxia (80% O2) during 1, 3 and 
5 days (A). *p<0.01 vs 21% O2. Representative Western blots showing IL-1β (17 kD), 
Sema3A (≈95 kDa) and VEGF (21 kDa) immunoreactive bands in retinal 
homogenates at P8 (B) or P10 (C) after normoxic (21% O2; as control) or hyperoxic 
(80% O2) exposure treated with vehicle, IL-1Ra or 101.10. Expression of IL-1R (80 
kDa) was increased by hyperoxia and suppressed by both IL-1R antagonists (D). 
RGC-5 cells treated with IL-1β (0.5 ng/ml) for 24 h and evaluated by Western blot in 
cell lysate showed increased Sema3A expression that was suppressed with IL-1Ra or 
101.10 (E). In all the cases β-actin (42 kDa) was used as internal control. 
 
 
 
Relative contributions: Suppl Figure 1 
A) Sample preparation and qPCR analysis performed by N Sitaras, JC Rivera 
and B Noueihed 
B) through E) Sample preparation and Western blot analysis performed by JC 
Rivera, B Noueihed and A Madaan 
 
Animal handling and sample collection: JC Rivera and N Sitaras 
Figure preparation: JC Rivera, N Sitaras, B Noueihed and S Chemtob 
Approximate Figure contribution: 20% 
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Supplemental Figure 2. Administration of IL-1 antagonists does not affect 
normal retinal vascularization. Representative lectin-stained retinal micrographs 
showing vascularisation, and vascular density histogram of animals treated with 
intraperitoneally with vehicle, IL-1Ra or 101.10 from P5 to P14 (sacrifice). Data are 
the mean ± SEM for n=3 independent experiments. 
 
 
 
 
 
 
Relative contributions: Suppl Figure 2 
Drug administration performed by JC Rivera, N Sitaras and JC Honoré 
Imaging and analysis performed by JC Rivera and N Sitaras 
 
Animal handling and sample collection: JC Rivera 
Figure preparation: JC Rivera and S Chemtob 
Approximate Figure contribution: <10% 
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Supplemental Figure 3. IL-1R inhibitors prevent pre-retinal neovascularization, 
and intravitreal IL-1β increases Sema3A expression and causes retinal 
microvascular injury. Representative lectin-stained retinal flat mounts (showing 
vascularity) at P18 (A) and compiled histograms of percent neovascularization. 
Intraperitoneal administration of IL-1Ra or 101.10 from P0-P14 prevented pre-retinal 
neovascularization . Data are the mean ± SEM for n=3 independent experiments. 
&p<0.001 vs normoxia, #p<0.01 vs OIR + vehicle. (B) Lectin-stained retinal 
photomicrographs in animals treated with intravitreal IL-1β (5ng/1μl) or vehicle (PBS). 
Below representative micrographs are the compiled histograms of vascular density 
and Sema3A mRNA expression. * p<0.01 vs vehicle. Scale bar = 50 μm. 
 
 
 
 
Relative contributions: Suppl Figure 3 
Drug administration performed by JC Rivera, N Sitaras and JC Honoré 
A) Immunohistochemistry, imaging and analysis performed by JC Rivera  
B) Immunohistochemistry, imaging and analysis performed by JC Rivera 
qPCR analysis performed by N Sitaras 
 
Animal handling and sample collection: JC Rivera 
Figure preparation: JC Rivera and S Chemtob 
Approximate Figure contribution: 10% 
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Supplemental Figure 4. The peptide 101.10 (rytvela) is mostly distributed in the 
retina in microglia and endothelial cells during hyperoxia. Peptide 101.10 was 
conjugated to FITC (green) and injected intraperitoneally in animals (at P5) exposed 
to normoxia (A) or hyperoxia (B); FITC alone was used a negative control (C). 
Fluorescence was analyzed 3-6 hours after peptide administration by confocal 
microscopy in retinal flat-mounts stained with lectin (red). Primarily upon exposure to 
hyperoxia (80% O2), 101.10-FITC co-localized with lectin (yellow), corresponding to 
microglial (thick arrows) and endothelial (thin arrows) cells. Nuclei were counter-
stained with DAPI (blue). Scale bars = 50μm. 
 
 
 
 
 
Relative contributions: Suppl Figure 4 
Drug administration performed by JC Rivera, N Sitaras and JC Honoré 
Imaging and analysis performed by JC Rivera and N Sitaras 
 
Animal handling and sample collection: JC Rivera 
Figure preparation: JC Rivera and S Chemtob 
Approximate Figure contribution: <10% 
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Supplemental Figure 5. Cellular internalization of 101.10 is dependent on the 
presence of the IL-1R. Internalization of 101.10-FITC in HEK blue cells (expressing 
IL-1R) was increased time-dependently at 3, 6 and 9 hours after stimulation with IL-
1β; HEK 293 cells (devoid of IL-1R) do not internalize IL-1R. FITC alone was used as 
control (n=3-4 per group). 
 
 
 
 
 
 
Relative contributions: Suppl Figure 5 
In vitro preparations, immunocytochemistry and analysis performed by JC 
Rivera and C Quiniou 
 
Figure preparation: JC Rivera, C Quiniou and S Chemtob 
Approximate Figure contribution: 0% 
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Supplemental Figure 6. IL-1β is minimally produced by astrocytes, neurons and 
endothelium during hyperoxia. Representative confocal images showing 
immunoreactivity to IL-1β (green), GFAP, NeuN, CD31 (red), merged with DAPI (blue 
and yellow) in retinal cryosections (n=3) from 8-day-old rats after 3 days of hyperoxia 
(80% O2). A slight colocalization of IL-1β with CD31 (endothelial marker) was 
detected. Scale bar = 50 μm. 
 
 
 
 
 
 
 
Relative contributions: Suppl Figure 6 
Imaging and analysis performed by JC Rivera and N Sitaras 
 
Animal handling and sample collection: JC Rivera and N Sitaras 
Figure preparation: JC Rivera and S Chemtob 
Approximate Figure contribution: 20% 
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Supplemental Figure 7. Localization of IL-1R in the retina. Representative 
confocal images from 3 experiments showing the immunoreactivity to IL-1RI 
(principally the inner plexiform layer [IPL], in green), IgG’s (Control) and DAPI in 
retinal cryosections from 8-day-old rats exposed for 3 days to normoxia or hyperoxia 
(80% O2). IL-1RI immunoreactivity was increased by hyperoxia and mainly detected 
on neurons (NeuN) in the ganglion cell layer (GCL), and very slightly in microglia (Iba-
1) and vessels (CD31), but not in astrocytes (GFAP). Scale bar = 50 μm. 
 
 
 
 
 
 
 
Relative contributions: Suppl Figure 7 
Imaging and analysis performed by JC Rivera and N Sitaras 
 
Animal handling and sample collection: JC Rivera and N Sitaras 
Figure preparation: JC Rivera and S Chemtob 
Approximate Figure contribution: 20% 
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Supplemental Figure 8. NLRP3 inflammasome, IL-1β and Iba-1 expression in 
microglia cultures are increased during hyperoxia. Measurement by quantitative 
PCR of the mRNA expression of NLRP3 (B), IL-1β (C), Iba-1 (F) and IL-1β secretion 
measured by ELISA (D) or cell viability evaluated by MTT assay (E) in primary 
microglial cultures exposed to hyperoxia (80% O2) or normoxia (21% O2) in presence 
or absence of N-acetylcysteine (NAC; 8mM). Data are the mean ± SEM for n=4-5 
independent experiments. #*p<0.01 versus 21% O2. 
 
 
 
 
 
 
 
Relative contributions: Suppl Figure 8 
 In vitro preparations performed by JC Rivera and N Sitaras 
A) Microglial cell viability assay performed by JC Rivera  
B) D) and E) qPCR performed by N Sitaras and B Noueihed 
C) ELISA performed by JC Rivera 
 
Animal handling and sample collection: JC Rivera and N Sitaras 
Figure preparation: JC Rivera, N Sitaras, B Noueihed and S Chemtob 
Approximate Figure contribution: 40% 
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Supplemental Figure 9. Autostimulation of IL-1β in HEK blue cells and 
macrophages. (A) Exogenous IL-1β (50 ng/ml; 4 h) induced IL-1β mRNA expression 
(qPCR) in HEK blue cells (containing IL-1R) but not in HEK 293 cells devoid of IL-1R; 
induction was prevented by IL-1Ra and 101.10. Histogram values are mean ± SD of 
three independent experiments. * p<0.05 vs Control, &#* p<0.05 vs IL-1β treatment. 
(B) Exogenous IL-1β (50 ng/ml; 4 h) induced IL-1β mRNA expression (qPCR) in 
RAW-Blue mouse macrophages; silencing of IL-1RI (siRNA-IL-1RI [see insert]) 
prevented this induction. Histogram values are mean ± SD of three independent 
experiments. # p<0.05 vs Control. 
 
 
 
 
 
 
 
 
Relative contributions: Suppl Figure 9 
A) and B) In vitro preparations, immunocytochemistry and analysis performed by 
JC Rivera and C Quiniou 
 
Figure preparation: JC Rivera, C Quiniou and S Chemtob 
Approximate Figure contribution: 0% 
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Supplemental Figure 10. Semaphorin 3A (Sema3A) is largely produced by 
retinal ganglion cells (RGC) in the retina under hyperoxia. Representative 
confocal images showing immunoreactivity of Sema3A (green) and NeuN (red) 
merged with DAPI (blue) in retinal cryosections (n=3) from 8-day-old rats after 3 days 
in normoxia (21% O2) or hyperoxia (80% O2). Co-staining of Sema3A with NeuN 
(yellow) was detected mainly on retinal ganglion cells (RGC) from hyperoxic pups 
treated with vehicle. Retinas from hyperoxic rat pups treated with IL-1Ra or 101.10 
reveal a decrement in Sema3A staining similar to the normoxic animals in the 
ganglion cell layer (GCL). Scale bar = 50 μm. 
 
 
 
 
 
Relative contributions: Suppl Figure 9 
In vitro preparations, immunocytochemistry and analysis performed by JC 
Rivera and N Sitaras 
 
Figure preparation: JC Rivera, N Sitaras and S Chemtob 
Approximate Figure contribution: 20% 
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Supplemental Figure 11. Conditioned media from retinal ganglion cells (RGC-5) 
stimulated with hyperoxic-microglia conditioned media (Hyp-MG-RGC-CM) 
induces activation of caspase-3 on endothelial cells (RBMVEC). Representative 
photomicrographs of endothelial cells (n=3) positively labeled with activated caspase-
3 polyclonal antibody (green) or β-actin monoclonal antibody (red) on RBMVEC 
treated for 48 hours with conditioned medium from RGC-5 cells previously stimulated 
with normoxia-(21% O2; Norm-MG-RGC-CM) or hyperoxia-exposed (80% O2) 
microglia media in absence (vehicle; Hyp-MG-RGC-CM) or presence of IL-1Ra or 
101.10. Co-localization of activated caspase-3 and β-actin staining was merged with 
RBMVECs nucleus stained with DAPI (blue). Scale bar = 50μm. 
 
 
 
Relative contributions: Suppl Figure 11 
In vitro preparations, immunocytochemistry and analysis performed by JC 
Rivera  
 
Figure preparation: JC Rivera and S Chemtob 
Approximate Figure contribution: 0% 
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Supplemental Figure 12. IL-1β released from neuro-microvascular endothelial 
cells (RMBVEC) exposed to hyperoxia does not induced Sema3A release on 
RGC-5 cells. The treatment with recombinant Sema3A (4.5 nM) for 24 hours 
decreased significantly (48%) the cell viability (evaluated by MTT assay) on RBMVEC 
cells compared to the control (A). *p<0.05 vs Vehicle. But, the mRNA VEGF levels 
determined by qPCR did not change with the Sema3A treatment (B). IL-1β protein 
was evaluated by ELISA (C) in the media of RBMVEC exposed to 21% or 80% of 
oxygen levels for 24 hours. IL-1β levels from RBMVEC exposed to hyperoxia does 
not significantly change compared to control. No changes were observed in cell 
viability (D) evaluated by MTT assay on RBMVEC cells (n=3) treated with conditioned 
media from RGC-5 previously treated with hyperoxic endothelial cell conditioned 
media (Hyp-EC-RGC-CM, containing IL-1β). By contrast, the conditioned media from 
RGC-5 cells treated with hyperoxic microglial cell conditioned media (Hyp-MG-RGC-
CM, containing high levels of IL-1β, used as positive control), increased the 
expression of the pro-apoptotic Sema3A from cultured RGC and induced a significant 
decrement (35%; p<0.05) in the endothelial cell viability compared to the control (D). 
*p<0.05 vs Nor-EC-RGC-CM. 	  	  	  
Relative contributions: Suppl Figure 11 
In vitro preparations performed by JC Rivera and N Sitaras 
A) and D) Cell survival assay and analysis performed by JC Rivera and N Sitaras 
B) qPCR analysis performed by N Sitaras and B Noueihed 
C) ELISA performed and analyzed by JC Rivera 
 
Figure preparation: JC Rivera, N Sitaras and S Chemtob 
Approximate Figure contribution: 20% 
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Appendix 3 
Supplementary Figures Sitaras N, et al. Am J Pathol 2014. 
Supplementary Table 1. Primers used for detecting mRNA expression  
Primer Species Sequence Annealing Primer  Amplicon 
    5' to 3' Temp. (ºC) Conc. (nM) Size (bp) 
    
 
      
PAR2 Fwd Mouse 
 
TGACCACGGTCTTTCTTCCG 58.0 500 175 
PAR2 Rev TCAGGGGGAACCAGATGACA 
  
  
      
PAR2 Fwd Rat 
 
TGGGAGGTATCACCCTTCTG 58.0 500 350 
PAR2 Rev GGGGAACCAGATGACAGAGA 
  
  
      
IL-1β  Fwd Mouse 
 
CTGGTACATCAGCACCTCACA 58.0 500 155 
IL-1β  Rev GAGCTCCTTAACATGCCCTG 
    
 
      
IL-1RI Fwd Mouse  TGAATGTGGCTGAAGAGCAC 58.0 500 235 
IL-1RI Rev & Rat CGTGACGTTGCAGACAGTT 
    
 
      
Sema3A Fwd Mouse 
 
GCTCCTGCTCCGTAGCCTGC 58.0 500 304 
Sema3A Rev TCGGCGTTGCTTTCGGTCCC 
  
  
      
VEGF-A Fwd Mouse 
 
GCCCTGAGTCAAGAGGACAG 58.0 500 215 
VEGF-A Rev CTCCTAGGCCCCTCAGAAGT 
Cyclophilin A Fwd 
Cyclophilin A Rev 
Mouse 
 
 
 
 
CAGACGCCACTGTCGCTTT 
  
 
 
58.0 
 
 
500 
 
 
133 
  
 
β III-tubulin Fwd Mouse 
 
TAGACCCCAGCGGCAACTAT 58.0 500 127 
β III-tubulin Rev GTTCCAGGTTCCAAGTCCACC 
  
  
      
CD-31 Fwd Mouse 
 
ACCGGGTGCTGTTCTATAAGG 58.0 500 165 
CD-31 Rev TCACCTCGTACTCAATCGTGG 
  
  
      
Thy1.1 Fwd Mouse 
 
TGCTCTCAGTCTTGCAGGTG 58.0 500 121 
Thy1.1 Rev TGGATGGAGTTATCCTTGGTGTT 
  
  
      
Rhodopsin Fwd Mouse 
 
TCATGGTCTTCGGAGGATTCAC 58.0 500 112 
Rhodopsin Rev TCACCTCCAAGTGTGGCAAAG 
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Supplementary Figure 1. PAR2 expression in neural retina. (A) High 
magnification immunohistochemical images of sagittal sections from P8 C57BL/6 
mice showing colocalization of PAR2 (green) in βIII-tubulin-positive RGCs (red). (B) 
PAR2 (green) also colocalizes with endothelial cells (CD31; red) albeit to a lesser 
extent. Nuclei are counterstained with DAPI (blue). NFL, nerve fiber layer; GCL, 
ganglion cell layer; IPL, inner plexiform layer; INL; inner nuclear layer. Scale bar = 30 
μm; original magnification 600x. (C) Comparison of wild-type and PAR2 null P8 mice 
retina stained with SAM11 antibody. PAR2-/- mice are devoid of immunofluorescent 
signal using SAM11 antibody. 
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Supplementary Figure 2. Laser capture microdissection on sagittal P8 mouse 
retina. (A) Cross sectional image of a P8 mouse retina depicting the delineated areas 
captured using laser-capture microdissection. Vessels are stained with lectin (red) 
while nuclei are counterstained with DAPI (blue). NFL, nerve fiber layer; GCL, 
ganglion cell layer; INL; inner nuclear layer; ONL, outer nuclear layer. Scale bar = 50 
µm; original magnification 300x (B) Expression profile of laser dissected retinal layers 
probed for cell markers CD31 (vessels), Thy1.1 (GCL), βIII-tubulin (GCL & INL) and 
Rhodopsin (ONL). 
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Supplementary Figure 3. PAR2 intact and transgenic mice share similar 
vascular phenotypes in OIR; shRNA-bearing Lentiviral constructs target PAR2 
in retinal ganglion cells. (A) Representative flatmounts of isolectin B4-stained 
retinas from PAR2 intact (Wild-Type C57BL/6) and transgenic (PAR2-/-) mice at P12, 
15 and P17 previously exposed to hyperoxia from P7 to P12. Original magnification 
100x. VO and NV areas are outlined with solid blue lines and yellow-hashed lines, 
respectively. Avascular areas and neovascularization is shown in right panels; no 
significant differences were observed between mice populations (n=5-12 retinas). RT-
PCR data (B) and Western blot data (C) from P12 PAR2 intact (C57BL/6) and 
transgenic (PAR2-/-) mice retina showing the presence or absence of PAR2 gene and 
protein, respectively. (D) Immunohistochemical staining showing colocalization of 
GFP (green) with retinal ganglion cells (βIII-tubulin; red) in P8 C57BL/6 mice retina 
following intravitreal injection (P3) with GFP reporter Lentiviral particles (~15.0 ng). 
Nuclei are counterstained with DAPI (blue). GCL, ganglion cell layer; IPL, inner 
plexiform layer. Scale bar = 30 µm. Original magnification 600x. (E) Western blot 
analysis of whole retina from P7 mice demonstrating effective knockdown of PAR2 
following intravitreal injection with Lv. shPAR2; contralateral eyes injected with Lv. 
shGFP served as control (n=2 retinas per group). 
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Supplementary Figure 4. PAR2 transgenic mice do not respond to SLIGRL or Lv. 
shPAR2 treatment. (A) Representative flatmounts from isolectin B4-stained P12 
PAR2-/- exposed to OIR and injected intravitreally at P7 with either vehicle (PBS), 
SLIGRL (100 µM), Lv. shGFP (~8.5 ng) or Lv. shPAR2 (~9.6 ng) show no change in 
VO (n=7-9 retinas). (B) Similar effects were observed in P17 PAR2-/- OIR mice 
injected intravitreally at P12 showing no change in VO or NV (n= 7-8 retinas). VO and 
NV areas are outlined with solid blue lines and yellow-hashed lines, respectively. 
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Supplementary Figure 5. Kineret treatment in vivo successfully dampens IL-1β 
in whole retina and PAR2 expression in various cell lines. (A) Intraperitoneal 
administration of Kineret® translated to decreased IL-1β mRNA in P8 mice whole 
retina exposed to OIR compared to saline treated animals (***=p<0.001; n=2 retinas 
per group). (B) Cell lysates from RBMVEC, RGC-5 and rat cerebral astrocytes (RCA) 
immunoblotted with PAR2 SAM11 antibody. RCA devoid of PAR2 show now band at 
55kDa. (C) PCR analysis of RBMVEC, RGC-5 and RCA showing PAR2 mRNA 
expression in these cell lines; PAR2 was not detected in RCA. 
 
 
 
 
	   286	  
 
	   287	  
Supplementary Figure 6. SLIGRL treatment in normoxia raised mice pups; 
PAR2 transgenic mice respond to IL-1Ra but not to SLIGRL treatment. (A) 
Western blot analysis and (B) immunohistochemical analysis of retinas from normoxia 
raised P9 C57Bl6 injected with vehicle or SLIGRL (contralateral eye) demonstrate 
slight decreases in IL-1RI levels. IL-1RI stained in green, retinal ganglion cells in red 
(bIII-tubulin) and nuclei are counterstained in blue. NFL, nerve fiber layer; GCL, 
ganglion cell layer; IPL, inner plexiform layer; INL; inner nuclear layer; OPL, outer 
plexiform layer; ONL, outer nuclear layer. Scale bar = 50 μm; original magnification 
300x. (C) Representative flatmounts from isolectin B4-stained P12 PAR2-/- exposed to 
OIR and injected intravitreally at P7 with either vehicle, SLIGRL (100 μM), IL-1Ra (10 
μM) or both (*=p<0.05, ***=p<0.001, n=6-8 retinas). VO areas are outlined with solid 
blue lines. Original magnification 100x. (D) Western blot analysis of P9 mice retina 
from WT (C57Bl6) and PAR2-/- mice showing an effective increase in IL-1RI upon 
exposure to OIR; however, there was no variation in IL-1RI levels in PAR2-/- 
compared to WT mice retina. Densitometry quantification at right (*=p<0.05, 
**=p<0.01, n=3 independent experiments). 
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Supplementary Figure 7. PAR2-mediated regulation of IL-1RI in RBMVEC; 
PAR2-induced reduction of IRAK1 phosphorylation in RGC-5. (A) PAR2-
expressing RBMVEC display dose-dependent increases in IL-1RI mRNA following 1h 
stimulation with SLIGRL as analyzed by qPCR (*=p<0.05, **=p<0.01, ***p<0.001, 
n=8). (B) RGC-5 infected with Lv. shPAR2 demonstrated effective decrease in PAR2 
levels; Lv. shGFP-infected RGC-5 served as controls. (C) RBMVEC cells show 
increased IL-1RI protein levels following SLIGRL stimulation. (D) Control RGC-5 cells 
pre-treated with SLIGRL successfully abolish IL-1β-dependent IRAK-1 
phosphorylation whereas PAR2-deficient RGC-5 do not. (E) RBMVEC cells pre-
treated with ERK1/2 inhibitor, PD98059, displayed no increase in SLIGRL-dependent 
ERK1/2 phosphorylation. (F) ERK1/2 inhibition using PD98059 did not affect SLIGRL-
dependent increases in IL-1RI mRNA in RBMVEC (***=p<0.001, n=6). (G) Western 
blot analysis of P9 mice retina from WT (C57Bl6) and PAR2-/- mice showing an 
effective increase in ERK1/2 phosphorylation upon exposure to OIR; however, there 
was no variation in phospho-ERK1/2 levels in PAR2-/- compared to WT mice retina. 
Densitometry quantification at right (*=p<0.05, n=3 independent experiments). 
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Supplementary Figure 8. PAR2 stimulates production of VEGF in retinal 
ganglion cells and promotes VEGF-dependent vascular sprouting. (A) Western 
blot analysis demonstrating effective downregulation of VEGF in P9 C57BL/6 mice 
whole retina exposed to OIR. Intravitreal injection of SLIGRL, however, increased 
VEGF levels compared to vehicle treated animals. Densitometry quantification at right 
(n=3 independent experiments).  (B) Immunohistochemical analysis of coronal 
sections from P9 C57BL/6 mice retina exposed to OIR and injected intravitreally with 
vehicle or SLIGRL. While hyperoxia treatment decreased VEGF immunoreactivity in 
the retina proper, intravitreal administration of SLIGRL augmented VEGF specifically 
in the GCL. Scale bar = 50 µm; original magnification 300x. (C) Control Lv.shGFP-
infected RGC-5 treated with SLIGRL but not IL-1β exhibited increased VEGF mRNA 
compared to vehicle controls after 24 h; Lv. shPAR2-infected RGC-5, however, 
showed no increases in VEGF mRNA following treatment with SLIGRL (*=p<0.05, 
***=p<0.001, n=8). (D) Aortic explants stimulated with SLIGRL reveal increased 
vascular sprouting; however, treatment with neutralizing antibody to VEGF abrogated 
SLIGRL-induced aortic sprouting (*=p<0.05, n=4-5). 	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Regeneration through IRE1a Degradation of Netrin-1 
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Summary 
In stroke and proliferative retinopathy, despite hypoxia driven angiogenesis, 
delayed revascularization of ischemic tissue aggravates the loss of neuronal function. 
What hinders vascular regrowth in the ischemic central nervous system remains 
largely unknown. Using the ischemic retina as a model of neurovascular interaction in 
the CNS, we provide evidence that the failure of reparative angiogenesis is temporally 
and spatially associated with endoplasmic reticulum (ER) stress. The canonical ER 
stress pathways of protein kinase RNA-like ER kinase (PERK) and inositol-requiring 
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enzyme-1a (IRE1a) are activated within hypoxic/ischemic retinal ganglion neurons, 
initiating a cascade that results in angiostatic signals. Our findings demonstrate that 
the endoribonuclease IRE1a degrades the classical guidance cue netrin-1. This 
neuron-derived cue triggers a critical reparative-angiogenic switch in neural 
macrophage/microglial cells. Degradation of netrin-1, by persistent neuronal ER 
stress, thereby hinders vascular regeneration. These data identify a neuronal-immune 
mechanism that directly regulates reparative angiogenesis. 
 
Introduction 
Central neurons require a secure metabolic supply to ensure adequate function 
and transmission of sensory information. The breakdown of vascular beds in ischemic 
conditions such as stroke and proliferative retinopathies prevents nutrient and oxygen 
delivery and leads to hypoxic/ischemic events and a constellation of biochemical 
changes that compromises cellular function (Eichmann and Thomas, 2012; Lo, 2008; 
Moskowitz et al., 2010; Sapieha, 2012, Sapieha et al., 2010a). While the ensuing 
hypoxia is a potent stimulator of vascular growth itself (Lange et al., 2011; Ritter et al., 
2006; Sapieha et al., 2010a, 2010b), initial attempts to revascularize the ischemic 
nervous tissue are typically inadequate (Fukushima et al., 2011; Joyal et al., 2011). 
Promoting faster revascularization is of great therapeutic interest, as this will 
decrease the damage secondary to ischemia and could prevent the destructive 
hypoxia-driven pathological neovascular phase associated with diseases such as 
diabetic retinopathy and retinopathy of prematurity (ROP). 
In the central nervous system (CNS), one cellular manifestation of 
hypoxia/ischemia is endoplasmic reticulum (ER) stress (Chen et al., 2008; Hayashi et 
al., 2005; Paschen and Doutheil, 1999; Tajiri et al., 2004), which activates a collection 
of signaling pathways that initially promote cellular survival in a compromised 
metabolic situation. When ER homeostasis is perturbed, the unfolded protein 
response (UPR) is initiated and activates phosphorylation of protein kinase RNA-like 
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ER kinase (PERK) and inositol-requiring enzyme-1a (IRE1a) (Bernales et al., 2006; 
Marciniak and Ron, 2006; Ron and Walter, 2007; Schröder and Kaufman, 2005). 
Together, these pathways signal to reduce the workload of folding machinery inside 
the ER (Figure 1A). ER stress is a short-term adaptive response, yet if it persists and 
is not resolved, it will contribute to tissue dysfunction (Tabas and Ron, 2011; Xu et al., 
2005). To date, the physiological reper- cussions of ER stress have largely been 
investigated in the context of insulin resistance (Lee et al., 2011), atherosclerosis 
(Tabas, 2010), or liver disease (Malhi and Kaufman, 2011) while its influence in 
neurovascular homeostasis remains undefined. 
The retina is a relevant model in which to study CNS neurovascular crosstalk 
due to its highly stereotyped apposition of central neurons, capillaries, venules, 
arteries, and veins (Dorrell and Friedlander, 2006; Joyal et al., 2011; Sapieha, 2012) 
(Figure S1A). Moreover, of immediate clinical relevance, compromised neuro- 
vascular networks result in proliferative retinopathies (PRs) such as diabetic 
retinopathy (Aiello, 2005) and retinopathy of prematurity (Sapieha et al., 2010b), 
which are the principal blinding diseases affecting pediatric and working-age 
populations in industrialized countries (Gilbert et al., 1997; Kempen et al., 2004). PRs 
are generally characterized by initial microvascular degeneration followed by an 
excessive and pathological neovascularization provoked by the hypoxic retina 
attempting to reinstate oxygen and energy supply (Chen and Smith, 2007; Cheung 
and Wong, 2008; Smith, 2008). This attempted compensatory vascular regrowth is 
initially concentrated at the avascular border of the injured retina and hence fails to 
adequately perfuse the hypoxic tissue (Figure 1B). Instead, the new vessels are 
misdirected into the vitreous chamber, resulting in tangential sheering of the retina 
and consequent vision loss. 
There has been a recent surge in our knowledge of the molecular mechanisms 
governing blood vessel growth (Carmeliet and Jain, 2011). During vascular 
development, several conserved regulatory cues are shared between neurons and 
vessels (Adams and Eichmann, 2010; Carmeliet and Tessier-Lavigne, 2005; Erskine 
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et al., 2011; Larivée et al. 2009; Miao et al., 1999; Soker et al., 1998). Vascular tip 
cells (Gerhardt et al., 2003) (analogous to axonal growth cones) probe and sense 
chemotropic attractant and repellent environmental cues and respond to the vascular 
endothelial growth factor (VEGF) by forming motile filopodia enriched in VEGFR2 and 
rich in guid- ance receptors for semaphorins (Neuropilins), netrins (UNC5B and DCC), 
ephrins (Ephs), and slits (roundabout) (Adams et al., 1999; Klagsbrun and Eichmann, 
2005; Larivée et al. 2009, 2007; Wilson et al., 2006). In addition, there is mounting 
evidence for the role of myeloid cells in vascular development (Stefater et al., 2011a, 
2011b), repair (Checchin et al., 2006; Ritter et al., 2006), remodeling (Lang and 
Bishop, 1993), and anastomosis (Fantin et al., 2010) where these cells associate 
directly with vessels at the vascular front to exert their modulatory effects. To date, 
the influence of guidance cues on myeloid-induced vascular growth and remodeling 
has not been addressed. 
Using the neural retina and its vascular system as a model of central 
neurovascular interaction, we set out to determine the outcome of hypoxia-induced 
neuronal ER stress on the vascular beds that perfuse this highly metabolic tissue. 
Employing the oxygen-induced retinopathy (OIR) model of vascular degeneration and 
regeneration (Smith et al., 1994), which serves as a proxy for human proliferative 
retinopathies such as diabetic retinopathy and retinopathy of prematurity, we 
uncovered a paradigm where ER stress in ischemic neurons provokes the 
suppression of vascular regeneration into hypoxic regions of CNS tissue. This results 
from an IRE1a-dependent downregulation of netrin-1, a protein we demonstrated to 
be required for myeloid-dependent revascularization. Either inhibition of IRE1a or 
treatment with netrin-1 accelerates retinal vascular regeneration and consequently 
alleviates the hypoxic stimulus for destructive neovascularization. Our data reveal an 
inherent capacity of CNS neurons to repair neighboring tissue by summoning a 
reparative innate immune response and provide evidence for neuronal-immune 
communication in ischemic retinopathies. Approaches to foster revascularization may 
be desirable to counter ischemic stress in the CNS. 
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Experimental Procedures 
Animals 
All studies were performed according to the Association for Research in Vision 
and Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and 
Vision Research and were approved by the Animal Care Committee of the University 
of Montreal in agreement with the guidelines established by the Canadian Council on 
Animal Care. C57Bl/6 wild-type were purchased from The Jackson Laboratory and 
CD1 nursing mothers from Charles River Laboratories. 
Depletion of Macrophages by Clodronate Liposomes 
We prepared clodronate liposomes (0.7 M) or control empty-liposomes (PBS- 
filled) as described (van Rooijen and van Kesteren-Hendrikx, 2003) and delivered 
them by intravitreal injection (0.5 mL) at P11. To visualize and ascertain uptake of 
liposomes in macrophages in vitro and in vivo, we incu- bated liposomes with the 
fluorescent lipophilic marker DiI according to the manufacturer’s protocol (Invitrogen). 
O2-Induced Retinopathy 
Mouse pups (C57Bl6; The Jackson Laboratory) and their fostering mothers 
(CD1; Charles River Laboratories) were exposed to 75% O2 from P7–P12 and 
returned to room air. This model serves as a proxy to human ocular neovascular 
diseases such as ROP and diabetic retinopathy characterized by a late phase of 
destructive pathological angiogenesis (Sapieha, 2012; Stahl et al., 2010). Upon return 
to room air, hypoxia-driven neovascularization (NV) develops from P14 onward 
(Smith et al., 1994). We enucleated eyes at different time points and dissected the 
retinas for mRNA or protein assays as described. Dissected retinas were flatmounted 
and incubated overnight with fluoresceinated isolectin B4 (1:100) in 1 mM CaCl2 to 
determine the extent of avascular area or neovascularization area at P17 using 
ImageJ and the SWIFT-NV method (Stahl et al., 2009). 
Semiquantitative and Real-Time PCR Analysis 
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We isolated RNA using the GenElute Mammalian Total RNA Miniprep Kit 
(Sigma-Aldrich) and performed a digestion with deoxyribonuclease I (DNase I) to 
prevent amplification of genomic DNA. We reverse transcribed the RNA using M-MLV 
reverse transcriptase and analyzed gene expression using Sybr Green in an ABI real-
time PCR machine (Applied Biosystems). b-actin was used as a reference gene. 
Primers sequences are displayed in Figure S7. We investigated the splicing of XBP1 
by incubating the XBP1 semiquantitative PCR product with 0.4 U/mL of PstI enzyme 
for 5 hr at 37_C followed by separation on 2.5% agarose gel. 
Laser-Capture Microdissection 
Eyes were enucleated from P14 pups in OIR or normoxic littermates and flash 
frozen in OCT. We then cut 12 mm sections using a Leica cryostat at -20_ C and air 
dried for 10 min. We dissected retinal layers using a Zeiss Observer micro- scope 
equipped with a PALM MicroBeam device for laser capture microdissection. We 
isolated mRNA from these sections and performed qPCRs as described above. 
Western Blotting 
For assessment of retinal protein levels, we enucleated eyes at varying time 
points and rapidly dissected and homogenized retinas. Protein concentrations were 
assessed by BCA assay (Sigma), and then 30 ug of protein was analyzed for each 
condition by standard SDS-PAGE technique. Antibodies used for western blotting are 
listed in Figure S7. 
Immunohistochemistry 
To localize protein expression, eyes were enucleated from mice and fixed in 
4% paraformaldehyde at room temperature for 4 hr, incubated in 30% sucrose 
overnight, and then frozen in OCT compound. We then embedded the whole eye in 
optimal cutting temperature compound at -20_C and performed 12 mm serial sections. 
We carried out immunohistochemistry experiments and visualized the sections with 
an epifluorescent microscope (Zeiss Axio Imager). Antibodies used for 
immunohistochemistry are listed in Figure S7. For visualization of panretinal 
vasculature, flatmount retinas were stained with fluoresceinated Isolectin B4 (Alexa 
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Fluor 594 [I21413]; Molecular Probes) in 1 mM CaCl2 in PBS for retinal vasculature. 
For assessment of vascular permeability, we injected the mice intracardially with 10 
mg/mL of 70 kDa FITC-dextran. After 5 min, the eyes were harvested and retinas 
were dissected for flatmouting and visualization under a fluorescent microscope. 
Preparation of Lentivirus 
We produced infectious lentiviral vectors by transfecting lentivector and 
packaging vectors into HEK293T cells (Invitrogen) as previously described (Dull et al., 
1998). Viral supernatants were concentrated by ultracentrifugation (>500-fold) and 
titers determined by ELISA for viral p24 antigen using a commercial kit (Clontech). 
The titers of the lentiviruses used were (in ng p24) LV.GFP (15.0 ng/mL), LV.sh.RNA 
IRE1a (8.52 ng/mL), and LV.sh.RNA.GFP (8.47 ng/mL). 
Generation of Stable PERK- and IRE1a-Deficient RGC-5 Cell Lines and 
Transfections  
We stably transfected RGC-5 cells with 500 ng of shRNA plasmids targeting 
PERK or IRE1a (Open Biosystems) or an unrelated shRNA (shGFP) for 16 hr at 37_C 
using Lipofectamine 2000 following the manufacturer’s directions. We generated 
stable cell lines by selecting with 2 mg of puromycin over 2 weeks. For analysis of 
cleavage of netrin-1, we transfected 1 mg of an expression plasmid for chicken netrin-
1 with or without the expression plasmids for shGFP, IRE1a or a dominant-negative 
mutant of IREa K599A, or the RNase dead mutant K907A in HEK293T cells using 
Lipofectamine 2000. Plasmids for IRE1a and IRE1a K599A were a gift from Fumihiko 
Urano (Addgene plasmid #20744 and #20745), and plasmid K907A was kindly 
provided by Randal J. Kaufman (Sanford-Burnham Medical Research Institute). 
Detection of Intravitreally Delivered Netrin-1 
We injected a recombinant Myc-tagged netrin-1 protein in P14 OIR animals. 
We collected eyes 3 hr later then fixed and dissected the retinas. We stained the 
retinas using a Myc antibody, Iba1, and fluoresceinated isolectin B4. Flatmounted 
retinas were visualized using a confocal microscope equipped with an argon laser 
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(LMS5; Zeiss). We generated a 3D reconstruction of >20 z stack layers using the 
Velocity software. 
Microvascular Sprouting of Aortic Rings 
Aortae from adult C57Bl6 mice were dissected and sectioned into 1 mm rings, 
which were immediately transferred to reduced growth factor Matrigel. After 3 days in 
EBM basal medium (Lonza), we incubated the rings with 500 uL of macrophage-
conditioned media. Rings were photographed with an inverted microscope (Zeiss Axio 
Imager) before and 48 hr post-treatment. Variation in the vascular area surrounding 
the aortic ring was calculated using ImageJ software. 
CyQUANT Proliferation Assay 
Primary human retinal microvascular endothelial cells (HRMEC passages six 
to ten from Cell Systems) were starved for 12 hr in EBM-2 medium (Lonza) plus 0.5% 
fetal bovine serum prior to treatment with macrophage-conditioned media or controls. 
We assessed the proliferation rates of 5,000 HRMEC cells/well using the CyQUANT 
NF Cell Proliferation Assay Kit (Invitrogen) (according to instructions given by the 
manufacturer) after 48 hr of incubation. 
Isolation of Primary Microglia 
Brains from P14 pups were homogenized in ice-cold L15 medium (GIBCO) and 
incubated for 15 min in 0.05% trypsin-EDTA (GIBCO) at 37_C. The reaction was 
stopped by addition of equal volumes of fetal bovine serum. We added 75 U/mL of 
DNase I (Sigma) before filtering through a 70 mm cell strainer. After 9 days of 
incubation in DMEM media (Invitrogen) supplemented with 10% fetal bovine serum 
and penicillin/streptomycin, microglia were detached from the plates by gentle 
shaking (150 rpm for 2 hr at 37_C). Purity of preparations was confirmed by FACS 
analysis. 
Matrigel Plug Assay 
Macrophage-conditioned media (80 ml) was mixed with 500 uL of reduced 
growth factor Matrigel (BD Biosciences) at 4_C. The mixture was injected 
subcutaneously in the abdominal region of C57Bl6 mice (6 weeks old). After 10 days, 
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we injected 200 ml of FITC-dextran (2,000,000 MW; 25 mg/mL) intravenously 15 min 
prior to dissection of the overlying skin and harvesting of the Matrigel plug. We 
photographed the plugs using an epifluorescent microscope (Zeiss AxioImager) then 
weighted and homogenized the plugs in 1 mg/mL of collagenase/dispase (Roche) 
overnight at 37_C in the dark. The next day, we centrifuged homogenates and 
measured fluorescence intensity of supernatants at 480/520 nm. 
FACS of Digested Retinas 
Retinas from clodronate or empty liposome-injected eyes were homogenized 
with a solution of 750 U/mL DNaseI (Sigma) and 0.5 mg/mL of collagenase D (Roche) 
for 15 min at 37_C with gentle shaking. Homogenates were the filtered with a 70 mm 
cell strainer and washed in RPMI + 2% fetal bovine serum. We used PE-F4/80, FITC-
CD11b, 7-AAD antibodies for detection of macrophages and performed analysis using 
a BD FACSCanto device (BD Biosciences) and the FlowJo 7.6 software. Antibodies 
are listed in Figure S7. 
Preparation of Macrophage-Conditioned Media 
Supernatants were collected from J774 cells that had been incubated for 24 hr 
in the presence of various concentrations of netrin-1 and/or inhibitors. Supernatants 
were centrifuged, filtered, and then frozen for subsequent use. Secondary Structure 
Reconstruction of Netrin-1 mRNA 
For prediction of the secondary structure of mRNA, we analyzed the murine 
sequence of netrin-1 mRNA using CentroidFold program (http://www.ncrna. 
org/centroidfold). 
IRE1a In Vitro Cleavage Assay  
Thirty micrograms of total RNA extracted from HEK transfected or not with an 
expression plasmid for netrin-1 was subjected to digestion by the IRE1a recombinant 
enzyme (5 mg) for 2 hr at 37_C in a 53 digestion buffer (250 mM Tris [pH 7.5], 600 
mM NaCl, 5 mM MgCl2, 5 mM MnCl2, 25 mM b-mercaptoethanol, 10 mM ATP). The 
digested RNA was analyzed by semi- quantitative PCR using sets of primers 
spanning different regions in the netrin-1 mRNA. 
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Northern Blotting 
Fifty micrograms of total RNA was separated on a formaldehyde agarose gel 
and transferred to a nitrocellulose membrane. The membrane was then incubated 
with a radiolabelled netrin-1-specific probe (<500 pb fragment of a SacII-PvuI 
digestion product of the netrin-1 expression plasmid) overnight at 42_ C. 
Statistical Analyses 
Data are presented as mean ± SEM. We used Student’s t test to compare the 
different groups; p < 0.05 was considered statistically different. 
Supplemental Information 
Supplemental Information includes seven figures and one movie and can be 
found with this article online at http://dx.doi.org/10.1016/j.cmet.2013.02.003. 
 
Results 
Neuronal ER stress Is Induced in Ischemic Conditions  
The activation of canonical ER stress pathways is a conserved mechanism 
that enhances cellular survival under low metabolic conditions by reducing protein 
synthesis. This is achieved via phosphorylation of ER membrane-resident proteins 
such as PERK and IRE1a (Figure 1A). PERK restricts the translational machinery to a 
selected subset of messenger RNAs (mRNAs) such as ATF4, whereas 
phosphorylated, active IRE1a promotes splicing of XBP1 into an active transcription 
factor (XBP1s) that pro- motes expression of genes involved in UPR while the 
unspliced form (XBP1u) blocks transcription of genes involved in UPR. ATF4 and 
XBP1s induce transcription of specific homeostasis genes, such as the chaperone 
GRP78, to in- crease the protein-folding capacity of the ER (Figure 1A) (Ron and 
Walter, 2007). To determine if ischemia in central nervous tissue can provoke ER 
stress, we used the mouse model of OIR (75% oxygen from P7–P12 [postnatal day 
7–12] and room air until P17), which yields a central avascular retina (Smith et al., 
1994). This vascular degeneration is followed by a second phase of deregulated 
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(albeit compensatory) vascular regeneration (Figure 1B). The secondary regrowth 
occurs upon return to room air (P12) for a period of approximately 7 days (Stahl et al., 
2010). 
We initially performed a time course for the expression of classical markers of 
ER stress throughout OIR. We focused on time points corresponding to the hyperoxic 
vasoobliterative phase (P10), upon return to normal air (P12), and in the initial phase 
of progressive vascular regrowth (P14). Phosphorylated PERK and IRE1a were found 
primarily in the ganglion cell layer (GCL) and colocalized with the RGC marker bIII-
tubulin (Figures 1C and 1D). The phosphorylation was evident in P14 OIR retinas 
during the early phase of vascular regeneration when reparative angiogenesis 
proceeds at a slow pace and the central retina remains hypoxic (Figures 1C and 1D). 
No phosphorylation of IRE1a and PERK was observed in the vascular layers (Figure 
1E), highlighting the neuronal nature of the ER stress. This expression pattern was 
associated robustly with the central avascular area of the retina as confirmed with 
endothelial isolectin B4 staining (Figure 1F). Moreover, using laser capture 
microdissection (LCM), we specifically isolated the RGC layer from the retina (Figure 
1G) and analyzed the expression of downstream effectors of ER stress pathways. 
Significantly enhanced expression of ATF4 and GRP78 transcripts was found in OIR 
mice compared to normoxic littermates at P14 (Figures 1H and 1I). 
These findings were confirmed using an in vitro model of retinal neuron 
precursors cells (RGC-5) (Joyal et al., 2011; Sapieha et al., 2008) exposed to hypoxic 
conditions (1% O2) in order to mimic the retinal ischemia present at P14 of OIR. First, 
we noted a pronounced phosphorylation of PERK and IRE1a (Figure 1J) representing 
the activation of ER stress pathways upon exposing RGC-5s to hypoxic conditions 
(starting at 4 hr). The activation of these pathways coincided with a marked upre- 
gulation of their effectors. ATF4 induction was detected at 8 hr and reached a greater 
than 8-fold increase in expression after 48 hr (Figure 1K). Concordantly, an increased 
splicing of XBP1 was observed, confirming the activation of IRE1a (ratio of 0.6327 at 
0 hr and 1.826 at 4 hr of spliced versus unspliced XBP1 mRNAr) (Figure 1L). GRP78 
	   303	  
expression was similarly elevated at 12 hr and increased by 8-fold at 24 hr (Figure 
1M). The same pattern was noted for C/EBP homologous protein (CHOP), a 
transcription factor whose expression is controlled primarily by ATF4 and to a lesser 
extent by XBP1s (Oyadomari and Mori, 2004) (Figure S1B). Together, these findings 
indicate that the microvascular degeneration and ensuing ischemia characteristic of 
proliferative retinopathies triggers ER stress in retinal ganglion neurons. 
 
Neuronal ER Stress Provokes Failure of Vascular Regeneration 
Recent studies demonstrate that RGCs are important effector cells for retinal 
angiogenesis (Edwards et al., 2012; Fukushima et al., 2011; Joyal et al., 2011; Kim et 
al., 2011; Sapieha et al., 2008). We therefore sought to determine if ER stress in 
these neurons could influence retinal revascularization in OIR. To specifically hinder 
ER stress in RGCs in vivo, we generated lentiviral (Lv) vectors carrying small hairpin 
RNAs (shRNAs). These Lv vectors exhibit high tropism for RGCs when delivered 
intravitreally (Joyal et al., 2011; Sapieha et al., 2008) (Figure S2A). A single 
intravitreal injection of lentivirus shIRE1a (Lv.shIRE1a) or Lv.shPERK at P7 led to a 
significant reduction in IRE1a and PERK expression in whole retinas (Figures S2B 
and S2C, respectively). Lv.shIRE1a injections robustly enhanced retinal vascular 
regeneration by 3.7-fold compared to vehicle-treated controls (as determined by the 
extent of remaining avascular areas at P17; Figure 1N). Importantly, the enhanced 
rate of reparative angiogenesis profoundly reduced destructive pre- retinal 
neovascularization associated with ischemic retinopathies by over 65% (Figure 1O). 
This is likely attributed to the alleviation of hypoxic stress. Conversely, injections of 
Lv.shPERK did not result in any significant changes in retinal vascularization (Figure 
1N) or neovascular tuft formation (Figure 1O), highlighting the central role of IRE1a in 
the control of reparative retinal angiogenesis. Importantly, we did not observe any 
differences in the extent of vasoobliteration at P12 upon treatment with either 
Lv.shIRE1a or Lv.shPERK (Figure 1P), thus confirming that the observed ER stress is 
primarily affecting the second phase regeneration and not the initial phase of vascular 
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degeneration. These findings illustrate that ER stress (more specifically IRE1a 
activity) in hypoxic retinal ganglion neurons contributes to stall- ing vascular regrowth. 
Inhibiting this neuron-associated stress directly impacts reparative vascularization 
and thus highlights the importance of neurovascular crosstalk in this model of 
ischemic retinopathies. 
 
Netrin-1 Is Degraded in Hypoxic Conditions by ER Stress 
ER stress has been classically described as evoking a non- specific response 
to restore cellular function. However, growing evidence points to a degree of 
selectivity with specific substrates being preferentially targeted by the effectors of the 
ER stress response. This is the case specifically with the endoribonuclease activity of 
IRE1a (Han et al., 2009; Hollien and Weiss- man, 2006). Given the elucidation of key 
roles for neuronal guidance cues in retinal vascularization (Eichmann and Thomas, 
2012; Fukushima et al., 2011; Jones et al., 2008; Joyal et al., 2011; Kim et al., 2011; 
Larivée et al 2007), we turned our attention to these molecules. 
Upon subjecting mice to the OIR model, we observed that the neuronal 
guidance protein netrin-1 (Kennedy et al., 1994) was profoundly downregulated at 
P14 (Figure 2A), a time that corre- sponds to elevated ER stress and initial attempts 
at vascular restoration (Figure 1B). In the retina, netrin-1 is mainly produced in the 
ganglion cell layer and colocalizes with the RGC marker bIII-tubulin (Figure 2B). In 
addition, cells of the inner nuclear layer showed a modest level of netrin-1 expression. 
This was con- firmed by performing LCM on retinal layers where netrin-1 expression 
was 16-fold higher in the ganglion cell layer when compared to the RPE layer. Cells of 
the outer and inner nuclear layers showed only modest expression of netrin-1 (Figure 
2C). We also confirmed that the expression of netrin-1 mRNA drops in the GCL layer 
as determined in LCM-isolated samples from P14 OIR and compared to normoxic 
littermates (Figure 2D). Interestingly, this drop in netrin-1 correlates with an increase 
in IRE1a-mediated XBP1 splicing activity at P14 OIR and thus temporally links IRE1a 
activity with a drop in netrin-1 mRNA (Fig- ure 2D). Importantly, the decrease in 
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netrin-1 mRNA seen at P14 (Figure 2E) is largely prevented by lentivirus small hairpin 
(Lv.sh)- mediated knockdown of IRE1a following intravitreal injection (Figure 2F), an 
effect not seen with Lv.shPERK. These data identify a specific link between the IRE1a 
arm of the ER stress pathway and netrin-1. Moreover, as observed in whole retinal 
mRNA at P14 OIR, the degradation of netrin-1 by IRE1a is selective for netrin-1 since 
levels of VEGF are not affected by intravitreal administration of Lv.shPERK or 
Lv.shIRE1a (Figure 2F). While the levels of VEGF are not elevated in whole retinas, 
analysis at the microenvironmental level will be required to tease out the contribution 
of individual cell populations to VEGF production. Concordantly, netrin-1 decreases in 
cultured RGC-5s under hypoxic conditions (1% O2) that mimic the ischemic phase of 
retinopathy while other transcripts such as VEGF increased as expected (Figure 2G). 
In this experimental paradigm, cultured RGC-5s were not serum starved in order to 
prevent premature induction of ER stress and UPR by amino acid deficiency. 
To ascertain if ER stress pathways are responsible for the downregulation of 
netrin-1 in RGCs under hypoxic conditions, we generated PERK- and IRE1a-deficient 
RGCs by stable transfection with shRNA. Using these cell lines, we determined that 
IRE1a is the primary negative regulator of netrin-1 mRNA, as IRE1a-deficient cells 
showed significantly increased levels of ne- trin-1 under hypoxic conditions. 
Importantly, PERK-deficient cells or cells deficient for both PERK and IRE1a did not 
show any additional preservation of netrin-1 mRNA when compared to IRE1a alone, 
thus confirming the prominent role for IRE1a in the downregulation of netrin-1 (Figure 
2H). 
Netrin-1 Is Cleaved by the RNase Activity of IRE1a Recent evidence suggests 
that the ribonuclease (RNase) activity of IRE1a, also termed IRE1-dependent decay 
(RIDD), specifically targets mRNAs encoding proteins that traverse the ER-Golgi 
secretory pathway (Hollien and Weissman, 2006). Therefore, to determine if netrin-1 
could be a substrate for IRE1a, we cotransfected human embryonic kidney (HEK) 
cells that express endogenously low levels of netrin-1 (Shekarabi and Kennedy, 2002) 
with a plasmid encoding netrin-1 with or without an expression plasmid for IRE1a, a 
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kinase-inactive/RNase-dead IREa (K599A), or an exclusively RNase-dead IRE1a 
(K907A) (Figure 3A) (Lipson et al., 2008). The overexpression of IRE1a drastically 
decreased the level of netrin-1 mRNA (Figure 3B), an effect also seen at the protein 
level (Figure 3C). In contrast, the degradation of netrin-1 was not observed with the 
kinase/endoribonuclease inactive dominant-negative mutant K599A (Lipson et al., 
2008) or the endoribonuclease-dead mutant K907A (Figures 3B and 3C). In this 
experimental paradigm employing HEK cells, no effect was noted on the level of 
VEGF in the time frame (48 hr) investigated, demonstrating the selectivity of the 
reaction (Figures 3B and 3C). These results were confirmed by northern blot using a 
netrin-1-specific probe (Figure 3D). 
IRE1a has been shown to target specific scission sites; these include 50-
CAGCAG-30 in adjacent mRNA stem loops. This was demonstrated for the transcripts 
of mouse insulin II (Han et al., 2009) or makorin RING finger protein 2 (Oikawa et al., 
2010). Using a bioinformatics approach, we generated the 2D structure of netrin-1 
transcript (Figure 3E) and noted two putative cleavage sites for IRE1a in positions 
1605–1610 and 1670–1675 located in stem loops (Figure 3E, red arrows). Exposure 
of cultured RGC-5s to hypoxia for 24 hr led to a substantial drop in netrin-1 mRNA as 
determined by semiquantitative PCR and was largely reversed when blocking IRE1a 
expression with shRNAs (Figure 3F). Netrin-1 fragments were very unstable using a 
cell transfection system, and no cleavage fragments were found by northern blot 
(Figure 3D), which could be due to the rapid activity of 5’-to-3’ and 3’-to-5’ 
exonucleases. We therefore employed a cell-free system to analyze the presence of 
these fragments using recombinant GST-fused IRE1a. We designed distinct sets of 
primers spanning the predicted sequences of IRE1a cleavage sites in netrin-1 mRNA. 
Loss of netrin-1 transcript was only observed when amplifying across the prospective 
IRE1a scission sites (959–1683 but not 511–891) (Figure 3G), thus confirming that 
IRE1a targets netrin-1. Together these data demonstrate that netrin-1 mRNA is a 
substrate for IRE1a. 
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Restoring Netrin-1 Accelerates Revascularization of the Ischemic Retina  
Given the pronounced reduction of netrin-1 (noted above; Figure 2) during a 
period in which retinal revascularization is compromised (Joyal et al., 2011; Stahl et 
al., 2010), we sought to determine if restoring netrin-1 levels by ectopic intravitreal 
administration would enhance reparative angiogenesis following OIR. A single 
intravitreal injection of netrin-1 at P14 accelerated vascular regeneration and 
consequently decreased the avascular area of retina in a dose-dependent manner: 
25% reduction with 50 ng/mL, 57% with 100 ng/mL, and 67% reduction with 200 
ng/mL (Figure 4A). This rapid restoration of retinal vascular- ization lead to reduced 
pathological preretinal neovascularization with the 100 ng/ml dose abrogating close to 
70% of this destructive angiogenesis (Figure 4B). To ascertain whether the 
regenerated vessels were healthy, we determined their barrier function by 
angiography with fluorescein isothiocyanate (FITC)-dextran. Regenerated vessels in 
netrin-1-injected retinas assumed a healthy disposition and did not present any signs 
of vascular leakage in contrast to vehicle-injected controls, which showed blebbing 
and poor retention of FITC-dextran (Figure 4C). These data attest to the stability of 
the neovessels in netrin-1- treated retinas.  
To further confirm the role of netrin in retinal angiogenesis, we designed a 
lentiviral vector carrying an shRNA targeting netrin-1 and administered it to the 
developing retina. Intravitreal injection of Lv.shNtn1 at P2 significantly reduced the 
expression of netrin-1 at P7 (Figure S3A) and resulted in an abnormal vascular front 
with several retracted tip cells (Figure S3B, solid white arrows). Isolectin-B4-positive 
microglial cells were found in the general vicinity of the growing vascular front, yet 
were less in direct contact with vascular tip cells in Lv.shNtn-1-treated retinas (Figure 
S3B, gray dotted arrows). Taken with the previous, these data demonstrate that a 
specific substrate of neuronal ER stress, namely netrin-1, has potent 
vasoregenerative properties. 
 
Netrin-1 Modulates the Expression of VEGF in Macrophage/Microglial Cells  
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To gain insight into the mechanisms by which netrin-1 acceler- ates retinal 
revascularization, we explored its influence on the prominent retinal proangiogenic 
factor VEGF (Pierce et al., 1995; Pierce et al., 1996). The same intravitreal injection 
of netrin-1 that significantly enhanced revascularization (Figure 4) induced a 
significant yet very modest increase in gene expres- sion of VEGF in the total retina 
24 hr postinjection (Figure 5A). Elevated panretinal levels of VEGF are associated 
with patholog- ical ocular neovascularization (Aiello et al., 1995). However, we 
observed only a modest rise in retinal VEGF in our experimental paradigm. Yet this 
increase in VEGF precipitated reparative angiogenesis. We therefore sought to 
explore the source of the VEGF production at a microenvironmental level and 
elucidate which cell population was responsible for this netrin-1-induced production of 
VEGF. 
Following administration of Myc-tagged recombinant netrin-1 protein to the 
vitreous as described above (Figure 4), we detected Myc-netrin-1 specifically 
localized to lectin and Iba1- positive microglia/macrophages at the vascular front 
(Figure 5B) in close proximity with tip cells (Figure 5B, white arrows). Confocal 
images were taken 3 hr post-injection. A 3D reconstruction shows the binding of 
exogenously applied netrin-1 to the cell surface of microglia/macrophages (Movie S1). 
To determine whether netrin-1 can have biological effects on these cells, we 
evaluated the expression of netrin-1 receptors in a murine macrophage cell line 
(J774) (Figure 5C) and in primary microglia (Figure S4A). Our results demonstrate 
that UNC5B, neogenin, and the putative receptor for netrin, adenosine A2B receptor 
(AA2BR), are expressed in macrophages (Figure 5C), with a similar pattern in primary 
microglial cells (Figure S4A). Conversely, UNC5A and DCC are undetectable or 
negligibly expressed in macrophages or microglia. Macrophages may thus be 
required for netrin-1 to exert proangiogenic effects, as netrin-1 alone has been 
elegantly shown to inhibit sprouting angiogenesis (Larrivée et al. 2007). 
We next analyzed the ability of netrin-1 to induce expression of VEGF and 
angiopoietins directly in macrophages. Netrin-1 (100 or 200 ng/ml) induced a 3-fold 
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increase of VEGF expression in macrophages (Figure 5D). Moreover, a significant 
increase in other proangiogenic factors such as Angiopoietin 2 was noted while the 
vasostabilizing Angiopoietin 1 was affected minimally, suggesting a general 
proangiogenic modulation by Netrin-1 (Figure S4B). Increased expression of VEGF 
was induced similarly in primary microglia by application of netrin-1 (Figure S4C). 
Given that Angiopoietin 2 requires VEGF to induce angiogenic growth, we focused 
our study on VEGF. We there- fore analyzed the expression of VEGF in the presence 
of various blockers of netrin-1 receptors. In this context, only the AA2BR antagonist 
PSB1115 or an AA2BR siRNA were able to decrease the induction of VEGF while 
neutralizing antibodies or siRNAs against UNC5B (Ly et al., 2005; Tadagavadi et al., 
2010), and Neogenin (Lejmi et al., 2008) did not prevent this induction (Figure 5D). 
We verified that these siRNAs were transfected effectively in macrophages using 
siGLO and fluorescence-activated cell sorting (FACS) analysis (Figure 5D, inset) and 
certified their specificity and potency (Figure S4D). 
To confirm that netrin-1 can exert a biological effect on macrophages, we 
analyzed the activation of the mitogen activated protein kinase (MAPK) ERK1/ERK2 
as a generic readout of intracellular activity. Relevantly, ERK1 and ERK2 are known 
to be activated by the AA2BR (Yang et al., 2011) and stimulated following netrin-1 
exposure to epithelial cells (Wang et al., 2009). Treatment of macrophages with a 100 
ng/mL dose of netrin-1 induced a rapid increase of ERK1/ERK2 phosphorylation 
starting at 5 min and peaking at 30 min (Figure 5E). Pre-incubation with PSB1115 
reversed ERK1/ERK2 phosphorylation (Figure 5F), confirming the involvement of this 
receptor in netrin-1- mediated signaling in macrophages. These data reveal that 
netrin-1 can prompt myeloid cell production of proangiogenic factors such as VEGF. 
This provides a paradigm in which netrin-1 induces an angiogenic switch in microglial 
cells and drives reparative angiogenesis at a microenvironmental level, thus 
promoting localized vascular regeneration without increasing overall pathological 
angiogenesis. 
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The Proangiogenic Properties of Netrin-1 Are Driven by Macrophages  
To investigate the contribution of macrophages to the proangiogenic effects of 
netrin-1, we conducted a series of ex vivo and in vitro angiogenesis assays. Cultured 
macrophages were exposed to 100 ng/mL netrin-1 for a period of 24 hr and used to 
condition fresh culture media (Figure 6A). The conditioned media (CM) containing 
factors secreted by macrophages secondary to netrin-1 stimulation was collected, 
filtered, and used to culture human retinal microvascular endothelial cells (HRMECs). 
Using a CyQUANT Cell Proliferation Assay, we found that supernatants from netrin-1-
stimulated macrophages induced a robust 30-fold induction in HRMEC proliferation 
com- pared to nonstimulated controls (Figure 6B). In line with the results above, the 
AA2BR inhibitor, PSB1115, abolished the proliferative effects of netrin-1 (Figure 6B). 
Direct addition of netrin-1 lead to less pronounced endothelial proliferation, 
suggesting that the proangiogenic effects of CM are mediated by factors produced by 
netrin-1-stimulated macrophages and not by exogenously added netrin-1. In order to 
confirm the angiogenic potential of netrin-1-stimulated macrophages in vivo, we used 
a Matrigel plug assay in which CM was solubilized with Matrigel and injected 
subcutaneously in mice. Ten days following introduction of plugs, mice were perfused 
with FITC- dextran, and the extent of invading vascularization was quantified by 
spectrofluorometry. Netrin-1 CM induced a 4-fold increase in plug angiogenesis 
(Figure 6C), an effect visualized by fluorescent microscopy (Figure 6C). Consistent 
with the data above, inhibition of AA2BR efficiently abolished the capacity of netrin-1 
to induce macrophage-dependent vascularization, as revealed by a decrease in 
vascular networks observed in PSB1115-CM-treated Matrigel plugs (Figure 6C). 
Next, we verified if netrin-1 CM from macrophages could induce sprouting 
angiogenesis in aortic explants. The results presented in Figure 6D demonstrate that 
CM from macrophages incubated with netrin-1 significantly increased aortic ring 
sprouting area com- pared to controls. As above, the CM harvested from 
macrophages pretreated with PSB1115 provoked considerably less vascular growth, 
thus confirming the role of this receptor in netrin-1-induced angiogenesis (Figure 6D). 
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Importantly, consistent with previous studies (Larrivée et al. 2007), direct 
incubation of aortic explants with netrin-1 alone lead to a dose-dependent reduction in 
vascular sprouting (Figure S5). These results underscore the importance of 
macrophages in mediating the proan- giogenic effects of netrin-1. Given the central 
role of VEGF in angiogenesis, including as a positive modulator of the effects of 
angiopoietins, we sought to determine if neutralization of VEGF would abrogate the 
proangiogenic effects of the CM from netrin-1-treated macrophages. Indeed, our data 
confirm that VEGF was the major proangiogenic effector in the CM, given that 
addition of a VEGF-neutralizing antibody reversed the observed sprouting 
angiogenesis (Figure 6E), an effect not seen with addition of a control goat 
immunoglobulin G (IgG) antibody. Combined, the findings presented in Figure 6 
provide evidence that the direct effect of netrin-1 on proliferation and migration of 
endothelial cells was either not significant or negligible compared to the pronounced 
effect of netrin-1 CM that was obtained from macrophages. Moreover, we showed 
that VEGF is a central proangiogenic effector secreted by netrin-1-stimulated 
macrophages. 
       
Neurovascular Regeneration by Netrin-1 In Vivo Is Macrophage/Microglial Cell 
Dependent  
Retinal myeloid cells (macrophages/microglia) participate in vascularization 
both during development (Stefater et al., 2011a, 2011b) and in pathological 
neovascularization (Stahl et al., 2010). To confirm that retinal macrophages/microglia 
mediate the observed netrin-1-induced vascular regeneration of the ischemic retina 
(Figure 4) and to further rule out a direct effect of netrin-1 on endothelium, we 
proceeded to deplete the retina of myeloid cells by intravitreal injection of clodronate 
liposomes prior to treatment with netrin-1. Clodronate liposomes have been used 
successfully to remove macrophages from distal organs (van Rooijen and van 
Kesteren-Hendrikx, 2002) as well as the retina (Ishida et al., 2003; Ritter et al., 2006). 
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We first confirmed the ability of our clodronate liposome preparation to induce 
apoptosis of macrophages in vitro (Figure S6). 
We next verified the efficacy with which clodronate liposomes deplete retinal 
macrophages/microglia by FACS analysis. Treatment with clodronate liposomes lead 
to a significant 2-fold reduction in retinal macrophages/microglia compared to control 
empty liposomes as confirmed by 7-AAD negative- F4-80/CD11b positive cells (4,500 
microglia for empty liposomes and ~2,300 microglia for clodronate liposomes/retina). 
7-AAD negative cells are viable (Figure 7A). 
As expected, intravitreal injection of netrin-1 enhanced vascular regeneration 
by ~50% as observed at P17 in empty-liposome-injected animals. Conversely, 
delivery of netrin-1 to macrophage/microglia-depleted retinas did not induce any 
significant difference in vascular regeneration, thus underscoring the importance of 
these immune cells in netrin-1-induced angiogenesis (Figure 7B). We next verified the 
contribution of the macrophage/macroglial-derived VEGF produced in response to 
netrin-1 (described in Figures 5 and 6). To this end, we simultaneously injected netrin-
1 and anti-VEGF neutralizing antibodies and analyzed the outcome on vascular 
regeneration at P17. Blocking antibodies for VEGF effectively abolished the pro-
regenerative effect of netrin-1, confirming the key role of this factor in the regeneration 
of the vasculature observed in our paradigm (Figure 7C). Our data indicate that netrin-
1 activates an angiogenic switch in macrophages/microglia, and thus drives 
microenvironmental revascularization, but does not contribute to pathological pre-
retinal neovascularization. Taken together, we demonstrate that sustained ER stress 
specifically targets netrin-1, which we identify as a potent retinal revascularization 
factor that mediates its effects through retinal myeloid cells. 
 
Discussion 
The neurovascular unit has been increasingly investigated in health and 
disease over the course of the last decade. In this study, we put forward two concepts 
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pertaining to the role of ER stress in hindering reparative angiogenesis within the 
CNS. First, we demonstrate that sustained neuronal ER stress, through the 
endoribonuclease IRE1a, provokes the degradation of netrin-1 and results in 
revascularization failure of the ischemic retina. Second, we present neuronal-derived 
netrin-1 as a potent mediator of myeloid-cell-induced CNS vascular regeneration 
(Figure 7C). Although mechanisms governing vascular degeneration and the ensuing 
pre-retinal neovascularization in proliferative retinopathies have been extensively 
studied (Ashton et al., 1954; Campbell, 1951; D’Amore and Sweet, 1987; Lundbaek et 
al., 1970; Michaelson, 1948; Simons and Flynn, 1999; Smith, 2004; Smith et al., 
1994; Tesfamariam, 1994), there are no strategies to date to accelerate 
revascularization of the vaso- obliterated retina and consequently alleviate the 
ischemic stress that is central to disease progression. Gaining insight into why 
vascular regeneration stalls or proceeds at compromised rates will be key to 
understanding the pathomechanisms of ischemic neuropathies. 
 Hypoxia is an activator of the unfolded protein response in conditions 
such as ischemic heart disease or cerebral ischemia (Tajiri et al., 2004). We 
demonstrate that both arms of the ER stress response, IRE1a (cleavage of XBP1) 
and PERK (induction of ATF4), are profoundly induced in response to neuronal 
hypoxia. Although it is well established that mild hypoxia (via hypoxia-inducible factor 
[HIF]) drives a cluster of over 70 genes that encode proteins that promote the 
adjustment to an oxygen deficient state (Bruick, 2003; Lange and Bainbridge, 2012; 
Paul et al., 2004), it is conceivable that when the ischemic shock persists, the nervous 
tissue segregates irreversibly damaged regions in an attempt to deviate metabolic 
stores to less-affected and more-salvageable areas (Joyal et al., 2011). Globally, this 
concept may in part explain the production of vasorepulsive guidance cues in 
ischemic cores secondary to severe vascular injury in stroke (Fujita et al., 2001) or in 
vasodeficient areas of the retina in retinopathy (Fukushima et al., 2011; Joyal et al., 
2011). The sustained activation of ER stress pathways, and specifically IRE1a, may 
provide the neuron with the appropriate enzymatic machinery to shift from a 
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prosurvival program to one that repels vessels and thus redistributes oxygen and 
nutrients to sectors of tissue that would preferentially benefit. In agree- ment, 
degradation of netrin-1 transcripts by IRE1a during a state of sustained hypoxia 
perturbs revascularization and thus permits vasorepellant factors such as 
semaphorins 3A and 3E to deviate nascent angiogenic sprouts from severely 
ischemic areas of nervous tissue (Fukushima et al., 2011; Joyal et al., 2011). 
The paradigm we present suggests that the cellular consequences of ER 
stress are finely tuned and selective. In an attempt to elucidate the mechanism by 
which ER stress in retinal ganglion neurons stalls neurovascular regeneration, we 
identified netrin-1 as a selective substrate for IRE1a via a mechanism previously 
described as IRE1a-dependent decay (RIDD) of messenger RNA (Hollien and 
Weissman, 2006). Specifically targeting effectors such as netrin-1, while permitting 
VEGF levels to increase, will hinder netrin-1-induced revascularization while 
maintaining adequate VEGF levels to provide neurotrophic support of neighboring 
retinal neural tissue (Robinson et al., 2001). Similarly, it is now believed that several 
substrates for IRE1a exist including the mRNas encoding insulin (Lipson et al., 2008), 
CD59 (Oikawa et al., 2007), HMG-CoA reductase, b2-microglobulin, and the 
microRNA for TXNIP (miR-17) (Lerner et al., 2012). IRE1a-mediated mRNA 
degradation provides a rapid mechanism to deplete cells of ER-localized mRNAs and 
alleviate the metabolic burden of protein folding inside the ER. Interestingly, in our 
experimental paradigms, we did not observe any direct effects of IRE1a on the 
induction of VEGF, as has been suggested (Drogat et al., 2007; Ghosh et al., 2010). 
This could be attributed to IRE1a’s ability to adjust its RNase versus transcriptional 
activity (via activation of XBP1) under conditions of prolonged ER stress (Hollien et al., 
2009). In conditions in which homeostasis could not be restored, such as that 
observed in our experimental paradigms, the RNase activity of IRE1a would be 
favored over the prosurvival transcriptional induction of angiogenic genes such as 
VEGF (Han et al., 2009) by IRE1a. Interestingly, as demonstrated in this study, VEGF 
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was found by other reports to be insensitive to the RIDD activity of IRE1a (Ghosh et 
al., 2010). 
Although the nervous system has long been considered immunologically 
privileged, evidence for direct interplay between the nervous and immune systems is 
mounting (Farina et al., 2007; London et al., 2011; Nguyen et al., 2002; Rosas-Ballina 
et al., 2011; Wong et al., 2011). Specifically, the innate immune system has been 
intimately tied to CNS health and disease. Neuroimmune crosstalk can orchestrate an 
innate response that participates in beneficial events such as nerve remyelination and 
microglia-derived neuroprotective trophic support of injured neurons (Nguyen et al., 
2002). In the retina, monocyte-derived macrophages participate in promoting RGC 
survival and nerve regeneration following traumatic optic nerve injury (Leon et al., 
2000) as well as neuroprotection against glutamate cytotoxicity and elevated 
intraocular pressure (London et al., 2011). Of direct pertinence, resident retinal 
microglia participate actively in promoting developmental vascularization of the 
ganglion cell layer (Checchin et al., 2006), and resident myeloid cells have the 
propensity to suppress angiogenic branching (Stefater et al., 2011). Bone marrow-
derived myeloid progenitors migrate to avascular areas, differentiate into microglia, 
and promote revascularization (Ritter et al., 2006). We demonstrate that netrin-1 
provokes an angiogenic switch in retinal macrophages and participates in guiding 
vascular regrowth into avascular areas of the retina. We show that microglial 
depletion by clodronate liposomes abolishes the enhanced rate of revascularization 
induced by netrin-1. In addition, ex vivo and in vitro assays indicate that the 
proangiogenic effects of netrin-1 are mediated via macrophages in a manner that is 
dependent on AA2BR function and activation of the ERK1/ERK2 kinase. Hence, the 
upregulation of VEGF occurs at a microenvironmental level at the vascular front and 
thus does not precipitate destructive preretinal growth as would be expected by an 
overall rise in VEGF during the vasoproliferative phase of retinopathy. Interestingly, 
selective antagonists of the AA2BR were shown to reduce preretinal 
neovascularization (Mino et al., 2001), suggesting a correlation between this G 
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protein-coupled receptor (GPCR) and retinal angiogenesis. Our data indicate that 
AA2BR is required for netrin-1 to activate microglia to provide the tissue with an 
adequate level of VEGF to revascularize the retina without contributing to extraretinal 
growth. This approach may be considered counterintuitive given the uncontestable 
involvement of VEGF in the pathogenesis of ocular neovascular disease (Aiello et al., 
1995; Caldwell et al., 2003; Ferrara and Kerbel, 2005) and the currently employed 
anti- angiogenic strategies for proliferative ocular disease (Stewart, 2012). However, 
providing minute doses of VEGF has been shown to reduce OIR-associated 
pathology (Dorrell et al., 2010). Consistent with our findings, the ability of 
physiological doses of netrin-1 (50–200 ng/mL) to promote vascularization and 
survival of endothelial cells has previously been demonstrated (Park et al., 2004; 
Wilson et al., 2006). At the same time, however, well-designed and sophisticated 
studies have 
described antiangiogenic properties for netrin-1 (Larrivée et al., 2007) acting 
through the UNC5B receptor (Lu et al., 2004). Our findings indicate that beyond a 
direct effect on endothelium, netrin-1 influences cell populations associated with the 
vascula- ture and suggest that this may account for some of the noted discrepancies 
(Castets and Mehlen, 2010). It is important to note that although it has been 
suggested that AA2BR functions as a receptor for netrin-1 (Corset et al., 2000; 
Mirakaj et al., 2011; Rosenberger et al., 2009), these results have been controversial 
(Stein et al., 2001). Alternatively, manipulating AA2BR function directly regulates the 
intracellular concentration of cyclic AMP (cAMP), which in neurons regulates the 
switch between chemoattractant and chemorepellent responses to a netrin-1 gradient 
(Nishiyama et al., 2003; Shewan et al., 2002). We speculate that a similar paradigm 
may thus apply to macrophages, with intracellular levels of cAMP potentiating the 
angiogenic switch. 
Collectively, these findings provide mechanistic insight into vascular 
regeneration in neuroischemic conditions. Our data present the ER of CNS neurons 
as a key sensor of hypoxic stress that has the propensity to modulate the reparative 
	   317	  
innate immune response under ischemic conditions. In doing so, we provide evidence 
for neuroimmune communication in neuroi- schemic conditions such as proliferative 
retinopathies. When driven beyond a hypoxic threshold however, central neurons via 
IRE1a have the ability to halt vascularization, possibly in order to deviate metabolic 
stores to more salvageable areas. To date, there are no therapeutic strategies that 
aim to enhance vascular regeneration in ischemic CNS tissue. In this regard, netrin-1- 
stimulated macrophages may be able to override the vasoinhibi- tory cues present 
within the ischemic neuronal retina (Fukushima et al., 2011; Joyal et al., 2011) and 
achieve functional vascular regeneration. The work presented in this study provides 
proof of concept for the modulation of ER stress and netrin-1 for an ischemic disorder 
of the CNS. Future investigation and stream- lining will be required to translate these 
findings and design therapeutic strategies to counter neuroischemic conditions such 
as retinopathies. 
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Figure 1. Neuronal ER Stress Is Induced in Hypoxic Retinas and Associated 
with Failure of Revascularization (A) Graphic depiction of canonical ER stress 
pathways. The PERK arm controls ATF4 expression while IRE1a mediates XBP1 
splicing. Both lead to GRP78 expression. (B) Representative photomicrographs of 
isolectin B4-stained flatmount retinas from the OIR model illustrate the progression of 
vascular growth following initial vasoobliteration. Upon exit from O2 at P12, the retina 
attempts to revascularize, yet there is an initial stall in regrowth followed by 
pathological preretinal neovascularization (white sprouts) that peaks at P17. 
Successively, vessels enter the avascular retina toward P19–P21, and the preretinal 
neovascularization regresses. (C) Sagittal retinal sections show that phosphorylated 
IRE1a is robustly induced at P14 OIR and expressed in the retinal ganglion cell layer 
(GCL) as demonstrated by colocalization with bIIItubulin-positive RGCs. P-IRE1a also 
stains cells of the inner nuclear layer (INL). Scale bar: 20 mm. (D) Sagittal retinal 
sections show that phosphorylated PERK is induced at P14 OIR and expressed in the 
retinal GCL as demonstrated by colocalization with bIII-tubulin-positive RGCs. (E) The 
expression of both markers is more robustin the avascular zones of the retina and 
does not colocalize with isolection B4 staining. ONL, outer nuclear layer; INL, inner 
nuclear layer; GCL, ganglion cell layer. Scale bar: 50 mm. (F) Whole retinal cross-
sections from P14 OIR confirm that p-IRE1a and p-PERK are expressed robustly in 
the central avascular area of the retina. Scale bar left panel: 20 mm, right panel: 500 
mm. Images and analysis are representatives of three independent experiments. (G) 
Sagittal sections of the retina showing the area harvested by LCM. (H and I) ATF4 (H) 
and GRP78 (I) gene expressions are  increased in OIR compared to normoxic 
littermates as determined by LCM of the ganglion cell layer of the retina. (J) PERK 
and IRE1a are phosphorylated in response to hypoxia in cultured RGCs. (K–M) ATF4 
gene expression (K), XBP1 mRNA splicing (L), and GRP78 gene expression (M) are 
increased following prolonged hypoxic exposure (n = 4 independent experiments for 
each gene studied). **p < 0.01 and ***p < 0.001. Values respresent a fold increase 
relative to time 0 hr ± SEM. (N–P) During the phase of vascular dropout (P8), an 
injection of a lentivirus coding for an sh.IRE1a at P3 dramatically enhanced vascular 
regeneration (N) and decreased the preretinal neovascular area (O) in the regrowth 
phase of OIR at P17. Injection with a shPERK lentivirus did not result in any 
significant amelioration of vascular regeneration or reduction of preretinal 
neovascularization. Treatment with either sh.IRE1a or shPERK at P3 did not lead to 
noticeable variations in vasoobliteration (P). Representative images of retinas from 
each condition are presented. Scale bar: 1 mm. n = 8 animals/group; *p < 0.05, **p < 
0.01, ***p < 0.001 relative to vehicle-treated retinas ± SEM. 	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Figure 2. Netrin-1 Is Downregulated by Hypoxia-Triggered ER Stress (A–C) 
Retinal Netrin-1 protein levels (western blot) drop during periods associated with 
elevated ER stress and vascular regeneration failure in OIR. n = 4 retinas/group, *p < 
0.05 relative to normoxia. Netrin-1 is predominantly expressed in the retinal ganglion 
cell layer and colocalizes with bIII-positive RGCs, as assessed by IHC (B) and LCM 
(C). RPE = retinal pigment epithelium (representative of three independent 
experiments; P10 normoxic mouse eye). Scale bar, 50 mm; *p < 0.05. (D) The drop in 
netrin-1 expression correlates with increased splicing of IRE1a in the ganglion cell 
layer isolated by LCM. *p < 0.05, ***p < 0.001 relative to normoxic controls and 
normalized to P10 ± SEM. n = 3 independent experiments. (E and F) Netrin-1 gene 
expression is significantly reduced at P14 OIR (E) but preserved in Lv.sh.IRE1a-
injected retinas (F). VEGF expression is not altered by Lv.shPERK and Lv.shIRE1a 
injections at P14 of OIR. n = 4 retinas. Injection of Lv.sh.PERK does not induce any 
significant change in netrin-1 gene expression. N.S., not significant; *p < 0.05, **p < 
0.01 relative to normoxic vehicle or lv.shGFP-injected retinas ± SEM. (G) Temporal 
gene expression of netrin-1 and VEGF in hypoxic cultured RGC-5 demonstrate the 
gradual increase of VEGF and the sharp drop in netrin-1. n = 4 independent 
experiments; *p < 0.05, ***p < 0.001 relative to time 0 hr ± SEM. (H) Lv.shIRE1a 
preserves netrin-1 mRNA against hypoxic exposure. Graph depicts netrin-1 gene 
expression after 8 hr of hypoxia in cultured RGCs stably expressing shRNAs for either 
PERK, IRE1, PERK and IRE1a, or controls. n = 5 independent experiments; *p < 0.05 
relative to shGFP-transfected cells ± SEM. 	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Figure 3. Netrin-1 Is Cleaved by the RNase Activity of IRE1a (A) Schematic 
representation of IRE1a RNase activity following kinase activation, which can be 
abolished using a K599A or K907A mutant. (B and C) Netrin-1 and IRE1a WT 
expression plasmid cotransfection results in the degradation of netrin-1 mRNA (B) 
and protein (C). Cotransfection with an IRE1a endoribonuclease/kinase-dead mutant 
(K599A), an endoribonuclease inactivated mutant (K907A), or an irrelevant 
expression plasmid (shGFP) does not induce degradation of netrin-1 mRNA (B) or 
protein (C). VEGF mRNA (B) and protein (C) are not degraded by IRE1a activity. 
IRE1a is highly expressed following transfection with IRE1a WT, K599A, or K907A 
plasmids (third panel) (B). (D) Northern blot showing degradation of the netrin-1 
mRNA using the same conditions as in (B) and (C). (E) 2D reconstitution of 
secondary structure of netrin-1 murine mRNA (position 1191–1960). Red arrows 
depict putative 50-CAGCAG-30 recognition sites for IRE1a RNase activity in stem 
loops (position 1605–1610 and 1670–1675). Each predicted base pair is colored with 
the heat color gradation from blue to red, indicating the base-pairing probability from 0 
to 1. (F) Netrin-1 mRNA degradation in hypoxic RGCs (1% O2) can be reversed with 
an shRNA directed against IRE1a. (G) Amplification products with primers spanning 
the putative cleavage sites (959–1683) show degradation of netrin-1 mRNA with 
recombinant IREa, an effect not seen with primers outside the cleavage sites (511–
891). Panels (B), (C), (D), (F), and (G) are representative of at least three separate 
experiments. 	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Figure 4. Administration of Netrin-1 to Ischemic Retinas Enhances Vascular 
Regeneration and Suppresses Pathologic Neovascularization (A and B) Isolectin 
B4 stained retinas from P17 mice injected intravitreally at P14 with 50, 100, or 200 
ng/mL of recombinant netrin-1 or vehicle (PBS). Netrin-1 effectively enhanced 
reparative angiogenesis (A) and diminished neovascular areas (B) as determined at 
P17. Representative images of retinas for each condition are presented. n = 10–13 
animals/group for each calculation; *p < 0.05, **p < 0.01,***p < 0.001 relative to 
vehicle-injected retinas ± SEM. Scale bar: 1 mm. (C) Neovessels induced by netrin-1 
treatment do not show any signs of leakage of FITC-dextran, as opposed to vehicle-
injected retinas. Representative images of three independent experiments. Scale bar: 
100 mm. 	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Figure 5. Netrin-1 Activates AA2BR on Macrophages and Provokes the Release 
of VEGF in an ERK1/ERK2-Dependent Manner (A) Intravitreal injection of netrin-1 
(100 ng/mL at P14) induces retinal VEGF gene expression at P15 OIR. n = 6 
animals/group; **p < 0.01 relative to vehicle injected retinas ± SEM. (B) Confocal 
images of c-Myc-tagged netrin-1 reveals binding to Iba1-positive macrophages/ 
microglia 3 hr postinjection (P14 OIR). Representative images of three independent 
experiments.(C) Macrophages express classic netrin-1 receptors UNC5B, Neogenin, 
and AA2BR. Expression was normalized relative to retinas of normoxic mice at P10. n 
= 3 independent experiments. (D) Netrin-1 induced VEGF gene expression in 
macrophages after 24 hr of incubation with varying doses of netrin-1. Pretreatment 
with PSB1115 (5 mM) lead to a significant reduction in VEGF expression while anti-
UNC5B or anti-neogenin neutralizing antibody (both used at 5 mg/mL) did not affect 
netrin-1-induced VEGF expression. n = 6 independent experiments. These results 
were confirmed using siRNA against AA2BR, UNC5B, and neogenin (checkered 
columns). *p < 0.05, **p < 0.01 relative to vehicle or 100 ng/mL netrin-1 ± SEM. Inset: 
FACS analysis shows that transfection was effective in macrophages using siGLO 
reagents (>90% FL-1+ in transfected cells as opposed to <5% FL-1+ in vehicle-
transfected controls). Representative of three independent experiments. (E and F) 
Netrin-1 (100 ng/mL) induced ERK1/ERK2 phosphorylation in macrophages while 
pretreatment with PSB1115 (5 mM) blocked the activation of ERK1/ERK2 (depicted at 
30 min following stimulation) (F). Representative image of three independent 
experiments. 	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Figure 6. Netrin-1 Triggers a VEGF-Dependent Proangiogenic Response in 
Macrophages (A) Schematic description of the experimental design used for 
assessing the angiogenic potential of macrophage supernatants after netrin-1 
challenge. (B) HRMEC proliferation was assessed by CyQUANT assay after a 48 hr 
incubation with conditioned media (CM) from macrophages stimulated with vehicle 
(Ctrl), netrin-1 (100 ng/mL), or netrin-1 stimulation following pretreatment with 
PSB1115 (5 mM) for 30 min. Cells were incubated in the presence of vehicle (PBS), 
netrin-1 (100 ng/mL), or macrophage CM. CM from Netrin-1-stimulated macrophages 
yielded a pronounced increase in cell proliferation in an AA2BR-dependent manner 
while netrin-1 alone provoked a more modest proliferation (n = 3 separate 
experiments). (C) Matrigel plug assay was employed to investigate the ability of 
macrophage CM to induce vascularization in vivo. CM from same conditions as in (B) 
were solubilized in Matrigel and implanted in adult mice. Vascular growth inside the 
subcutaneously injected Matrigel was evaluated by intravenous FITCdextran 
injections and spectrophotometric quantification. CM from netrin-1-stimulated 
macrophages yielded a robust increase in vascular growth in an AA2BR-dependent 
manner while netrin-1 alone did not influence vascularization. Representative images 
from Matrigel plugs collected 10 days postintroduction. Scale bar: 2 mm. n = 3 
separate experiments. (D) Area of vascular sprouting from aortic explants incubated 
with same conditions as in (B). Assessment was made after 48 hr of incubation. 
Representative images from each condition assessed are shown. n = 12–16 aortic 
rings from four separate experiments. Scale bar: 1mm. (E) CM were preincubated 
with either goat IgG (Gt IgG) or an anti-VEGF neutralizing antibody (5 mg/mL) before 
addition to aortic explants. Representative images are shown. Scale bar: 1 mm; n = 
9–11 aortic rings from three different experiments. *p < 0.05, **p < 0.01, ***p < 0.001 
relative to vehicle, netrin-1 100ng/mL, Ctrl CM, or netrin-1 CM ± SEM. 	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Figure 7. Netrin-1-Dependent Vascular Regeneration Is Macrophage/Microglial 
Cell and VEGF Dependent (A) Intravitreal injection of clodronate liposomes 
efficiently eliminated retinal macrophages/microglia. Retinas were injected at P11 with 
1 mL of empty (PBS) or clodronate liposomes and collected at P14 for FACS analysis. 
The proportion of CD11b+/F4-80+ (microglia) was calculated by first gating the 7-AAD 
negative (viable) population. Histograms showing the numbers of macrophages/ 
microglia according to the proportion measured by FACS analysis. Representative dot 
plots are shown; n = 6 retinas/group. (B) Depletion of retinal macrophages abrogated 
netrin-1-induced revascularization of OIR retinas. Avascular areas were determined in 
retinas pretreated with 0.5 mL of empty or clodronate-containing liposomes at P11 
then injected with 100 ng/mL netrin-1 at P14. Retinas were analyzed at P17. 
Representative images of flatmount retinas are shown; n = 8–10 animals/group. *p 
<0.05, **p < 0.01 relative to vehicle-injected retinas ± SEM. Scale bar: 1 mm. (C) 
Simultaneous injections of anti-VEGF neutralizing antibodies at P14 abolished the 
ability of netrin-1 to induce vascular regeneration. Representative images of n = 8–10 
retinal flatmounts per group are shown below. ***p < 0.001 relative tovehicle-injected 
retinas ± SEM. (D and E) Graphical depiction of principal findings of the study. Mildly 
ischemic retinal ganglion neurons produce netrin-1, which activates a critical 
reparative angiogenic switch in macrophages/microglia and precipitates vascular 
regeneration of ischemic retinas (D). Sustained hypoxic stress on RGCs provokes the 
degradation of netrin-1 mRNA by an IRE1a-dependent mechanism and consequently 
impedes vascular regeneration (E). 	  
